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GEnErAl IntroDuCtIon
The kidney performs two functions that are essential for life. First, it participates in the 
homeostasis  of the extracellular environment that is required for adequate functioning 
of the cells. This is achieved by excretion of some of the waste products of metabolism 
and by specifically adjusting the urinary excretion of water and electrolytes to match 
net intake and endogenous production. Second, it secretes hormones that participate 
in the regulation of systemic and renal hemodynamics, red blood cell production, and 
bone metabolism. 
Many medicines have nephrotoxic potential, either by direct damage of tubular 
cells or by glomerular or interstitial damage following immune-complex formation (1). 
Well-known examples of nephrotoxicity include cytotoxic chemotherapeutic agents 
such as cisplatin and aminoglycoside antibiotics such as gentamycin. Despite the risk of 
nephrotoxicity, use of these drugs is justified in case no safer alternatives are available 
and if the underlying condition is more serious than the risk of renal damage. However, 
history provides several examples where these conditions were not met. Examples are 
the chronic nephropathy caused by non-steroidal anti-inflammatory drugs (NSAIDs) 
and related analgesics, most notably phenacetin, that was ultimately withdrawn in 1983 
(2), and the acute renal failure associated with lactic acidosis from phenformin that was 
ultimately withdrawn in 1976 (3). A more recent example is the combined use of drugs 
affecting the renin-angiotensin system. In relation to this, the Pharmacovigilance Risk 
Assessment Committee  (PRAC) issued a negative advice against combined use of these 
drugs in 2014 (4). 
It is estimated that between 18-27% of all cases of acute kidney injury in United 
States hospitals are drug-induced (5). Although only severe renal function impairment 
requires dialysis or a renal transplant, also a subtle impairment in renal function has 
clinical consequences as it is associated with an increase in cardiovascular and all-cause 
mortality (6). Moreover, renal function can also have consequences for the metabolism 
of other drugs. Both EU and US legislations on drug authorization recognize the fact 
that pharmacokinetics studies are important in patient with impaired renal function (7, 
8). In addition, to detect potential renal toxicity in an early stage, studies evaluating the 
pharmacokinetics of a drug have become standard in the pre-authorization phase of 
medicine authorization (9). Post-marketing, regulatory authorities, such as the Food and 
Drug Administration (FDA) and the European Medicines Agency (EMA), continuously 
evaluate the safety of a drug through spontaneous reporting and post-marketing safety 
studies to ascertain a positive benefit risk balance. 
Despite these measures, undesirable drug effects involving the kidney, either 
through direct kidney damage or as a result of modified kidney function, still do occur 
in current clinical practice. First, a substantial number of medicines that are currently 
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available, were approved years ago, in a period with less stringent requirements with re-
gard to (pre-authorization) clinical studies. Second, it is well known that the population 
and conditions in clinical trials do not necessarily reflect large-scale drug use in clinical 
practice. In general, clinical trial patients are younger and healthier than the population 
which ultimately uses the medicine in real life (10). This is illustrated with the example 
of acute renal failure after use of dronedarone, an anti-arrhythmic drug, in patients with 
heart failure. When this adverse drug reaction was further investigated, it was observed 
that patients with heart failure were underrepresented in the dronedarone trials ex-
plaining why acute renal failure was only identified post-registration. If a medicine is 
metabolized or excreted via the kidney, patients with impaired kidney function might 
especially be at risk to develop adverse drug reactions.  Third, potential nephrotoxic 
effects of medication might be enhanced when used in combination with other neph-
rotoxic drugs. Again, as clinical studies are generally conducted in a selected patient 
population, according to strict protocols, it is difficult to investigate all potential drug 
interactions. An example of drug-drug interactions resulting in increased nephrotoxicity 
is the combined use of non-steroidal anti-inflammatory drugs with tenofovir disoproxil 
fumarate, an antiretroviral drug (11). Fourth, as adverse drug reactions might be rare 
and idiosyncratic, clinical studies often have insufficient sample size to demonstrate a 
difference between treatment arms. Because of their infrequent nature, these adverse 
drug reactions might be less interesting from a population perspective.  However for 
the individual patient, early recognition of such adverse drug reactions remains highly 
important. Examples include proton-pump inhibitor induced acute interstitial nephritis 
(12) and benzodiazepine induced hyponatremia (13). 
All of the above mentioned arguments underline the importance of post-marketing 
studies to better characterize the safety profile of drug therapy in the clinical setting. 
These post-marketing studies complement spontaneous reporting systems, which 
might identify but not quantify new drug safety issues. [These post-marketing studies 
might then also be used to evaluate how safety measures laid down in the summary 
of product characteristics result in the appropriate actions in clinical practice to avoid 
adverse drug reactions.  
Aims and outline of this thesis
The objectives of this thesis are the following: 
• to describe the epidemiology of chronic kidney disease in the general population
• to study the association between the use of drugs and renal function decline
• to study the association between the use of drugs and water and electrolyte balance
• To check adherence to guidelines on kidney function monitoring upon initiation of 
antihypertensive drug treatment
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The epidemiology of chronic kidney disease is described in chapter 2. For this 
research, we used data from the Integrated Primary Care Information (IPCI) project, an 
electronic primary care information database from the Netherlands including more than 
1.1 million individuals. In this paper, we describe the incidence and prevalence of CKD, 
stratified by gender, age category and calendar year. 
The second and main objective of this thesis was to identify and quantify undesir-
able renal effects of medicines with data from the Rotterdam Study, a large prospective 
population-based cohort study among elderly, and from the IPCI project.
Effects of medicines which may cause kidney damage are described in chapter 3, 
including the results of a study on the effects of overanticoagulation and renal function 
decline (chapter 3.1) and the results of a study that describes the occurrence of simple 
renal cysts in relation to serum uric acid levels. This association was relevant for the 
research as outlined in this thesis as uric acid levels may be increased by several drugs 
such as diuretics (chapter 3.2). Effects of medicines that are possibly mediated through 
the kidney are described in chapter 4.  The important role of the kidney in the body’s 
regulation of the sodium and water might be disrupted by medicines. We investigated 
whether diuretics with a similar indication of use (chlorthalidone and hydrochlorothia-
zide) are differently associated with hyponatremia (chapter 4.1). Also, we investigated 
the association of antidepressants and hyponatremia (chapter 4.2), benzodiazepines 
and hyponatremia (chapter 4.3), and medicines in relation to hypovolemia (chapter 4.4).
As part of the fourth objective we studied the adherence to renal function monitor-
ing guidelines in patients starting antihypertensive therapy with diuretics and renin-
angiotensin system inhibitors (chapter 5). 
In Chapter 6, we discuss the main findings of the studies included in this thesis and 
we provide suggestions for future research. 
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ABStrACt
Background 
Because most population-based studies on the epidemiology of chronic kidney disease 
(CKD) are cross-sectional, there is, except for end-stage renal disease, hardly any infor-
mation on incidence rates.
methods
We conducted a retrospective cohort study in a dynamic population, using data of 
784,563 adult participants retrieved from the Integrated Primary Care Information 
database, a primary care database containing the complete electronic longitudinal 
medical records. CKD (both incidence and prevalence) was based on (1) an increased 
urine albumin-to-creatinine ratio, (2) a decreased estimated glomerular filtration rate, or 
(3) explicit statement in the medical record. Results were stratified by age according to 
the WHO standard population, sex, and diabetes mellitus.
results
Based on a single measurement only, the incidence rate of CKD in adults was 1,213 per 
100,000 person-years, and 6.7 percent of the adult population had a prevalent diagnosis 
of CKD. The incidence rate increased by age and was the highest in participants with 
diabetes with an incidence of 25,000 per 100,000 person-years, affecting over 75 percent 
of participants with diabetes.
Conclusions
This is the first study to report the incidence rates of all stages of CKD for the entire adult 
population, stratified by sex, 5-year age groups, and diabetes. Our data demonstrate 
that the incidence of CKD increases with age and is the highest in participants with 
diabetes mellitus.
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IntroDuCtIon
Background
The prevalence of chronic kidney disease (CKD) has been widely studied in population-
based, cross-sectional studies, with marked heterogeneity in prevalence data ranging 
from 19 to 71 percent for the highest age category [1-3], probably due to selection bias 
[4]. Limited information is available on (age-specific) incidence rates for CKD [2, 5-13]. 
CKD is associated with an increased risk of hospitalization, cardiovascular and 
all-cause mortality and constitutes a major health problem with substantial healthcare 
costs [14-18]. A recent meta-analysis showed that the relative risk of mortality, stratified 
by estimated Glomerular Filtration Rate (eGFR), is similar in those with and without dia-
betes [19]. This suggests that the underlying CKD is an important predictor for mortality. 
Another meta-analysis reported a similar pattern in patients with hypertension [20] 
emphasizing the importance of CKD as a predictor of clinical outcomes [19, 21].
objective
The objective of this study was to investigate the epidemiology, in particular the 
incidence, of CKD using prospectively gathered electronic health care records from a 
community-dwelling adult population. We studied the incidence and prevalence of CKD 
in the adult population stratified by sex, 5 year age categories (WHO standard popula-
tion) [22], and the presence of diabetes mellitus. 
mEtHoDS
Setting
All data were retrieved from the Integrated Primary Care Information (IPCI) project, a 
longitudinal observational, dynamic database which contains the electronic medical 
records of a group of 150 general practitioners (GPs) in the Netherlands. In the Dutch 
health care system, the GP plays a pivotal role and acts as a gatekeeper of medical 
care and information. All persons are registered with a GP, independent of their health 
status. Details of the IPCI database have been described elsewhere [23, 24]. Briefly, the 
database contains the complete electronic medical records of approximately 1,000,000 
patients. These records contain anonymous longitudinal data on patient demographics, 
symptoms and diagnoses (coded and in free text), referrals, laboratory findings, hospi-
talizations, discharge letters, and drug prescriptions (inclusive indication and dosage 
regimen). To maximize completeness of the data, general practitioners participating in 
the IPCI project are not allowed to maintain a system of paper-based records besides the 
electronic medical records. The system complies with European Union guidelines on the 
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use of data for medical research and has been proven valid for pharmaco-epidemiologic 
studies [24]. The Scientific and Ethical Advisory Board of the IPCI project approved the 
study.
Study design
Retrospective cohort study in a dynamic population 
Participants
The source population comprised all adults (20 years or older) who were registered with 
a GP for at least 365 days. The study period started on January 1st, 1996 and ended on 
March 1st, 2011. Subjects with (a history of ) a renal transplant prior to study entry were 
excluded. Subjects were followed until renal transplant, death, transfer out of practice, 
last data draw-down, or end of the study period, whichever came first. 
outcome
CKD was based on abnormalities in estimated glomerular filtration rate (eGFR), albumin-
uria as a marker of kidney damage, or an explicit statement in the medical record, and 
stratified by stages 1-5 [25]. The eGFR was obtained from the equation published by the 
Chronic Kidney Disease Epidemiology (CKD-EPI) Collaboration [26]:
eGFR = 141 * min(Scr/κ,1)α * max(Scr/κ,1)-1.209 * 0.993Age * 1.018 [if female] * 1.159 [if 
black].
Where Scr is serum creatinine (mg/dL), κ is 0.7 for females and 0.9 for males, α is –0.329 
for females and –0.411 for males, min indicates the minimum of Scr/κ or 1, and max 
indicates the maximum of Scr/κ or 1.
For the urine Albumin to Creatinine Ratio (ACR) we used a cut-off of 3.5 mg/mmol 
(~30mg/g) for women and 2.5 mg/mmol (~22mg/g) for men for (micro-) albuminuria 
as a marker for kidney damage to define stages 1 and 2 of CKD. The last eGFR before 
the ACR measurement was used to distinguish between stage 1 and 2 of CKD. If no SCR 
measurement was available, the eGFR was assumed to be >90 ml/min/1.73m2.
In addition the complete electronic medical record was screened using an algo-
rithm including “kidney/renal” in combination with “insufficiency/failure”, “renal replace-
ment therapy”, “dialysis” and “transplantation”.
A definite diagnosis of CKD was made according to KDIGO guidelines if there were 
two measurements, at least 90 days apart, indicating either (micro-) albuminuria or 
eGFR<60 ml/min/1.73m2, or two explicit statements in the medical record (at least 90 
days apart) indicating CKD. The first date was used as index date. A ‘possible diagnosis’ 
was based on a single measurement or at least one explicit statement indicating CKD 
in the medical record. Subjects with a statement in the medical record indicating CKD 
before the start of follow-up that could not be confirmed by subsequent measurements 
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were excluded from the stage specific analysis. Subjects with a statement in the medical 
record indicating CKD after start of follow-up that could not be confirmed by subse-
quent measurements were not accounted and follow-up was censored from that date. 
The following stages were used: stage 1 “eGFR≥90 ml/min/1.73m2 with kidney dam-
age”, stage 2 “eGFR 60-89 ml/min/1.73m2 with kidney damage”, stage 3 “eGFR 30-59 ml/
min/1.73m2”, stage 4 “eGFR 15-29 ml/min/1.73m2”, stage 5 “eGFR <15 ml/min/1.73m2 or 
dialysis” [27]. 
Diabetes mellitus
Because diabetes is a risk factor for the development of End Stage Renal Disease (ESRD) 
we stratified our analyses by underlying diabetes [14-16]. The diagnosis of diabetes was 
based on a prescription of a drug within the World Health Organization (WHO) Anatomi-
cal Therapeutic Chemical (ATC) classification system “A10” (Drugs used in diabetes) [28].
Statistical analysis
The incidence rate was determined by dividing the number of cases by the total number 
of person-years of follow-up. Subjects were censored on the date of first diagnosis for 
the respective disease stage. Overall incidence rates were calculated for the adult study 
population. Incidence rates were expressed per 100,000 person-years. Ninety-five per-
cent confidence intervals were calculated based on a Poisson distribution [29].
Prevalence was determined by dividing the number of cases by the number of per-
sons with follow-up in the study population on 1st January of each calendar year. Cases 
included subjects with a prevalent diagnosis or an incident diagnosis of CKD prior to the 
1st of January. As CKD is a progressive disease, subjects were allowed to move between 
stage specific categories of CKD. Results displayed were weighted for the calendar year 
specific denominator.  Ninety-five percent confidence intervals were calculated based 
on normal distribution.
The results on the incidence and prevalence of CKD were stratified for age accord-
ing to the WHO standard population, sex, and presence of diabetes mellitus [30]. 
rESultS
Participants
The source population consisted of 784,856 adult subjects with a valid history of at least 
365 days in the IPCI database. A total of 293 participants were excluded because of a 
history of a renal transplant prior to start of follow-up, leaving 784,563 subjects available 
for analysis.  
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Descriptives
The median age of the study population was 44.4 years at start of follow-up (Interquar-
tile Range [IQR]: 31.7 – 59.2 years), 48.1% were males and 4.3% of participants had a 
diagnosis of diabetes. A total of 2.1 million person-years of follow-up was available for 
the study population, the maximal duration of follow-up being 10.7 years, with a median 
of 2.3 years (IQR: 1.3-3.4 years). Detailed population characteristics are available (online 
table 1 and 2). 
outcome data
For the study population, 1,379,097 eGFR measurements and 178,425 ACR measure-
ments were available. A total of 42,870 participants had evidence of CKD prior to start of 
follow-up; of these, 41,343 subjects had an abnormal measurement and in an additional 
1,437 subjects the presence of CKD was explicitly stated in the medical record with no 
measurement available prior to start of follow-up. There were 23,643 incident cases of 
CKD; of these, 22,722 were based on abnormal measurements and an additional 921 
cases were based on explicit statements in the medical record.
main results
Incidence of CKD
The overall incidence of a possible diagnosis of CKD in adults was 1,213 per 100,000 
person-years (95% CI 1,198-1,283 per 100,000 person-years). The overall incidence of a 
definite diagnosis of CKD was 479 per 100,000 person-years (95% CI 470-489 per 100,000 
person-years). Confirmation of the first incident abnormal SCR or ACR measurement by 
a subsequent abnormal measurement (as required for definite diagnosis of CKD), was 
obtained after a median of 301 days (Interquartile Range 148-444 days). 
For a possible diagnosis, the incidence rate was higher in females (1,362 per 100,000 
person-years) than in males (1,029 per 100,000 person-years), p<0.001. The incidence 
rates were higher in subjects with diabetes (7,120 per 100,000 person-years) than in 
those without (973 per 100,000 person-years; p<0.001). The highest incidence rate of 
CKD was reached in women with diabetes, older than 85 years (25,000 per 100,000 
person-years). Results stratified by age, sex and diabetes are shown in figure 1 and table 
1. There was a marked increase of the incidence rate for stage 3 and 4 CKD as of the age 
of 50 years and older, both in subjects with and without diabetes, whereas the incidence 
rate of stage 2 CKD only increased with age in subjects with diabetes. (Figures 2a-e) 
Comprehensive stage-specific tables are available (online tables 3A-E)
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abnormal measurement, and in an additional 1,437 partic-
ipants, the presence of CKD was explicitly stated in the
medical record with no measurement available prior to the
start of follow-up. There were 23,643 incident cases of
CKD; of these, 22,722 were based on abnormal measure-
ments, and an additional 921 cases were based on explicit
statements in the medical record.
Incidence of CKD
The overall incidence of a possible diagnosis of CKD in
adults was 1,213 per 100,000 person-years (95 % CI
1,198–1,283 per 100,000 person-years). The overall
incidence rates for stages 1–5 CKD were 205, 11, 859,
41, and 24 per 100,000 person-years. The overall inci-
dence of a definite diagnosis of CKD was 479 per
100,000 person-years (95 % CI 470–489 per 100,000
person-years). The overall incidence rates for stages 1–5
CKD were 60, 5, 370, 25, and 18 per 100,000 person-
years. Confirmation of the first incident abnormal SCR or
ACR measurement by a subsequent abnormal measure-
ment (as required for definite diagnosis of CKD) was
obtained after a median of 301 days (interquartile range
148–444 days).
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abnormal me surement, and in an additional 1,437 partic-
ipants, the pres nce of CKD was explicitly stated in the
medical record with no measurement available prior to the
start of follow-up. There w 23,643 incident cases of
CKD; of these, 22,722 were based on abnormal me sure-
ments, and an a ditional 921 cases were based on explicit
statemen s in the medical re ord.
Incidence of CKD
The overall incidence of a p ssible d agnosis of CKD in
adults was 1,213 per 100,000 person-years (95 % CI
1,198–1,283 per 100,000 person-years). The ov rall
incidence rates for tages 1–5 CKD were 205, 11, 859,
41, and 24 per 100,00 person-years. The overall inci-
dence of a definite diagnosis of CKD was 479 per
100,000 person-years (95 % CI 470–489 per 100,000
person-years). The overall incidence rates for tages 1–5
CKD were 60, 5, 370, 25, and 18 per 100,000 person-
years. Confirmation of the first incident abnormal SCR or
ACR measurement by a subseq ent abnormal me sure-
ment (as required for definite diagnosis of CKD) was
obtained aft r median of 301 days (interquartile range
148–44 days).
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figur  2 Incid e of chronic ki ey di a  (possible diagnosis): 2a chronic kidney disease stage 1; 2b 
chronic kidney disease stage 2; 2c chronic kidney disease stage 3; 2d chronic kidney disease  stage 4; 2e 
chronic kidney disease stage 5
For the urine albumin-to-creatinine ratio (ACR), we
used a cutoff of 3.5 mg/mmol (*30 mg/g) for women and
2.5 mg/mmol (*22 mg/g) for men for (micro-) albumin-
uria as a marker for kidney damage to define stages 1 and 2
of CKD. The last eGFR before the ACR measurement was
used to distinguish between stages 1 and 2 of CKD. If no
SCR measurement was available, the eGFR was assumed
to be[90 ml/min/1.73 m2.
In addition, the complete electronic medical record was
screened for an explicit statement indicating CKD, using an
algorithm including ‘‘kidney/renal’’ in combination with
‘‘insufficiency/failure’’, ‘‘renal replacement therapy’’,
‘‘dialysis’’, and ‘‘transplantation’’.
A definite diagnosis of CKD was made according to
KDIGO guidelines if there were two measurements, at least
90 days apart, indicating either (micro-) albuminuria or
eGFR\ 60 ml/min/1.73 m2, or two explicit statements in
the medical record (at least 90 days apart) indicating CKD.
The first date was used as index date. A ‘‘possible diag-
nosis’’ was based on a single abnormal measurement or
explicit statement indicating CKD in the medical record.
Participants with a statement in the medical record indi-
cating CKD before the start of follow-up that could not be
confirmed by subsequent measurements were excluded
from the stage-specific analysis. Participants with a state-
ment in the medical record indicating CKD after start of
follow-up that could not be confirmed by subsequent
measurements were not accounted, and follow-up was
censored from that date. The following stages were used:
stage 1 ‘‘eGFR C 90 ml/min/1.73 m2 with kidney dam-
age’’, stage 2 ‘‘eGFR 60–89 ml/min/1.73 m2 with kidney
damage’’, stage 3 ‘‘eGFR 30–59 ml/min/1.73 m2’’, stage 4
‘‘eGFR 15–29 ml/min/1.73 m2’’, stage 5 ‘‘eGFR\ 15 ml/
min/1.73 m2 or dialysis’’ [28].
Diabetes mellitus
Because diabetes is a risk factor for the development of
end-stage renal disease (ESRD), we stratified our analyses
by underlying diabetes [14–16]. The diagnosis of diabetes
was based on a prescription of a drug within the World
Health Organization (WHO) Anatomical Therapeutic
Chemical (ATC) classification system ‘‘A10’’ (drugs used
in diabetes) [29].
Statistical analysis
The incidence rate was determined by dividing the number
of cases by the total number of person-years f follow-up.
Participants were censored on the date of first diagnosi for
the respective disease stage. Overall incidence r tes were
calculated for the adult study population. Incid c rates
were expressed per 100,000 person-years. Ninety-five
percent confidence intervals were calculated based on a
Poisson distribution [30].
Prevalence was determined by dividing the number of
cases by the number of persons with follow-up in the study
population on January 1 of each calendar year. Cases
included participants with a prevalent diagnosis or an
incident diagnosis of CKD prior to the 1st of January. As
CKD is a progressive disease, participants were allowed to
move between stage-specific categories of CKD. Results
displayed were weighted for the calendar year-specific
denominator. Ninety-five percent confidence intervals were
calculated based on normal distribution.
The results on the incidence and prevalence of CKD
were stratified for age according to the WHO standard
population, sex, and presence of diabetes mellitus [31].
Results
The source population consisted of 784,856 adult partici-
pants with a valid history of at least 365 days in the IPCI
database. A total of 293 participants were excluded because
of a history of a renal transplant prior to start of follow-up,
leaving 784,563 participants available for analysis.
The median age of the study population was 44.4 years at
the start of follow-up [interquartile range (IQR)
31.7–59.2 years]; 48.1 % were males and 4.3 % of partic-
ipants had a diagnosis of diabetes. A total of 2.1 million
person-years of follow-up were available for the study
population, the maximal duration of follow-up being
10.7 years, with a median of 2.3 years (IQR 1.3–3.4 years).
Detailed population characteristics are available (online
table 1 and 2).
For the study population, 1,379,097 eGFR measure-
ments and 178,425 ACR measurements were available. A
total of 42,780 participants had evidence of CKD prior to
the start of follow-up; of these, 41,343 participants had an
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figure 1 Incidence of Chronic Kidney Disease (possible diagnosis) - all stages
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For a possible diagnosis, the incidence rate was higher
in females (1,362 per 100,000 person-years) than in males
(1,029 per 100,000 person-years), p\ 0.001. The inci-
dence rates were higher in participants with diabetes (7,120
per 100,000 person-years) than in those without (973 per
100,000 person-years; p\ 0.001). The highest incidence
rate of CKD was reached in women with diabetes,
aged C 85 years (25,000 per 100,000 person-years).
Results stratified by age, sex, and diabetes are shown in
Fig. 1 and Table 1. There was a marked increase in the
incidence rate for stages 3 and 4 CKD as of the age of
50 years and older, both in participants with and without
diabetes, whereas the incidence rate of stage 2 CKD only
increased with age in participants with diabetes. (Fig-
ures 2a–e) Comprehensive stage-specific tables are avail-
able (online tables 3A-E).
Prevalence of CKD
The overall prevalence of CKD (possible diagnosis) was
6.7 % (95 CI % 6.6–6.7 %) and 0.55, 0.03, 5.38, 0.41,
0.16 % for stages 1–5. The overall prevalence of CKD
(definite diagnosis) was 5.1 % (5.1–5.1 %) and 0.32, 0.03,
4.17, 0.38, 0.15 % for stages 1–5. In line with the incidence
data, the prevalence of CKD increased with age, female
sex, and diabetes to more than 75 % in diabetic female
participants aged C 85 years as shown in Table 2 and
Fig. 3. Prevalence of all stages of CKD, except for stage 1,
increased with age (Fig. 4a–e). In participants with diabe-
tes, the prevalence of stages 1 and 2 CKD was higher in
males. In participants without diabetes, stage 5 CKD was
significantly more prevalent in males than in females from
the age of 75 onward (Fig. 4e). Irrespective of the presence
of diabetes, the prevalence of stage 3 CKD was higher in
females than in males for all age groups. Comprehensive
stage-specific tables are available (online tables 4A–E).
Discussion
This is the first study to report incidence rates of CKD for
the entire community-dwelling adult population for stages
1–5 of CKD, stratified by sex, 5-year age groups, and
diabetes. The overall incidence of CKD in adults in our
Table 2 Overall prevalence of chronic kidney disease
Age (years) No diabetes Diabetes
Males Females Males Females
Cases* % 95 %CI Cases* % 95 %CI Cases* % 95 %CI Cases* % 95 %CI
20–24 112 0.1 (0.1–0.1) 113 0.1 (0.1–0.1) 3 1.0 (0.0–2.1) 4 1.4 (0.0–2.7)
25–29 89 0.1 (0.1–0.1) 172 0.2 (0.1–0.2) 7 2.0 (0.5–3.5) 29 7.3 (4.7–9.8)
30–34 119 0.1 (0.1–0.1) 239 0.2 (0.2–0.3) 55 7.9 (5.9–9.9) 45 6 (4.4–7.8)
35–39 261 0.2 (0.2–0.3) 430 0.4 (0.3–0.4) 108 8.8 (7.2–10.4) 100 8.2 (6.6–9.7)
40–44 400 0.3 (0.3–0.4) 803 0.6 (0.6–0.7) 194 9.0 (7.8–10.2) 189 10.0 (8.6–11.3)
45–49 746 0.6 (0.6–0.7) 1,345 1.1 (1.1–1.2) 324 9.4 (8.4–10.4) 301 11.0 (9.8–12.1)
50–54 1,088 1.0 (1.0–1.1) 2,346 2.2 (2.1–2.3) 565 11.8 (10.9–12.7) 583 14.4 (13.3–15.5)
55–59 1,925 2.1 (2.0–2.2) 3,651 3.9 (3.8–4.1) 962 13.4 (12.6–14.2) 877 16.4 (15.4–17.3)
60–64 3,471 4.3 (4.1–4.4) 6,121 7.3 (7.1–7.4) 1,723 18.9 (18.0–19.7) 1,562 21.9 (21.0–22.9)
65–69 4,779 8.4 (8.2–8.6) 7,777 12.5 (12.3–12.8) 2,189 26.3 (25.4–27.3) 2,254 30.7 (29.7–31.8)
70–74 6,720 15.2 (14.9–15.5) 11,026 21.2 (20.8–21.5) 2,815 36.1 (35.1–37.2) 3,169 40.5 (39.4–41.6)
75–79 8,376 25.7 (25.2–26.1) 13,549 30.8 (30.3–31.2) 3,161 49.5 (48.3–50.7) 4,347 53.9 (52.9–55.0)
80–84 7,465 36.8 (36.1–37.4) 14,318 42.9 (42.4–43.5) 2,574 61.3 (59.8–62.7) 4,475 67.1 (66.0–68.3)
85? 6,033 48.2 (47.3–49.0) 5,818 54.3 (53.8–54.9) 1,528 72.9 (71.0–74.8) 3,973 77.1 (76.0–78.3)
* Chronic kidney disease was determined from a single abnormal measurement (possible diagnosis)
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 figure 3 Prevalence of Chronic Kidney Disease (possible diagnosis) - all stages
study was 1,213 per 100,000 person-years. The incidence
rate increased with age and was the highest in females and
in participants with diabetes mellitus. Indeed, in female
diabetic participants, the incidence rate was close to 25,000
per 100,000 person-years. For stage 1 of CKD—especially
in participants with diabetes—the prevalence decreased
with advancing age, despite an increase in incidence rate,
possibly due to a more rapid decline in eGFR with
reclassification to prevalent stage 3 of CKD or excess
mortality. Strengths of our data are the population-based
setting, large sample size, and the use of laboratory data to
define CKD. In addition, the risk of selection bias is unli-
kely as almost all inhabitants of the Netherlands are reg-
istered with a GP, and data are collected as part of routine
patient care, irrespective of any research questions.
As for all observational research, our study has potential
limitations as well. Diagnostic bias might be a concern as
laboratory results were taken in the process of day-to-day
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study was 1,213 per 100,000 person-years. Th incidence
rate increased with age and was the highest in females and
in participants with diabetes mellitus. Indeed, i f male
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figur  4 Prevalenc  of hronic kidne  isease (possibl  diagnosis): 2a chronic kidn y dis ase stage 1; 2b 
chronic kidney disease stage 2; 2c chronic kidney disease stage 3; 2d chronic kidney disease  stage 4; 2e 
chronic kidne  disease stage 5
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Prevalence of CKD
The overall prevalence of CKD was 6.7 % (95CI% 6.6 – 6.7 %) for a possible diagnosis of 
CKD and 5.1% (5.1 – 5.1%) for a definite diagnosis of CKD. In line with the incidence data, 
the prevalence of CKD, increased with age, female sex, and diabetes to more than 75% 
in diabetic female subjects aged ≥85 years as shown in table 2 and figure 3. Prevalence 
of all stages of CKD, except for stage 1, increased with age (figure 4a-e). In patients 
with diabetes, the prevalence of stage 1 and 2 CKD was higher in males, especially in 
patients with diabetes. In patients without diabetes, stage 5 CKD was significantly more 
prevalent in males than in females from the age of 75 onwards (figure 4e). Irrespective 
of the presence of diabetes, the prevalence of stage 3 CKD was higher in females than 
in males for all age groups. Comprehensive stage-specific tables are available (online 
tables 4A-E).
DISCuSSIon
Key results
This is the first study to report incidence rates of CKD for the entire community-dwelling 
adult population for stage 1-5 of CKD, stratified by sex, 5-year age groups and diabetes. 
The overall incidence of CKD in adults in our study was 1,213 per 100,000 person-years. 
The incidence rate increased with age and was the highest in females and in patients 
with diabetes mellitus. Indeed, in female diabetic patients, the incidence rate was close 
to 25,000 per 100,000 person-years. For stage 1 of CKD - especially in patients with dia-
betes – the prevalence decreased with advancing age, despite an increase in incidence 
rate, possibly due to a more rapid decline in eGFR with reclassification to prevalent stage 
3 of CKD or excess mortality. Strengths of our data are the population-based setting, 
large sample size and the use of laboratory data to define CKD. In addition, risk of selec-
tion bias is unlikely as almost all inhabitants in the Netherlands are  registered with a 
GP and data are collected as part of routine patient care, irrespective of any research 
questions. 
limitations 
As for all observational research, our study has potential limitations as well. Diagnostic 
bias might be a concern as laboratory results were taken in the process of day-to-day 
patient care – in asymptomatic patients this could imply that the incidence and preva-
lence of CKD are underestimated as no laboratory results were available. Estimated GFR 
might not adequately reflected actual GFR, especially in those with diabetes [31-38]. Our 
data reflect clinical practice because there is no general accepted formula to estimate 
GFR from serum creatinine with adjustment for diabetes at this point in time. In addition, 
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potential misclassification is reported to be limited for GFR<90 ml/min/1.73m2 [31]. 
Finally, patients with stage 5 CKD are detected, however, for those patients referred to 
the specialist,, there is limited correspondence after initial diagnosis. Therefore, it is not 
possible to evaluate whether the patient progressed to end-stage renal disease. 
Interpretation
Few studies have reported incidence rates for CKD in the general population [5-13]. Of 
those studies that did, comparison of incidence data is difficult as different case defini-
tions of CKD were used. The overall prevalence of our study is in line with findings from 
previous cross-sectional studies, although there is substantial heterogeneity among 
these studies as well, with reported prevalence rates of 19 to 71 percent in the older 
age categories (table 3) [2]. In prospective studies, where data are progressively col-
lected during the study period, it is possible to confirm a first abnormal measurement 
(indicating CKD), with a second abnormal measurement (“definite diagnosis”) within 
a reasonable time. In our study population that reflects day-to-day clinical practice, a 
first abnormal measurement is followed by a second measurement only after a median 
tABlE 3 Prevalence of reduced estimated Glomerular Filtration Rate (< 60 ml/min/1.73m2)
Age
(years)
IPCI: 
(Current 
Study) 
subjects
IPCI 
(Current 
Study)‡
Viktorsdottir 
et al. 
2005[39]
Coresh et al. 
2005 [40] 
*,**
Nitsch et al. 
2006[41]
Cirillo et 
al. 2006 
[42]
Hallan et 
al. 2006   
[3]*
Brown 
et al. 
2005 
[43]
McClellan 
et al. 2006 
[1]
20 to 24 98,712 0.0 NA
0.2
†4.6
†0.2
0.2
†2.5
NA
25 to 29 73,241 0.1 NA
0.3
NA
30 to 34 72,520 0.1 NA
5.7
NA
35 to 39 79,139 0.2 1.5
0.4
NA
40 to 44 78,280 0.3 1.9
1.8 1.4
NA
45 to 49 73,208 0.7 2.9
1.9
10.3
19.3
50 to 54 64,338 1.4 4.2
55 to 59 58,002 2.8 5.3
15.2 6.2 31.6
60 to 64 53,439 5.8 8.8
7.2 6.3
26.765 to 69 39,505 11.0 26.4
25.3
12.8 51.3
70 to 74 32,973 19.3 28.5
24.9 18.6
75 to 79 26,934 30.4 28.6
32.7 43.1
62.7
80 to 84 19,286 43.0
43.8
85+ 14,986 54.7 71.0
*categories 15-29 and 30-59 ml/min/1.73m2 combined; **1988-1994 data; †age 18 and above; ‡ Prevalent 
Chronic Kidney Disease, stage 3,4 and 5 (possible diagnosis)
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301 days (IQR: 148-444 days). Therefore, the use of a definite diagnosis of CKD likely 
underestimates the real values in a population-based study. 
In conclusion, this study is the first to report incidence rates for stages 1-5 of CKD 
stratified by age, sex and diabetes. CKD is a major health problem, which affects the 
majority of the population at older age, especially in those with diabetes. 
Generalizability
Our results are generalizable to a western, predominantly Caucasian population.   
funding
The first author works for the Medicine Evaluation Board, the drug regulatory agency 
in the Netherlands. The author declares not to have any competing interests. The views 
expressed in this article are the personal view of the author and may not be understood 
or quoted as being made on behalf of or reflecting the position of the regulatory agency.
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Chapter 3 
Drug use and renal function decline

Chapter 3.1 
overanticoagulation and renal 
function decline
Jan C. van Blijderveen, Katia M. Verhamme, Loes E visser, 
Silvana A. Romio, Peter N. Buhre, Miriam C. Sturkenboom, 
Albert Hofman, Sabine M. Straus, Bruno H. Stricker
Overanticoagulation is associated with renal function decline. 
J Nephrol. 2013 Jul-Aug;26(4):691-8.
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ABStrACt
Background
Recent studies suggest that overanticoagulation impairs renal function in patients on 
warfarin therapy, due to renal tubular obstruction from glomerular hemorrhage.
methods
Data from the Rotterdam Study (The Netherlands), a prospective population-based 
cohort study of patients 55 years and older, were used for this study. Information on 
vitamin K antagonist (VKA) therapy was obtained from the regional anticoagulation 
clinic, where prothrombin times were monitored every 1-6 weeks depending on target 
level and stability of the international normalized ratio (INR). Linear regression was 
performed to study the association between the cumulative number of instances of 
overanticoagulation (defined as a measurement of an INR >6.0) and the change in renal 
function between baseline and third examination round based on estimated glomerular 
filtration rate (CKD-EPI equation). Age, sex, baseline renal function, baseline and incident 
heart failure, and indication for VKA therapy were included as potential confounders.
results
Information was available for analysis on 2,802 study participants in whom overantico-
agulation was significantly associated with a decline in renal function, after adjustment 
for confounding by age, sex, heart failure, baseline glomerular filtration rate and indica-
tion for VKA therapy (-0.180 ml/min per 1.73 m(2) per year per event for INR >6.0, p = 
0.030).
Conclusions
Overanticoagulation (INR >6.0) is associated with a decline in renal function. Further 
studies are needed to evaluate the causal role of different degrees of overanticoagula-
tion, including transient effects, in high-risk groups, and the association with the new 
oral anticoagulants.
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IntroDuCtIon
Background
Vitamin K antagonists (VKA) comprise several therapeutic agents, including warfarin, 
acenocoumarol and phenprocoumon. Warfarin is a commonly used anticoagulant, with 
roughly two million persons initiating warfarin each year in the United States alone [1]. 
In the Netherlands, the majority of patients are treated with acenocoumarol or phen-
procoumon. In 2010, approximately 398,000 patients of the Dutch population of 16.6 
million people were treated with VKA[2-3]. 
An association between warfarin and renal function has been described in two case re-
ports and one case series of 9 patients [4-6]. More recently, two cohort studies reported 
overanticoagulation, defined as an International Normalized Ratio (INR)>3.0, as a cause 
of decline of renal function in patients on warfarin therapy [7-10]
Because of the risk of bleeding, anticoagulant treatment is tightly monitored via INR, 
which has been investigated in multiple studies [11-22]. However these did not address 
specific effects of overanticoagulation on renal function. 
objective
In this study we investigated whether overanticoagulation, and in particular repeated 
events of INR>6.0, during VKA therapy is associated with a decline of renal function. 
Additionally, we investigated whether the association is present at a lower threshold 
for overanticoagulation, down to an INR>3.0, as previously reported from two cohort 
studies. [8-9]
SuBJECtS AnD mEtHoDS
Study design
We used data from baseline and the third examination round of the Rotterdam Study, 
a prospective population-based cohort study designed to study chronic diseases in the 
elderly.
Setting
In the Rotterdam study, 10,275 inhabitants of the Rotterdam district Ommoord, aged 
55 years or older, were invited to the baseline examination round of the study. The first 
cohort included 7,983 participants. Serum Creatinine (SCR) was measured at baseline 
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(1989-1993) and during the third examination round (1997-1999). The design of the 
Rotterdam study have been described elsewhere [23].
Participants
For this study, we used data of participants who had a baseline SCR measurement and a 
SCR measurement during the third examination round.
Variables
The outcome of this study is the difference in estimated Glomerular Filtration Rate (eGFR) 
between first and third examination round. eGFR was estimated with the equation of the 
Chronic Kidney Disease Epidemiology (CKD-EPI) Collaboration, which is a follows [24]: 
eGFR = 141 * min(Scr/κ,1)α * max(Scr/κ,1)-1.209 * 0.993Age * 1.018 [if female] * 1.159 [if 
black]  ;Where Scr is serum creatinine (mg/dL), κ is 0.7 for females and 0.9 for males, α is 
–0.329 for females and –0.411 for males, min indicates the minimum of Scr/κ or 1, and 
max indicates the maximum of Scr/κ or 1.
The following variables were included as potential confounders: age, sex, baseline renal 
function, baseline and incident heart failure, and indication for VKA therapy. 
Data sources
Glomerular Filtration Rate was estimated from serum creatinine.  Age, sex and baseline 
renal function were determined at the first (baseline) examination round. Heart failure 
at the first examination round was assessed using a validated score of the European 
Society of Cardiology. [25-26]. Cases of incident heart failure were obtained by continu-
ous monitoring of participants and case validation [25, 27]. 
Overanticoagulation, duration and indication for VKA therapy were obtained from the 
regional anticoagulation clinic, which monitors all outpatients in the Rotterdam region. 
This clinic has a near complete coverage of participants from the Rotterdam Study. Data 
were available from as of January 1984 to September 2009. The physician who treats the 
patient decides about the type of anticoagulant prescribed and the prothrombin times 
are monitored every 1–6 weeks, depending on the target level and stability of the INR.
[28]  The cumulative number of events of overanticoagulation, defined as an INR>6.0 
was calculated for the period between baseline and third examination round. We used 
the most recent indication for VKA therapy prior to the third examination round. The 
number of individual indications was reduced to four groups, (1) treatment of deep 
venous thrombosis and pulmonary embolism, (2) perioperative, (3) peripheral arterial 
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and structural heart disease, and (4) atrial fibrillation and other heart rhythm disorders, 
based on their expected potential to confound the studied association.
Statistical methods
We included overanticoagulation as a linear variable in the model. Age was included as 
a linear variable. Sex, baseline and incident heart failure, indication for VKA therapy and 
baseline renal function were included as a categorical variables. For the latter, stages 
G1-5 were used according to Kidney Disease: Improving Global Outcomes (KDIGO) clini-
cal practice guidelines [29]. 
We performed sensitivity analyses for different cut-offs of overanticoagulation (INR>3.0, 
>4.0, and >5.0). Additionally we studied a possible non-linear effect of overanticoagula-
tion categorizing the cumulative number of overanticoagulation using quartiles when 
possible and tertiles in case of low numbers or skewed distribution. 
Statistical analyses were performed using the statistical package SPSS, Version 20 (IBM; 
Armonk, N.Y., USA).
rESultS
Participants
At the baseline examination round 7,121 out of 7,983 participants provided a blood 
sample; SCR was measured in 5,280 of these samples. Of these, 4,336 participants were 
alive at the start of the third examination round and 2,910 participants provided a blood 
sample; SCR was measured in 96.2% of these samples, leaving 2,802 participants avail-
able for analysis. 
Descriptive data
Median age of the study population was 67 years, with 61% female (table 1). During the 
interval between baseline and third examination round a total of 354 participants used 
any VKA therapy. Median duration of VKA therapy was 251 days, during which a total of 
181 events of INR>6.0 were observed, being 8 events per 10,000 days of VKA therapy. 
Except for one, all had one single indication for use of VKA therapy during follow-up 
(figure 1; table 2). 
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table 1 Baseline population characteristics of participants with serum creatinine measurement during 
baseline and third examination round
Number of participants 2 802
Age at baseline examination round in years (median,IQR) 66.5 (61.1 - 71.4)
Sex - female (n,%) 1 699 (60.6)
Prevalent heart failure (n,%) 37 (1.3)
Baseline estimated  Glomerular  Filtration Rate  ml/min/1.73m2 (mean, standard deviation) 74 (13.1)
- ≥90+ ml/min/1.73m2 (n,%) 376 (13.4)
- 60-90 ml/min/1.73m2 (n,%) 2 023 (72.2)
- 30-60 ml/min/1.73m2 (n,%) 401 (14.3)
- 15-30 ml/min/1.73m2 (n,%) 0 (0.0)
- <15 ml/min/1.73m2 (n,%) 2 (0.1)
Prior use of vitamin K antagonists (n,%) 73 (2.6)
Duration of prior vitamin K antagonist use in days  (median, IQR) 89 (55 - 246)
IQR: Interquartile range; n: number; %: percentage
figure 1 Cumulative number of overanticoagulation instances during vitamin K antagonist therapy – for all 
indications. INR =international normalized ratio.
table 2 Vitamin K Antagonist therapy
Indication for VKA 
therapy
Number of 
participants
Duration of VKA therapy (days) Cumulative number of excess anticoagulation 
measurements(participants)*
Median IQR Sum INR>3.0 INR >4.0 INR >5.0 INR >6.0
Perioperative 99 78 (62;109) 10,921 288 (78 ) 74 (31) 20 (10) 6 (4)
DVT/PE 36 218 (156;939) 19,505 602 (33) 153 (25) 48 (18) 17 (10)
AF /oHRD 76 663 (214;1,501) 63,249 2,156 (75) 663 (63) 146 (47) 41 (23)
PAD / SHD 143 768 (171;1,531) 126,434 4,804 (141) 1,687 (128) 378 (9) 117 (61)
All indications 354 251 (250;1,231) 220,109 7,850 (327) 2,577 (247) 592 (174) 181 (98)
* = Participants and measurements are not mutually exclusive for different cut-offs of overanticoagulation; 
AF = Atrial Fibrillation; DVT = Deep Venous Thrombosis; INR = International Normalized Ratio; IQR = Inter-
quartile range; oHRD = Other Hearth Rhythm Disorder; PAD = Peripheral Artery Disease; PE = Pulmonary 
Embolism; SHD = Structural Heart Disease; VKA = Vitamin K antagonist
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outcome data
The median time interval between baseline and third examination round was 6.5 years, 
during which the median eGFR in the 2,802 participants changed with a median -.29 ml/
min/1.73m2/year.
main results
In the univariable analysis, there was a significant association between the cumulative 
number of instances of overanticoagulation (INR>6.0) and the change in eGFR between 
baseline and third examination round (figure 2). After adjustment for confounding fac-
tors the additional change in eGFR associated with the cumulative number of INR>6.0 
remained significant [-0.180 ml/min/1.73m2 per year per INR>6.0, p-value=0.030 (table 
3)]. Similar trends were observed if indications were analyzed separately (results not 
shown).
figure 2 Change in estimated glomerular filtration rate in participants who used vitamin K antagonist ther-
apy – per indication. AF = atrial fibrillation; DVT/PE = deep venous thrombosis/pulmonary embolism; INR = 
international normalized ratio;PAD = peripheral artery disease.
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other analysis
In univariable analysis using categories, renal function decline was significantly greater 
with a higher cumulative number of instances of overanticoagulation compared to 
the reference with the lowest cumulative number. This also applied to other cut-offs 
of INR, with exception of the 4th quartile of INR>3.0 as shown in table 4.  Trends over 
the categories of cumulative overanticoagulation, adjusted for age, sex, baseline eGFR, 
baseline and incident heart failure, and indication for VKA therapy, were not significant 
at p<0.05, except for INR>6.0. If participants were assigned to mutually exclusive cat-
egories by maximum overanticoagulation observed during follow-up, the association 
was significant for INR>6.0 after adjustment for confounding factors (results not shown). 
We examined the cause of death in the 944 participants, who died before the start 
of the third examination round. A total of 12  participants died due to chronic kidney 
disease (CKD) and two due to acute renal failure. Of these, 3 had used VKA therapy but in 
table 3 Change in estimated Glomerular Filtration Rate between baseline and third examination round
Variable estimate* p-value 95% Confidence interval
(Constant) -1.213 .000 (-1.434 ; -.992)
Baseline age above 50 years (years) -.033 .000 (-.043 ; -.023)
Female sex 
(male = referent)
.705 .000 (.567 ; .843)
Baseline eGFR (ml/min/1.73m2)
(≥90 ml/min/1.73m2 = referent)
- 60 to 89 1.143 .000 (.945 ; 1.340)
- 30 to 59 2.157 .000 (1.885 ; 2.429)
Heart failure (no heart failure during follow-up = referent)
-At baseline .505 .125 (-.141 ; 1.151)
-During follow-up -.678 .000 (-1.018 ; -.339)
Indication vitamin K antagonist therapy (no use = referent)
-DVT/PE -.453 .092 (-.980 ; .074)
-Perioperative -.149 .361 (-.470 ; .171)
–PAD / structural heart disease -.425 .007 (-.733 ; -.117)
- AF /other heart rhythm disorders -.220 .284 (-.623 ; .183)
Per event of overanticoagulation (defined as INR>6.0) -.180 .030 (-.342 ; -.017)
*  =  Change in estimated glomerular filtration rate is calculated from baseline and third examination round 
serum creatinine, fully adjusted model; AF = Atrial Fib rillation; DVT = Deep Venous Thrombosis; eGFR = esti-
mated Glomerular Filtration Rate (Chronic Kidney Disease Epidemiology Collaboration equation); INR = In-
ternational Normalized Ratio; PAD = Peripheral Artery Disease; PE = Pulmonary Embolism
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2 VKA therapy was discontinued more than 3 years before date of death. One participant 
died due to CKD while on VKA therapy for 13 months. 
DISCuSSIon 
Key results
In this paper, we found a significant association between the cumulative number of 
instances of overanticoagulation (INR>6.0) and the change in eGFR after adjustment for 
confounding factors. We were not able to identify an association between VKA therapy 
and renal failure, possibly by a relative lack of power. Strengths of our study are its 
table 4 Contribution to change in estimated Glomerular Filtration Rate per year between baseline and 
third examination round for different cut-offs of overanticoagulation
Cumulative number 
of INR measurements 
above cut-off
Number of 
participants
*
Estimate
**
p-value 95% Confidence 
Interval
p-value for trend 
over categories**
INR>3.0
0 84 Ref.
3-8 84 -.675 .006 (-1.159 ; -.192)
.9459-42 94 -1.169 .000 (-1.699 ; -.639)
43+ 92 -.272 .330 (-.820 ; .275)
INR>4.0
0 107 Ref.
1-7 123 -.668 .003 (-1.103 ; -.233)
.253
8+ 124 -.618 .012 (-1.101 ; -.134)
INR>5.0
0 180 Ref.
1-2 87 -.467 .046 (-.925 ; -.009)
.100
3+ 87 -.663 .006 (-1.139 ; -.188)
INR>6.0
0 256 Ref.
1 60 -.625 .015 (-1.128 ; -.122)
.031
2+ 38 -.749 .015 (-1.350 ; -.147)
*  =  For each INR cut-off the total number of participants with VKA therapy is 354 ; **  =  Change in esti-
mated glomerular filtration rate is calculated from baseline and third examination round serum creatinine, 
adjusted for age, sex, baseline estimated glomerular filtration rate, baseline and incident heart failure, and 
indication for VKA therapy; INR  =  International Normalized Ratio; Ref.  =  Referent category
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population-based design, the long-term follow-up, insensitivity to detection bias, and 
the gathering of data without prior knowledge of the research question.
limitations
Results are conditional on participation in the third examination round of the Rotterdam 
Study. The majority of our study population did not have CKD. Therefore the studied 
association might be stronger and present at INRs ≤ 6.0. Participants might have died 
with renal failure from other causes, with renal failure not reported as a cause of death. 
Interpretation
Our results are consistent with the mechanism proposed by Brodsky et al. who reported 
renal function decline in individuals who experienced events of overanticoagulation in 
two cohort studies [7,8]. We did observe an association for INRs >6.0, which is in line 
with the suggestion that renal tubular obstruction from bleeding might be an important 
step in the causal pathway, especially as the chance of bleeding increases exponentially 
for high INR [22]. Selection bias and information bias are unlikely. We were not able to 
demonstrate an effect of INRs ≤6.0 over the studied period, possibly due to a relatively 
small sample size, differences in study design as we studied the cumulative effect of re-
peated events, or because effects are transient and renal function might have recovered 
before re-evaluation during the third study examination round. Alternatively, previously 
reported effects at lower INRs might include false positive findings. Therefore, confirma-
tion for our results should come a prospective study which is specifically designed to 
test these hypotheses [8].    
We were not able to demonstrate an association between overanticoagulation and 
acute renal failure. The previously reported cases of acute renal failure following overan-
ticoagulation support our findings, although it should be mentioned that the majority 
of these cases had an active glomerular disease, for which acute renal failure has been 
described without the use of VKA therapy [4-6, 30-33]. Therefore, it remains difficult to 
distinguish amongst VKA therapy as a cause, innocent bystander, or effect modifier of 
underlying disease such as IgA nephropathy. 
Best evidence thus far comes from two animal studies showing an increase in serum 
creatinine with increasing INR, reversible on vitamin K administration [34-35] . The gen-
eralizability of these findings to other more common glomerulopathies in men, such as 
diabetic nephropathy warrants further evaluation. A study with random assignment to 
overanticoagulation is not ethical, however secondary analysis of data on renal function 
possibly available in studies that randomized between VKA therapy and other modalities 
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of anticoagulation (e.g. Active W study), might help to better understand the association 
between overanticoagulation and renal function [36].
Generalizability
In conclusion, our result are the first that support the previously reported association 
between events of overanticoagulation for INRs>6.0 and a decline of renal function. Our 
results apply to a healthy elderly Caucasian population without underlying CKD. Further 
studies are needed to demonstrate effects of INRs≤6.0, to identify high risk groups, and 
to establish its role in acute kidney injury.
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ABStrACt
Background 
A recent study suggested that simple renal cysts are more frequent in patients with 
gout. An increased serum uric acid is often present in patients with gout. Our objective 
was to study whether increased serum uric acid is associated with an increased risk of 
simple renal cysts and to confirm the association with gout.
methods
We used data on 4,437 participants from the Rotterdam study, a population-based 
cohort study, including individuals ≥45 years, living in a suburb of Rotterdam, the Neth-
erlands, who had their serum uric acid measured and underwent abdominal ultrasound. 
results 
In females the risk of a simple renal cyst increased by 78% from the lowest to the highest 
serum uric acid measurement with a point estimate of 0.14 (per unit increase serum uric 
acid in mg/dl), p-value=0.024, 95%CI 0.02 to 0.26. In males a serum uric acid < 4.0 mg/dl 
was associated with a significantly lower risk of a simple renal cyst when compared to a 
serum uric acid ≥4.0 mg/dl: odds ratio adjusted for age, estimated glomerular filtration 
rate and (earlier) presence of renal stones 0.40, p-value=0.037, 95% CI 0.16 to 0.95. 
Conclusions 
High Serum uric acid level is associated with the presence of a simple renal cyst.
The association between serum uric acid and the presence of a simple renal cyst 63
IntroDuCtIon
Simple renal cysts are frequently observed in normal kidneys and account for approxi-
mately 65 to 70 percent of renal masses [1, 2]. Their prevalence depends on the imaging 
modality, the population studied and the prevalence is the highest in patients >50 years 
of age and in men [3-9].
Typically, simple renal cysts are asymptomatic although large cysts may cause renal 
artery and/or vein compression,  massive hematuria or severe loin pain [10] and oc-
casionally a renal cyst might become infected and require specific treatment [11]. A 
recent large study found cysts ≥5 mm to be associated with higher albumin excretion, 
hypertension, and hyperfiltration [8]. The association with hypertension has also been 
reported in other studies [12-16], although not in a series of  >1000 patients [4]. Other 
studies also describe associations with an increased serum creatinine [9] and reduced 
estimated glomerular filtration rate (eGFR) [12, 17]. Renal abnormalities that are reported 
in association with simple renal cysts include increased parenchymal echogenicity [18], 
atrophic kidney(s) [18], renal stones [18, 19], hydronephrosis/dilatation of the pelvicaly-
ceal system [18] and hematuria [18]
Despite the high prevalence of simple renal cysts, only a limited number of risk factors 
has been reported in addition to age, male gender and hypertension such as smoking 
[19], renal stones [18-20] and obesity [21, 22]. A recent case-control study reported a 
higher prevalence of simple renal cysts in patients with gout (26%) in comparison to a 
control group of age- and sex-matched healthy kidney donors (11%) [20]. However, as 
the prevalence of gout is relatively low (3 to 41 per 1,000 adults, depending on age), the 
population impact would be limited [23, 24]. Serum uric acid (SUA) is a well-recognized 
risk factor for gout [25-27]. The prevalence of asymptomatic hyperuricemia is much 
higher than the prevalence of gout and  ranges between 130 and 210 per 1,000 adults, 
depending on age [24]. Consequently, any association between increased levels of SUA 
and renal cysts might be of clinical importance. Therefore, we investigated this associa-
tion in a large prospective cohort study in a community-dwelling aged population.
SuBJECtS AnD mEtHoDS
Setting
Data were obtained from the Rotterdam Study, an ongoing prospective population-
based cohort study of chronic diseases in the elderly. All inhabitants of Ommoord, a 
suburb of the city of Rotterdam in the Netherlands, aged 55 years or older were invited 
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in 1990 to participate in the study. The medical ethics committee of the Erasmus Medical 
Center approved the study and informed consent was obtained from all participants. 
The rationale and design of the study are described elsewhere [28]. The first cohort 
encompassed 7,983 individuals who were interviewed and examined at baseline in 
1989-1993 (Rotterdam Study-1 [RS-I]). In 2000, all inhabitants of Ommoord 55 years and 
older at that time and not yet participating in RS-I were invited to participate in the 
second cohort (RS-II). This cohort encompassed 3,011 individuals who entered the study 
after giving written informed consent. In 2006, a further extension of the cohort (third 
cohort, RS-III) was initiated, in which 3,932 individuals 45 years and older were included.
Study Population
For the analysis of the association with SUA we included all participants with a SUA 
measurement in whom both kidneys were visualized during abdominal ultrasound. We 
excluded patients with gout prior to the date of SUA measurement. Gout was defined 
by the use of anti-gout medication (ATC code ‘M04’) from medication dispensing data or 
medication home interview. Medication dispensing data have been monitored continu-
ously since January 1, 1991, through computerized pharmacy records of the pharmacies 
in the Ommoord district. The pharmacy data include ATC code, dispensing date, total 
number of drug units per prescription, prescribed daily number of units, and product 
name of the drug. During the medication home interview, in the month preceding 
the study center visit, participants were asked to show containers of all drugs, both 
prescription and over-the-counter, taken at any time during the 2 weeks preceding the 
interview. We only used data from participants with complete medication dispensing 
data, evidenced by at least one medication dispensing after the date of SUA measure-
ment  or the denial of the use of prescription medication during the medication home 
interview. SUA was measured during the third examination visit of first cohort (RS-I-3) 
between April 1997 and December 1999, the first visit of the second cohort (RS-II-1) be-
tween January 2000 and December 2001, and the first visit of the third cohort (RS-III-1) 
between March 2006 and January 2009. It was also measured during the baseline visit of 
the first cohort (RS-I-1) between November 1989 and June 1993. This measurement was 
only used to evaluate within subject change over time for the first cohort. SUA was ex-
pressed in milligram per deciliter (mg/dl). Strata of SUA were created according to those 
used by Kuo et al. [30]. SUA below 4.0 and SUA levels ≥7.0 mg/dl were combined due 
to a limited number of observations in these strata. Because we also wanted to assess 
the association with gout we also studied participants with gout newly diagnosed after 
SUA measurement in whom both kidneys were visualized during abdominal ultrasound.
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Study outcome
The outcome of this study was the presence of a unilateral or bilateral simple renal 
cyst during abdominal ultrasound investigation, which was performed during the fifth 
examination round between January 2009 and April 2014 encompassing the fifth visit of 
the first cohort (RS-I-5), the third visit of the second cohort (RS-II-3), and the second visit 
of the third cohort (RS-III-2). All of the following 4 ultrasound criteria had to be met for 
the diagnosis of a simple renal cyst: (1) spherical or ovoid shape; (2) absence of internal 
echoes; (3) presence of a thin, smooth wall that is separate from the surrounding paren-
chyma; and (4) enhancement of the posterior wall, indicating ultrasound transmission 
through the water-filled cyst [29].
Co-variables
The following other variables measured at the date of abdominal ultrasound were stud-
ied as potential confounders or effect modifiers based on the results of prior studies: 
age and sex [3-9], renal stones[18-20], hypertension [8, 12-15], estimated glomerular 
filtration rate (eGFR) [12], smoking [19] and Body Mass Index (BMI) [21, 22]. Variables 
were stratified to account for possible non-linear effects and included in the final model 
if there was a significant association with the presence of a simple renal cyst after adjust-
ment for age and sex. Age was included in the analyses within 5-year age strata. Ages 
≥85 years were combined due to the low number of observations. The presence of renal 
stones was determined from self-reported medical history and abdominal ultrasound 
investigation. Hypertension was assumed to be present if the participants had a systolic 
blood pressure ≥140 mm Hg or a diastolic blood pressure ≥ 90 mm Hg, or received 
blood-pressure lowering medication at the fifth examination round. Body mass index 
(BMI) was included with strata as proposed by the National Institutes of Health’s [30]. 
Underweight (<18.5 kg/m2) and normal weight (18.5–24.9 kg/m2), as well as the obesity 
class 2 (35–39.9 kg/m2) and extreme obesity class 3 ≥40 kg/m2 were combined due to 
the limited number of observations. eGFR was used, because it is already adjusted for 
age and sex, in contrast to serum creatinine. eGFR was estimated from serum creatinine 
measured during the fifth examination round with the equation of the Chronic Kidney 
Disease Epidemiology (CKD-EPI) Collaboration [31]. Strata for eGFR were made accord-
ing to the Kidney Disease Improving Global Outcomes (KDIGO) foundation 2012 Clinical 
Practice Guideline for the Evaluation and Management of Chronic Kidney Disease[32]. 
eGFR strata G4 severely decreased (15-29 ml/min/1.73m2) and G5 kidney failure (<15 
ml/min/1.73m2) were combined due to the limited number of observations.
Statistics
We performed logistic regression to study the association between SUA and the pres-
ence of a simple renal cyst. Age and sex were included in all multivariable models to 
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account for confounding by age and sex. Other covariables that remained significant 
after adjustment for age and sex were also included in the final model. Because SUA 
level as well as the prevalence of a simple renal cysts are different between males and 
females we also performed a stratified analysis by gender. SUA was included as a con-
tinuous and a categorical determinant with strata as detailed above. We converted odds 
to probabilities by the following formula: probability=odds/(odds+1). For continuous 
determinants the odds for one unit increase is provided. P-values <0.05 were considered 
significant. Analyses were performed with SPSS version 20  (IBM Inc., Chicago, IL, USA).
rESultS
SUA measurement was available for 9,939 participants during examination visits RS-I-3, 
RS-II-1 and RS-III-1. The medication dispensing history was complete for 9,465 (95.2%) 
participants at the date of SUA measurement. Of these, 117 (1.2%) participants were 
excluded because of use of anti-gout medication prior to the date of SUA measurement. 
Between February 3, 2009 and April 1, 2014, 5,195 of the remaining participants un-
derwent abdominal ultrasound during the fifth examination round (RSI-5,RSII-3,RSIII-2) 
(figure 1). A total of 29 (0.6%) of participants were excluded because of a missing kidney 
(congenital, extirpation, donation) and an additional 729 patients were excluded as not 
both kidneys were visualized resulting in a total of 4,437 participants. 
Visits 
SUA 
measurement 
used to study 
the 
association 
with a simple 
renal cyst  
SUA 
measurement 
only used to 
evaluate 
within subject 
change over 
time 
RS-I 
Cohort 
RS-I-1 RS-I-2 RS-I-3 RS-I-4 RS-I-5 
Abdominal 
ultrasound 
RS-II RS-II-1 RS-II-2 RS-II-3 
RS-III RS-III-1 RS-III-2 
figure 1 Study scheme
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Median age of study population at abdominal ultrasound was 69 years (Interquartile 
Range (IQR) 63 to 76 years). A total of 1,962 (44.2%) participants were males. Detailed 
patient characteristics are given in table 1. 
table 1 Partipicant characteristics at the date of abdominal ultrasound
Variable number percentage(%)
Serum uric acid (mg/dl) <4.0 597 (13.5)
4.0-4.9 1,271 (28.6)
5.0-5.9 1,347 (30.4)
6.0-6.9 775 (17.5)
7.0+ 447 (10.1)
Renal stone No 4,422 (99.7)
Yes  15 (0.3)
Age at fifth examination round (years) 50-54 237 (5.3)
55-59 545 (12.3)
60-64 646 (14.6)
65-69 1024 (23.1)
70-74 792 (17.8)
75-79 658 (14.8)
80-84 358 (8.1)
85+ 177 (4.0)
Sex Males 1,962 (44.2)
Females 2,475 (55.8)
eGFR (ml/min/1.73m2) 90+ 736 (16.8)
60-89 3,045 (69.7)
45-59 480 (11.0)
30-44 91 (2.1)
15-29 14 (0.3)
0-14 4 (0.1)
Missing eGFR 67
Hypertension no 1,561 (35.3)
yes 2,857 (64.7)
Missing hypertension status 19
BMI (kg/m2) <18.5 16 (0.4)
18.5-24.9 1,242 (28.0)
25.0-29.9 2,153 (48.5)
30.0-34.9 795 (17.9)
35.0-39.9 184 (4.1)
40.0+ 45 (1.0)
Missing BMI 2
Smoking Never 1,399 (31.7)
Former 2,506 (56.7)
Current 513 (11.6)
Missing smoking status 19
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table 2 Logistic regression analysis for the presence of a simple renal cyst 
model 1a model 2b model 3c
Variable Case / Total ORd P 95%CI ORd P 95%CI ORd p 95%CI
Uric acid (mg/dL) 619 / 4,437 1.20 1.13 - 1.28   1.11 1.03 - 1.20   1.09 1.01 - 1.18
Renal stone,
No=ref.d
613 4,422
yes 6 15 4.14 1.47 - 11.68 4.17 1.38 - 12.64 3.94 1.30 - 11.91
Age (years) 
50-54=ref. d
17 / 237
55-59 40 / 545 1.03 1.85 - 3.04 1.02 0.56 - 1.84 1.02 0.56 - 1.85
60-64 44 / 646 0.95 1.69 - 2.85 0.94 0.52 - 1.68 0.94 0.52 - 1.70
65-69 133 / 1,024 1.93 3.27 - 5.40 1.93 1.13 - 3.27 1.93 1.12 - 3.31
70-74 130 / 792 2.54 4.31 - 6.60 2.58 1.52 - 4.39 2.70 1.55 - 4.69
75-79 142 / 658 3.56 6.03 - 8.44 3.61 2.12 - 6.13 3.58 2.05 - 6.25
80-84 73 / 358 3.31 5.78 - 8.33 3.43 1.96 - 6.01 3.26 1.80 - 5.88
85+ 40 / 177 3.78 6.93 - 8.96 4.17 2.26 - 7.69 3.71 1.93 - 7.12
Sex, male=ref. d 373 / 1,962
female 246 / 2,475 0.47 0.40 - 0.56 0.45 0.38 - 0.54 0.50 0.41 - 0.61
eGFR (ml/min/1.73m2) 
90+=ref. d
72 / 736
60-89 404 / 3,045 1.41 1.08 - 1.84 0.88 0.66 - 1.18 0.86 0.64 - 1.15
45-59 103 / 480 2.52 1.82 - 3.49 1.22 0.84 - 1.76 1.14 0.79 - 1.67
<45 32 / 109 3.83 2.37 - 6.19 1.66 0.98 - 2.79 1.51 0.89 - 2.57
Hypertension, 
no=ref. d
147 / 1,561
yes 467 / 2,857 1.88 1.54 - 2.29 1.23 0.99 - 1.53
BMI (kg/m2), <25=ref. 154 / 1,258
25-29 321 / 2,153 1.26 1.02 - 1.54 1.13 0.91 - 1.39
30-34 109 / 795 1.14 0.88 - 1.48 1.12 0.85 - 1.46
35+ 34 / 229 1.25 0.84 - 1.87 1.45 0.96 - 2.19
Smoking, no=ref. d 165 / 1,399
current 64 / 513 1.37 1.13 - 1.67 1.08 0.88 - 1.33
past 389 /  2,506 1.07 0.78 - 1.45   1.12 0.81 - 1.54          
BMI Body Mass Index, eGFR estimated Glomerular Filtration Rate, OR Odds Ratio, Ref. Reference; a unadjust-
ed model; b model adjusted for age and sex; c fully adjusted model ; d p-values for type 3 analysis of effects
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619(14.0%) participants had a simple renal cyst. In the univariate analysis, SUA as con-
tinuous variable  was significantly associated with the presence of a simple renal cyst, 
OR 1.20, 95%CI 1.13 to 1.28, p-value<0.001(table 2 model 1). This association remained 
in the final model upon adjustment for age, sex, eGFR, and renal stones, OR 1.09, p-
value=0.033, 95%CI 1.01 to1.18 (table 2, model 3). The association between SUA and 
the presence of a simple renal cyst differed between sexes: in females the prevalence 
of a simple renal cyst increased with SUA across the entire range, whereas in males only 
SUA <4.0 mg/dl was associated with a lower prevalence of a simple renal cyst (figure 2). 
In analyses stratified for sex  (data not shown), SUA as a continuous variable was signifi-
cantly associated with the presence of a simple renal cyst in females, OR adjusted for 
age 1.15, 95%CI 1.02 to 1.29, p-value=0.024. Adjustment for eGFR and renal stones was 
not indicated, because these were not significantly associated with a simple renal cyst 
in females after adjustment for age. In females the range in SUA is 9.2 mg/dl, from 1.9 
mg/dl to 11.1 mg/dl. Across this range the risk of a simple renal cyst increased by 78%: 
figure 2 Association between presence of a renal cyst and serum uric acid
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exp(9.2*(ln(1.15))/(1+ exp(9.2*(ln(1.15))). In males SUA as a continuous variable was not 
significantly associated with the presence of a simple renal cyst (OR adjusted for age, 
eGFR and renal stones 1.06, 95%CI 0.96-1.18). However, in males a SUA <4.0 mg/dl was 
associated with a significantly lower risk of a simple renal cyst compared to a SUA ≥ 4.0 
mg/dl (OR adjusted for age and eGFR and renal stones 0.40, 95%CI 0.16-0.95).
For 673 participants of RS-I SUA was also measured during the first examination visit 
(RS-I-1), a median 6.4 years (Interquartile range 6.3 to 6.5 years) before RS-I-3 (figure 3). 
The median within subject change in SUA per 10 years was -0.11 mg/dl (IQR -0.86 to 0.62 
mg/dl). 
If participants who used anti-gout medication prior to SUA measurement were not 
excluded, a total of 4,007 participants who underwent abdominal ultrasound also had 
a complete medication history until the fifth examination round or used anti-gout 
medication. In males the prevalence of a simple renal cyst was similar in those who 
used anti-gout medication [23 out of 93 (24.7%)] to those who did not [326 out of 1,676 
(19.5%)]. In females, the  prevalence of a simple renal cyst was higher in those who used 
anti-gout medication [8 out of 37 (21.6%)] compared to those who did not [221 out of 
2,219 (10.0%). In females this association remained significant after adjustment for age, 
OR adjusted for age 2.29, 95%CI 1.02 to 5.15, p-value=0.046 (data not shown). 
DISCuSSIon
In this study, we found an association between increased SUA and risk of renal cysts in 
females. In males only a SUA <4.0 mg/dl was associated with a significantly lower risk 
of a simple renal cyst compared to a SUA ≥ 4.0 mg/dl. A recent study that reported a 
significant association between gout and simple renal cysts was conducted in a pre-
dominantly (>85%) male study population [20]. Although for renal cysts we found only a 
limited association with SUA in males and no association with gout in males, the results 
of this study might be consistent with our results in relation to SUA. In the former study, 
the control group consisted of healthy kidney donors only. Although no information 
on SUA levels in controls was provided, these are generally low (<4.0 mg/dl) in healthy 
kidney donors [33]. 
Various (combinations of ) pathophysiological mechanisms might underlie the asso-
ciation between gout or SUA and simple renal cysts. First, the signal transducer and 
activator of transcription 3 (STAT3) which is important for renal cyst growth is strongly 
expressed in kidneys of simple renal cyst patients and barely in normal kidneys [34]. 
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STAT3 is activated by phosphorylation by hyperuricemia [35, 36] and  monosodium 
urate (MSU) crystals [37], and also STAT3 binding activity is strongly increased by mono-
sodium urate crystals [38]. Indirectly, SUA is related to STAT3 through Interleukin (IL)-6 
[39, 40], Il-18 [41, 42], tumor necrosis factor-α [39, 43], and leptin [44, 45].  It is possible 
that in males androgen receptor activation of signal transducer and activator of tran-
scription 3 (STAT3) is more important than the actual SUA level with SUA ≥4.0 mg/dl 
[34] explaining why we did not observe the association between increase of SUA and 
renal cysts in males. Second, because simple renal cysts are associated with renal stones 
[18, 19], cyst formation might result from mechanical obstruction by renal stones in the 
kidney. Nephrolithiasis is common in gout: nephrolithiasis (diagnosed by helical CT) was 
found in 34% of male patients with gout and 68% of the patients with nephrolithiasis 
did not suffer from symptoms compatible with nephrolithiasis [46]. This might also play 
a role in hyperuricemia because patients with hyperuricemia have an increased risk of 
nephrolithiasis via uric acid precipitation in the urine because of low pH 
Strengths of our study are its population-based design, the large study population and 
the ability to adjust for previously reported risk factors. A limitation to this study is a 
possible degree of misclassification of gout in participants who were exclusively treated 
with non-steroidal anti-inflammatory drugs (NSAIDs), but not with anti-gout medication. 
In our study SUA and the presence of simple renal cysts were determined by a single 
measurement. We showed that variation in SUA within participants is limited over time. 
Therefore we consider that the use of one single SUA measurement, determined during 
a preceding study center visit, is justified, although  repeated abdominal ultrasound 
and measurements of SUA would allow a more precise analysis on causality. Finally, we 
might have missed small and asymptomatic renal stones during abdominal ultrasound 
investigation, because ultrasound sensitivity to detect renal stones is low.
In conclusion, our results showed an association between increasing values of SUA and 
the presence of a simple renal cyst.  Consistent with previous studies we also found an 
association between a reduced eGFR and higher prevalence of a simple renal cyst[12]. 
Currently one trial including 113 patients with chronic kidney disease shows that treat-
ment with allopurinol slows the decline in eGFR[47]. As many more small cysts may have 
been below the limit of detection[48], we seems possible that SUA might contribute at 
least in part to the progression of renal function decline through renal cyst formation.
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ABStrACt
Background 
Chlorthalidone and hydrochlorothiazide are often considered as interchangeable. 
However, greater (nighttime) blood pressure reduction, and alleged pleiotropic effects 
have renewed the interest in chlorthalidone. A recent study showed an increased risk of 
adverse events with chlorthalidone, including hyponatremia.
methods
To investigate differences in risk of hyponatremia between chlorthalidone and hydro-
chlorothiazide, adjusted for daily dose, we conducted a population-based case–control 
study within the Dutch IPCI (Integrated Primary Care Information) database. The study 
population included all subjects ≥18 years, without diabetes mellitus, heart failure, liver 
failure and malignancy, who were registered in the IPCI database from 1996 to 2011. 
Cases were subjects with a serum sodium <130 millimole per liter or hospitalization due 
to hyponatremia. Controls were matched on practice, age within 5 years, sex and date 
of onset.
results
A total of 1,033 cases of hyponatremia were identified. Hyponatremia was more com-
mon with chlorthalidone than with hydrochlorothiazide at equal dose per day:  adjusted 
odds ratio was 2.09 (95%CI 1.13 to 3.88) for 12.5 milligram per day and 1.72 (95%CI 1.15 
to 2.57) for 25 milligram per day. Risks were not significantly increased with chlorthali-
done compared to twice the dose per day of hydrochlorothiazide.
Conclusions
This is the first study that shows an increased risk of hyponatremia with chlorthalidone 
relative to hydrochlorothiazide at equal milligram-to-milligram dose per day. The need 
for a lower dose of chlorthalidone than hydrochlorothiazide to achieve similar blood 
pressure reduction likely compensates for the increased risk of hyponatremia at equal 
dose.
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IntroDuCtIon
Background
A review from 2004 states that the diuretics chlorthalidone (CTDN) and hydrochloro-
thiazide (HCTZ) are  often considered as interchangeable, despite differences in cardio-
vascular outcomes, pharmacokinetics and pharmacodynamics, as well as in pleiotropic 
effects [1]. This impression might be strengthened by an identical World Health Organi-
zation (WHO) defined daily dose of 25 milligram per day (mg/d). Also in the Netherlands 
recommended initial dose is identical, being 12.5mg/d, whereas the recently published 
Joint National Committee 2014 Evidence-Based Guideline for the Management of High 
Blood Pressure in Adults suggests to start treatment with CTDN 12.5 mg/d or HCTZ 12.5-
25 mg/d[2] . Since the review of 2004, two meta-analyses [3, 4] and two randomized 
clinical studies [5, 6] showed greater blood pressure reduction with CTDN than HCTZ, 
in particular for the nighttime mean systolic blood pressure, which contributed to the 
renewed interest in CTDN [7]. 
In absence of direct head-to-head studies with clinical endpoints, a debate is 
ongoing whether CTDN should be preferred over HCTZ, because it appears to be more 
effective in the prevention of cardiovascular events [8, 9] and whether this is due to a 
difference in blood pressure reduction and/or pleiotropic effects [10]. 
Also the relative difference in the incidence of adverse events, in particular hypo-
kalemia and hyponatremia, is a topic of debate [4, 11]. These events are not without 
consequences, as hypokalemia might result in rhabdomyolysis and cardiac arrhythmia 
[12-14], whereas acute kidney injury is common in association with hyponatremia [15]. 
A recent propensity score–matched observational cohort study showed that sub-
jects treated with CTDN were 1.7 times more likely to be hospitalized with hyponatremia 
than those prescribed HCTZ (all dosing regimens within each treatment combined) [11].
objective
The objective of this study was to investigate the risk of hyponatremia between CTDN 
and HCTZ, comparing the risk with both treatments at equal milligram-to-milligram dose 
per day and CTDN with twice the dose of HCTZ per day, using prospectively gathered 
electronic health care records from a community-dwelling adult population. 
mEtHoDS
Design overview
We performed a population-based case–control study, nested in a cohort of patients who 
were registered in the Dutch Integrated Primary Care Information (IPCI) general practice 
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research database, to investigate the risk of hyponatremia with CTDN and HCTZ. The 
Scientific and Ethical Advisory Board of IPCI project approved the study (study protocol 
N. 02/13). 
Setting
All data were retrieved from the IPCI project, a longitudinal observational, dynamic 
database which contains the electronic medical records of a group of more than 600 
general practitioners  in the Netherlands. In the Dutch health care system, the general 
practitioner plays a pivotal role and acts as a gatekeeper of medical care and informa-
tion. Almost all inhabitants of the Netherlands are registered with a general practitioner, 
independently of their health status. Details of the IPCI database have been described 
elsewhere[16, 17]. Briefly, the database contains the complete electronic medical 
records of approximately 1,000,000 participants. These records contain anonymous 
longitudinal data on demographics, symptoms and diagnoses (coded and in free text), 
referrals, laboratory findings, hospitalizations, discharge letters, and drug prescriptions 
(inclusive indication and dosage regimen). To maximize completeness of the data, gen-
eral practitioners participating in the IPCI project are not allowed to maintain a system 
of paper-based records besides the electronic medical records. The system complies 
with European Union guidelines on the use of data for medical research and has been 
proven valid for pharmaco-epidemiologic studies [17]. 
Study population
The study population comprised all subjects from the IPCI database who were ≥18 years 
during the study period (January 1st, 1996 to March 1st, 2011) and had ≥1 year of data 
registered in the database before the study period. Subjects were censored from the 
first date indicating malignancy, except for squamous and basal cell carcinoma of the 
skin, because certain malignancies are known to cause hyponatremia and also chemo-
therapy has been associated with hyponatremia [18]. Subjects with heart failure and/
or liver failure might also receive specialist treatment, including diuretics, that is not 
completely captured in the database. Therefore, they were censored from the first cal-
endar date indicating such conditions. Finally, also subjects with diabetes mellitus were 
excluded, because hyperglycemia might cause hyponatremia. All remaining subjects 
were followed until, hyponatremia, death, transfer out of practice, last data draw-down, 
or end of the study period, whichever came first.
Cases and controls
Cases were all subjects who were first diagnosed with a serum sodium level <130 mmol/l 
and/or subjects who were hospitalized with a specialist diagnosis of hyponatremia at 
admission. All cases were validated through manual review of the electronic medical 
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record while blinded to the exposure. All available controls were selected by incidence 
density sampling [19] and matched to each case on practice, sex and age within a range 
of 5 years.
Exposure definition
Exposure to CTDN and HCTZ - and other medications mentioned below that might con-
found the association of interest - was obtained from the prescription files. Fixed dose 
combinations were recoded into their individual active pharmaceutical ingredients. The 
duration of treatment was calculated by dividing the prescribed number of units by the 
dosing regimen. The dose per day was obtained from the last prescription prior to the 
index date and calculated from the prescribed strength and the dosing regimen. 
Co-variables
We considered the following co-variables: practice, age, sex, and date of onset (match-
ing variables), and medical conditions, based on their ICPC diagnosis code, during the 
analyses: Addison’s disease [20], alcoholism [21], cerebrovascular disease (transient 
ischemic attack, stroke)[22] , diabetes insipidus [23], hypothyroidism [24], ischemic 
heart disease (angina pectoris and myocardial infarction) [25], Parkinson’s disease [26] 
and pulmonary obstructive disease (asthma and chronic obstructive pulmonary disease 
)[27] .
We assessed potential confounding by other medications that have been reported 
to cause hyponatremia, based on a literature review [18, 28, 29] at 5th level (chemical 
substance), at 4th level (chemical subgroup), or at 3rd level (pharmacological subgroup) 
of the anatomical therapeutical chemical (ATC) coding system [30]: proton pump inhibi-
tors (PPI) (plain and in combinations for eradication of Helicobacter Pylori), amiodarone, 
lorcainide, propafenone, diuretics, agents acting on the renin-angiotensin system, 
bromocriptine, vasopressin and analogues, thyroid preparations, mineralocorticoids, 
trimethoprim-sulfamethoxazole, ciprofloxacin, cefoperazone, sulbactam, rifabutin, 
azithromycin, carboxamide derivatives, valproic acid, lamotrigine, anti-parkinson drugs, 
opioids, non-steroidal anti-inflammatory drugs (NSAIDS), phenothiazines, butyrophe-
none derivatives, anxiolytics combined with barbiturates (plain and in combination), 
anti-depressants, and theophylline. If a chemical or pharmacological subgroup, but 
none of its chemical substances, indicated possible confounding, we included all medi-
cations of the subgroup in the adjusted analysis (but at 3rd level). Also here fixed dose 
combinations were coded into their individual active pharmaceutical ingredients.
Statistical Analysis
We compared characteristics of cases and controls by using conditional logistic regres-
sion analysis. Current exposure to CTDN or HCTZ was included in the first model as a 
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single categorical variable, including: no use, CTDN only, HCTZ only and overlapping 
prescriptions (most likely indicating a recent switch). In the subsequent models, we 
replaced use of CTDN only and HCTZ only with their respective dosage per day, be-
ing: <12.5mg/d, 12.5mg/d, >12.5mg and <25mg/d, 25mg/d, >25mg/d and <50mg d, 
50mg/d and >50mg/d. We compared CTDN to HCTZ in a milligram-to-milligram dose 
per day, because of their reported interchangeability and with twice the amount dose 
per day of HCTZ, because these dosages are often compared during clinical studies. As 
not all conditions and medications known to cause hyponatremia might confound the 
association between CTDN or HCTZ and hyponatremia to a relevant extent, we included 
only those co-variables that changed the odds ratio between CTDN and HCTZ by 5% 
or more, in order to avoid an unnecessary loss of statistical power. We conducted all 
conditional logistic regression analyses with SAS 9.2, (SAS Institute Inc., Cary, NC, USA). 
We set the level of significance for all statistical tests at a P-value less than 0.05. We 
discarded comparisons that included cells with less than 5 subjects. For the incidence 
figure we used data on all subjects included in the study population. The incidence rate 
was determined by dividing the number of cases by the total number of person-years 
of follow-up by the study population. Subjects were censored on the first date of hypo-
natremia. Incidence rates were calculated per 100,000 person-years. Ninety-five percent 
confidence (95%CI) intervals were calculated based on a Poisson distribution [31].
rESultS
The study population comprised 738,016 subjects with a total of 1.96 million person-
years of observation. The study population included 17,631 subjects who received one or 
more prescriptions of CTDN, contributing to a combined exposure of 6,710 person-years 
and 57,696 subjects who received one or more prescriptions of HCTZ, with a combined 
exposure of 151,389 person-years. A total of 1,033 subjects developed hyponatremia. 
The incidence increased from approximately 5 per 100,000 person-years below 40 years 
of age to 730 per 100,000 person-years in subjects aged 85 and above (figure 1). Females 
were more likely to develop hyponatremia - 706 (68%) of cases were female subjects, 
with the highest risk relative to males between 80-84 years of age [incidence rate ratio 
of 3.0 (95%CI 2.0-4.4)]. 
The characteristics of cases and controls are provided in table 1.  A total of 46 cases 
were current users of CTDN and 308 cases were current users of HCTZ, details on the 
dose per day are provided in table 2. 
If current use of CTDN or HCTZ (all dose per day of current use combined) was 
compared to no use of either medication, only current use of an angiotensin receptor 
blocker (ARB) led to a ≥5% change in estimate and was therefore added as confounder 
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18-20 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+
Males IR 3 6 5 4 7 9 17 35 43 58 65 109 208 236 393
Males IR 95%CI LL 0 2 2 1 3 5 10 24 30 42 45 78 155 164 268
Males IR 95%CI UL 14 13 11 11 13 17 26 49 59 78 92 148 272 331 556
Females IR 6 5 5 4 2 17 8 34 41 62 108 192 397 702 877
Females IR 95%CI LL 1 2 2 1 0 10 4 24 28 45 82 153 332 598 745
Females IR 95%CI UL 20 12 11 10 6 26 15 48 57 83 140 239 470 820 1027
IR ratio 2.1 0.8 1.0 1.0 0.3 1.8 0.5 1.0 1.0 1.1 1.7 1.8 1.9 3.0 2.2
IR ratio 95%CI LL 0.2 0.2 0.2 0.2 0.1 0.8 0.2 0.6 0.6 0.7 1.1 1.2 1.4 2.0 1.5
IR ratio 95CI UL 23.1 3.0 3.9 3.9 1.4 3.9 1.1 1.6 1.6 1.7 2.6 2.6 2.7 4.4 3.3
Males cases 1 5 4 4 7 10 17 32 33 38 30 37 49 31 29
Females cases 2 4 4 4 2 18 8 31 31 41 53 77 128 154 149
Males Persontime ( x 1000) 34 82 85 90 103 107 102 91 78 66 46 34 24 13 7
Females persontime ( x 1000) 32 82 87 91 105 108 102 90 76 66 49 40 32 22 17
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figure 1: Age-specific incidence rate of hyponatremia per 100,000 person-years stratified by sex.
 IR = Incidence Rate; 95%CI =  95% Confidence Interval; LL  =  Lower Limit; UL  =  Upper Limit
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table 1 Characteristics of cases and controls
Variable
Cases Controls
(n=1,033) (n= 130,814)
Age† (years: median; IQR) 76 (63-83) 62 (51-75)
Age † (years: n(%)
- 18-40 37 (4) 13,596 (10)
- 40-60 180 (17) 42,859 (33)
- 60-80 453 (44) 57,609 (44)
- 80+ 363 (35) 16,750 (13)
Sex† n(%)
- Male 327 (32) 49,303 (38)
- Female 706 (68) 81,511 (62)
Medical history present n(%)
- Cerebrovascular disease 141 (14) 5,632 (4)
- Ischemic Heart disease 221 (21) 12,882 (10)
- Obstructive respiratory disease 167 (16) 12,815 (10)
- Hypothyroidism 80 (8) 5,540 (4)
- Parkinson’s disease 17 (2) 687 (1)
- Alcohol abuse 51 (5) 1,550 (1)
- Addison’s disease 5 (<1) 30 (<1)
- Diabetes insipidus 15 (1) 184 (<1)
Medication use
- Hydrochlorothiazide 308 (30) 12,179 (9)
- Chlorthalidone 46 (4) 1,254 (1)
 Other diuretics 
- Aldosterone antagonists 22 (2) 282 (<1)
- Amiloride 26 (3) 651 (<1)
- Epitizide 19 (2) 577 (<1)
- Loop diuretics 45 (4) 1,709 (1)
- Triamterene 46 (4) 1,784 (1)
- Chlorothiazide 0 (<1) 2 (<1)
- Mefruside 0 (<1) 3 (<1)
- Indapamide 1 (<1) 1 (<1)
Agents acting on the renin-angiotensin system
- Angiotensin converting enzyme inhibitors 154 (15) 9,020 (7)
- Angiotensin receptor blockers 194 (19) 8,098 (6)
Other medications
- Proton pump inhibitors 154 (15) 7,862 (6)
- Propafenone 0 (<1) 25 (<1)
- Amiodarone 1 (<1) 116 (<1)
Risk of hyponatremia with diuretics: chlorthalidone versus hydrochlorothiazide 85
table 1 Characteristics of cases and controls (continued)
Variable
Cases Controls
(n=1,033) (n= 130,814)
- Bromocriptine 0 (<1) 7 (<1)
- Vasopressin and analogues 3 (<1) 20 (<1)
- Mineralocorticoids 2 (<1) 8 (<1)
- Thyroid preparations 26 (3) 2,192 (2)
- Trimethoprim-sulfamethoxazole 11 (1) 71 (<1)
- Ciprofloxacin 7 (1) 76 (<1)
- Azithromycin 2 (<1) 68 (<1)
- Non-steroidal anti-inflammatory drugs 61 (6) 4,151 (3)
- Opioids 44 (4) 1,307 (1)
- Carboxamide derivatives 22 (2) 171 (<1)
- Valproic acid 8 (1) 147 (<1)
- Lamotrigine 3 (<1) 26 (<1)
- Anti-parkinson drugs 10 (1) 382 (<1)
- Phenothiazines 1 (<1) 41 (<1)
- Butyrophenone derivatives 13 (1) 187 (<1)
- Anxiolytics and barbiturates 169 (16) 6,524 (5)
- Tricyclic antidepressants 10 (1) 914 (1)
- Selective serotonin re-uptake inhibitors 36 (3) 2,282 (2)
- Monoamine Oxidase Inhibitors (selective and 
non-selective) 1 (<1) 10 (<1)
- Theophylline 1 (<1)   53 (<1)
†Age and sex differ between cases and controls because of incidence density sampling where all potential 
controls were selected matched on age and gender. Because of the population demographics, the number 
of controls per case varies. This difference was accounted for via the conditional logistic regression
table 2 Use of chlorthalidone and hydrochlorothiazide
Cases
(n=1,033)
Controls
(n= 130,814)
nr % nr %
No use 681 (66) 117,401 (90)
Use of hydrochlorothiazide:
- dose unknown 5 (<1) 143 (<1)
- <12.5mg/day 3 (<1) 91 (<1)
- 12.5mg/day 140 (14) 6,535 (5)
- >12.5mg/day and <25mg/day 0 (<1) 18 (<1)
- 25mg/day 130 (13) 4,770 (4)
- >25mg/day and <50mg/day 0 (<1) 2 (<1)
- 50mg/day 28 (3) 594 (<1)
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table 2 Use of chlorthalidone and hydrochlorothiazide (continued)
Cases
(n=1,033)
Controls
(n= 130,814)
nr % nr %
- >50mg/day 0 (<1) 6 (<1)
Use of chlorthalidone
- <12.5mg/day 1 (<1) 9 (<1)
- 12.5mg/day 11 (1) 291 (<1)
- 25mg/day 31 (3) 877 (1)
- >25mg/day and <50mg/day 0 (<1) 5 (<1)
- 50mg/day 1 (<1) 52 (<1)
Combined use 2 (<1) 20 (<1)
table 3 Association between the current use of hydrochlorothiazide or chlorthalidone and hyponatremia
unadjusted model   adjusted model†
Current use (mg per day)
(Ref. = no use)
Cases/controls Odds ratio p-value 95%CI   Odds ratio p-value 95%CI
Hydrochlorothiazide 12.5 140/6,535 3.64 <0.001 3.03 - 4.36 2.61 <0.001 2.13 - 3.20
25 130/4,770 4.60 <0.001 3.81 - 5.55 3.27 <0.001 2.64 - 4.06
50 28/594 7.81 <0.001 5.35 - 11.39 6.56 <0.001 4.49 - 9.60
Chlorthalidone 12.5 11/291 6.32 <0.001 3.48 - 11.46 5.46 <0.001 3.01 - 9.92
25 31/877 5.92 <0.001 4.13 - 8.48   5.62 <0.001 3.92 - 8.06
†model adjusted for current use of angiotensin receptor blockers  proton pump inhibitors, carboxamide 
derivatives and triamterene
table 4 Risk of hyponatremia compared between current use of hydrochlorothiazide or chlorthalidone
  unadjusted model   adjusted model†
Current use (mg per day)‡
Odds ratio p-value 95%CI   Odds 
ratio
p-value 95%CI
Chlorthalidone 12.5 vs. hydrochlorothiazide 12.5 1.74 0.078 0.94 - 3.21 2.09 0.019 1.13 - 3.88
Chlorthalidone 12.5 vs. hydrochlorothiazide 25.0 1.37 0.313 0.74 - 2.54 1.66 0.110 0.90 - 3.11
Chlorthalidone 25.0 vs. hydrochlorothiazide 25.0 1.29 0.207 0.87 - 1.90 1.72 0.009 1.15 - 2.57
Chlorthalidone 25.0 vs. hydrochlorothiazide 50.0 0.76 0.289 0.45 - 1.26   0.86 0.551 0.51 - 1.43
†model adjusted for current use of angiotensin receptor blockers, proton pump inhibitors, carboxamide 
derivatives and triamterene; ‡last-referred medication acts as reference
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to the final model. Current use of CTDN, adjusted odds ratio (ORadj) 5.62 (95%CI 4.14 to 
7.63) or HCTZ, ORadj 5.46 (95%CI 2.97 to 4.04) significantly increased the risk of hypo-
natremia compared to no use. The risk was 62% higher with current use of CTDN, ORadj 
1.62 (95%CI 1.18 to 2.23), compared to current use of HCTZ (data not shown).  
With all studied doses per day, current use of CTDN or HCTZ significantly increased 
the risk of hyponatremia in comparison to no use. The risk was lowest for HCTZ 12.5 
mg/d ORadj 2.61 (95%CI 2.13 to 3.20) (table 3).
 In the adjusted model, the risk of hyponatremia attributed to CTDN 12.5 mg/day was 
significantly higher at equivalent milligram dose per day in comparison to HCTZ 12.5 
mg/d: ORadj: 2.09 (95%CI 1.13 to 3.88). This also applied to the comparison between 
CTDN 25 mg/d and HCTZ 25 mg/d, where CTDN was associated with a higher risk of 
hyponatremia (ORadj 1.72 (95%CI 1.15 to 2.57), (tables 3 and 4). However, there was 
no significantly increased risk when CTDN and HCTZ were compared at approximately 
equipotent dose per day (CTDN compared with twice the amount the dose of HCTZ per 
day), which showed an adjusted OR for CTDN 12.5 mg/d compared to HCTZ 25 mg/d 
of  1.66 (95%CI  0.89 to 3.11) and adjusted OR for CTDN 25 mg/d compared to HCTZ 50 
mg/d of 0.85 (95%CI 0.51 to 1.42).
DISCuSSIon
We found an increased risk of hyponatremia compared to no use with CTDN and HCTZ 
for all studied doses per day, with the lowest risk increase for HCTZ 12.5 mg/d,  To our 
knowledge this is the first study that shows that hyponatremia is more common with 
CTDN than HCTZ in equal dose. However, we did not find a significantly increased 
risk of hyponatremia with CTDN compared to twice the dose of HCTZ per day (CTDN 
12.5mg/d versus HCTZ 25 mg/d and CTDN 25mg/d versus HCTZ 50mg/d), despite de-
cent exposure to both CTDN and HCTZ. Although dose recommendations for initiation 
of therapy for hypertension with CTDN or HCTZ in prescribing information and clinical 
guidelines are identical [32], it is evident that these medications are not equipotent on 
a milligram-to-milligram basis. The majority of clinical studies report a similar drop in 
(daytime) blood pressure for CTDN compared to twice the amount of HCTZ [5, 6, 33-
35], and during a titrate-to-target blood pressure trial, significantly more patients in the 
HCTZ arm required up-titration to meet the target goal compared to those treated with 
CTDN [36]. Therefore, the need for a lower dose of CTDN relative to HCTZ to achieve 
similar reduction in blood pressure and cardiovascular outcomes might also reduce the 
risk of hyponatremia that exists at equal milligram-to-milligram dose. We consider that 
the increased risk of hospitalization with hyponatremia in subjects on CTDN relative 
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to subjects on HCTZ (all dosing regimens within each treatment combined) observed 
by Dhalla et al. [11] might result from an imbalance in the equipotent dose per day 
between CTDN and HCTZ at baseline, as there was little evidence for an increased risk of 
hyponatremia with CTDN relative to twice the dose of HCTZ per day similar to the results 
of the current study.
From a physiological perspective, two properties of CTDN might increase the risk 
of hyponatremia relative to HCTZ. First, in contrast to HCTZ [37-40], CTDN activates the 
sympathetic nervous system, independently of blood pressure [41], which increases 
arginine vasopressin (AVP) plasma levels [42, 43].  Second, CTDN’ s half-life (35-67 hours) 
[44] is longer than that of HCTZ (7-11 hours) [45, 46], which might put subjects at in-
creased risk when a medical condition disturbs sodium and water balance. 
In our study, the majority of concomitant medications and conditions did not confound 
the estimate of CTDN relative to HCTZ, which is possible as a similar degree of confound-
ing would not influence the relative effect, whereas exposure to other confounders 
might be rare and hence not result in a relevant degree of confounding. Unexpectedly, 
the risk of hyponatremia with CTDN relative to HCTZ was influenced by ARBs, but not 
by angiotensin-converting-enzyme inhibitors, whereas others found a similar risk of 
hyponatremia [47]. We consider confounding by indication unlikely as the indication is 
similar. Although unmeasured confounding [48] cannot be excluded also actual differ-
ences might underlie. ARBs suppress aldosterone more effectively[49] and selectively 
block the angiotensin II subtype 1  receptor that increases sodium reabsorption[50], but 
not the angiotensin II subtype 2  receptor that promotes sodium excretion[51],[52-55] 
[56]Also angiotensin II levels are higher with long-term ARB treatment[49] and if HCTZ 
is used concomitantly, the angiotensin II induced sodium reabsorption via the sodium 
chloride symporter is abolished [57], which might also apply to CTDN that targets the 
same renal sodium transporter.
Strengths of our study include its population-based design, representing the popula-
tion receiving treatment with CTDN and/or HCTZ on a day-to-day basis, the application 
of strict exclusion criteria, as well as the critical appraisal of, and the adjustment for a 
large number of important confounders, including medical conditions and concomitant 
medications. Limitations include the relatively low number of cases that used CTDN 
and the fact that our data do not allow adjustment for all previously reported risk fac-
tors, such as weight [58] and renal function [59], although there is no a-priori reason to 
believe that these would differ between subjects using CTDN and HCTZ. Finally, medica-
tion exposure was based on prescriptions and not on actual intake but as both drugs 
are chronically used, the mostly timely refills make it likely that the drugs were actually 
taken.
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PErSPECtIVES
Our results indicate that the risk of hyponatremia in users of CTDN is higher than in 
users of HCTZ when used at the same - but not equipotent - dose of 12.5 or 25 mg/day. 
We did not find an increased risk of hyponatremia with CTDN compared to twice the 
dose of HCTZ per day, which is needed to achieve similar reduction in blood pressure. 
Recent network meta-analyses suggest that CTDN is superior to HCTZ in preventing 
cardiovascular events, which cannot be attributed entirely to the lesser effect of HCTZ 
on office systolic blood pressure [8].  Based on our results we conclude that this benefit 
is not offset by an increased risk of hyponatremia, hence results remain in favor for 
CTDN. Evaluation of the benefits of CTDN relative to HCTZ should be continued with 
consideration of the risk of hyponatremia, during future head-to-head clinical studies 
and antihypertensive treatment selection for the individual patient.
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ABStrACt 
Background
Drug-induced hyponatremia is a common adverse drug reaction in the elderly. Of 
the antidepressant drugs, only Selective Serotonin Reuptake Inhibitors (SSRIs) have 
consistently been associated with hyponatremia. Our objective was to investigate the 
association between antidepressants and hyponatremia within a large database of 
community-dwelling adults.  
methods
Design: Matched case-control study. Setting: Data from the Dutch Integrated Primary 
Care Information database. Participants: We included subjects aged ≥18 years during 
the period 1996-2011. Cases had a serum sodium level ≤130 mmol/l or were hospital-
ized due to hyponatremia. Up to 10 controls were matched on practice, year of birth, 
sex and date of onset. Measurements: Exposure to antidepressants was derived from 
prescription records and categorized as Tricyclic antidepressants (TCAs), SSRIs or other. 
Conditional logistic regression was used to estimate odds ratios.   
results
In total, 2,312 cases of hyponatremia were identified and matched to 18,295 controls. 
Current use of antidepressants increased the risk for hyponatremia relative to non-use: 
SSRIs (odds ratio (OR) =2.99 (95%CI: 2.11 – 4.22)), TCAs, (OR=1.63 (95%CI: 1.04 – 2.57)) 
and other antidepressants (OR=1.98 (95% CI: 1.20 – 3.26). The risk was higher during the 
first month of treatment, for SSRIs (OR=13.37; 95%CI: 6.31 – 28.33) and TCAs (OR=3.70, 
95%CI: 1.59 – 8.59) respectively. 
Conclusion
Use of all of the antidepressant classes was associated with an increased risk for hy-
ponatremia. Especially within the first month of SSRI and TCA treatment the risk for 
hyponatremia is higher. Monitoring of sodium levels in daily clinical practice during this 
period might help to reduce the incidence of hyponatremia.
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IntroDuCtIon
Hyponatremia is associated with an increased risk of morbidity and mortality, even 
in mild forms [1, 2]. Clinical symptoms of hyponatremia depend on the severity and 
acuteness, varying from headache and confusion to convulsions and coma [2, 3]. The 
use of certain drugs, mainly diuretics and some psychotropic agents, are a risk factor for 
hyponatremia [4]. 
Of the psychotropic agents, Selective Serotonin Reuptake Inhibitors (SSRIs) and 
venlafaxine have consistently been associated with hyponatremia [5-12]. SSRI-induced 
hyponatremia is an adverse drug reaction with a reported incidence varying from 0.5% 
to 32%, [8], which develops more frequently in the elderly [12, 13]. Hyponatremia in 
relation to tricyclic antidepressants (TCAs) and other newer antidepressants has been 
studied to a lesser extent. The main evidence comes from case reports of hyponatremia 
related to amitriptyline, imipramine and mirtazapine [14-19]. The number of pharmaco-
epidemiological studies on TCAs and hyponatremia is limited and results are conflicting 
[5, 9, 20-22]. Also the underlying biological mechanism of antidepressant drug-induced 
hyponatremia is still under debate [6, 10, 21, 23]. 
All previous studies on SSRI-induced hyponatremia have important limitations, 
including a limited sample size or missing information on current medical illnesses 
and drug use. For TCAs and other antidepressants the number of studies is limited and 
results are inconsistent, but based on the hypothesized biological mechanisms we could 
also expect an increased risk for some of the TCAs and other antidepressants. There-
fore, we investigated the association between all antidepressants and hyponatremia 
within a large database of prospectively gathered electronic health care records from a 
community-dwelling adult population. 
mEtHoDS
Setting
All data were retrieved from the Integrated Primary Care Information (IPCI) project. 
The IPCI project is a longitudinal observational, dynamic database which contains the 
electronic medical records of a group of more than 600 general practitioners (GPs) in 
the Netherlands. The database contains the complete electronic medical records of ap-
proximately 1,5 million patients. These medical records are de-identified and contain 
data on demographics, symptoms and diagnoses (coded and in free text), referrals, 
laboratory findings, hospitalizations, discharge letters, and drug prescriptions (which 
includes the ATC code and dosage regimen). In the Dutch health care system, the GP 
has a crucial role and functions as a gatekeeper of medical care and almost all inhabit-
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ants of the Netherlands are registered with a GP. Details of the IPCI database have been 
described elsewhere [24, 25]. The system complies with European Union guidelines on 
the use of electronic healthcare data for medical research and has been proven valid for 
pharmaco-epidemiologic studies [24]. The Scientific and Ethical Advisory Board of IPCI 
project approved the study (study protocol N. 02/13). 
Study population
The source population comprised all subjects from the IPCI database, aged 18 years and 
above, during the study period from January 1st, 1996 until March 1st, 2011. Subjects 
should have at least 1 year of data registered in the database, with no occurrence of 
hyponatremia, before inclusion in our study. All subjects were followed until first occur-
rence of hyponatremia, death, transfer out of practice, last data draw-down, or end of 
the study period, whichever came first.
Cases and controls
Subjects who were diagnosed with a serum sodium level below 130 millimole per liter 
and/or subjects (obtained from laboratory measurement files) or who were hospitalized 
with a specialist diagnosis of hyponatremia at admission were defined as cases. This 
serum sodium level was chosen to select the more substantial cases of hyponatremia, 
representing moderate to severe hyponatremia [26]. All possible cases were validated 
through manual review of the electronic medical record while blinded to the exposure. 
Up to 10 controls were selected from the same practice by incidence density sampling 
[27] and matched to each case on sex, year of birth and index date. The index date was 
defined as the date of onset of hyponatremia. 
Exposure definition
Exposure to antidepressant drugs was obtained from the prescription records. Anti-
depressants were grouped, based on the anatomical therapeutic coding system (ATC) 
[28], into SSRI (ATC=N06AB), TCA (ATC=N06AA), and other (ATC=N06AF, N06AG, N06AX) 
antidepressants. The duration of treatment was calculated by dividing the prescribed 
amount of pills/suspension by the dosing regimen. The treatment episode was consid-
ered to be continuous if the gap between consecutive antidepressant drug prescrip-
tions was less than 30 days. Exposure was classified  at the index date and categorized in 
never, past, current or recurrent antidepressant drug use. Past users were not exposed to 
an antidepressant at the index date, but were exposed at some time point between start 
of follow-up and the index date. Subjects were considered to be recurrent users if they 
were exposed to an antidepressant at the index date and had also used an antidepres-
sant in the past. 
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Co-variables
We considered medical conditions and other medication use at the index date as po-
tential confounders in our analyses. Medical conditions were based on the International 
Classification of Primary Care (ICPC) diagnosis code [29], as potential confounders we 
included: cerebrovascular disease (transient ischemic attack, stroke), diabetes insipidus, 
hypothyroidism, heart failure, liver failure, alcoholism, ischemic heart disease (angina 
pectoris and myocardial infarction), malignancies, Parkinson’s disease and pulmonary 
disease (asthma and chronic obstructive pulmonary disease) [2, 22, 30, 31].  In addition, 
potential confounding drug use was based on previous reports on their association with 
hyponatremia, and assessed at the 3rd ATC coding system level [32]. We considered the 
following drugs: drugs for acid related disorders (A02), glucose lowering agents (A10), 
cardiac therapy (C01), diuretics (C03), beta-blocking agents (C07), calcium channel 
blockers (C08), agents acting on the renin-angiotensin system (C09), thyroid therapy 
(H03), anti-bacterial agents (J01), analgesics (N02), anti-epileptics (N03), anti-Parkinson 
drugs (N04), psycholeptics (N05) and anti-inflammatory and anti-rheumatic drugs (M01) 
(6, 33, 34). 
Statistical analysis
Characteristics of the study population are presented for the cases and controls sepa-
rately. Differences between cases and controls were tested with chi-square statistics or 
independent t-test, for dichotomous or continuous variables, respectively. Conditional 
logistic regression analyses were used to assess the association between antidepres-
sants and hyponatremia. As potential confounders, we included co-variables in the 
model that changed the association between antidepressants and hyponatremia by 
minimal 5%. The model included 3 categorical variables for the different antidepressant 
drug classes (SSRI, TCA or other). Duration of current antidepressant drug treatment 
was categorized in different groups: 0-30 days, 31-180 days, >180 days.  In separate 
analyses we considered past users as the reference population to control for confound-
ing by indication. First, by including all past users, and secondly by including all past 
users who ceased antidepressant use at least 1 year before the index date respectively, 
to minimize the effect of exposure misclassification. Furthermore, we studied the in-
dividual antidepressant drugs with a sufficient number of exposed cases (>10). Three 
additional analyses were performed. First, we analyzed only cases defined by a specialist 
diagnosis of hyponatremia, to restrict the possibility of diagnostic bias by GP routine 
measurements. Second, cases were restricted to sodium levels below 125 mmol/L to 
focus on more severe hyponatremia [26]. Third, subjects with a diagnosis of liver or heart 
failure were excluded from the analysis and we assessed effect modification by common 
co-morbidities or thiazide use. 
98 Chapter 4.2
Analyses were performed with SPSS Statistics for Windows (Version 21.0, IBM, 
Somers, NY, USA). We considered a p-value less than 0.05 as statistically significant. 
rESultS
A total of 2,312 subjects with hyponatremia were identified within the IPCI database 
between January 1st, 1996 and March 1st, 2011 and matched to 18,295 control sub-
jects. The mean age was 71.5 years and 67.8% was female. Detailed characteristics of 
the cases and controls are presented in table 1. Despite matching, the mean age of the 
cases was slightly higher  than controls, which is due to variation in the number of avail-
able controls per case. The most frequently prescribed antidepressants at the time of 
hyponatremia onset  were amitriptyline (n=96), paroxetine (n=81), citalopram (n=77), 
and mirtazapine (n=53). 
table 1. Baseline characteristics
Cases (n=2312) Controls (n=18295) P-value 
Female gender 1579 (68.3) 12386 (67.7) 0.550
Age years, mean (SD) 74.1 (14.4) 71.1 (13.4) <0.001
Antidepressant drug use
Current SSRI use 62 (2.7) 154 (0.8) <0.001
Current TCA use 32 (1.4) 109 (0.6) <0.001
Current Other antidepressant use 30 (1.3) 80 (0.4) <0.001
Concomitant medication 
Drugs for acid related disorders (A02) 630 (27.2) 2479 (13.5) <0.001
Glucose lowering agents (A10) 353 (15.3) 1715 (9.4) <0.001
Cardiac therapy (C01) 254 (11.0) 1028 (5.6) <0.001
Diuretics (C03) 975 (42.2) 3911 (21.4) <0.001
Beta-blocking agents (C07) 676 (29.2) 3538 (19.3) <0.001
Calcium channel blockers (C08) 305 (13.2) 1741 (9.5) <0.001
Agents acting on the renin-angiotensin system (C09) 841 (36.4) 3959 (21.6) <0.001
Thyroid therapy (H03) 133 (5.8) 764 (4.2) <0.001
Antibacterials for systemic use (J01) 211 (9.1) 229 (1.3) <0.001
Analgesics (N02) 270 (11.7) 668 (3.7) <0.001
Antiepileptic drugs (N03) 132 (5.7) 221 (1.2) <0.001
Anti-parkinson drugs (N04) 36 (1.6) 99 (0.5) <0.001
Psycholeptic drugs (N05) 541 (23.4) 1857 (10.1) <0.001
Antiinflammatory and antirheumatic products (M01) 130 (5.6) 595 (3.3) <0.001
Co-morbidities
Heart failure 371 (16.0) 1124 (6.1) <0.001
Liver failure 40 (1.7) 112 (0.6) <0.001
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Different antidepressant drugs
Current use of an SSRI was associated with a three times higher risk for hyponatremia 
compared to non-use (Table 2). Current use of TCAs and other antidepressants showed 
a more than 1.5 and almost two times higher risk. Also past TCA use was associated with 
a significantly higher risk (OR=1.25, 95% CI: 1.01 – 1.52), whereas recurrent use of any 
of the antidepressants was not associated with an increased risk for hyponatremia. In 
comparison to past use, current SSRI use showed a more than 2.5 times higher risk for 
hyponatremia, which was not the case for TCAs and other antidepressants. Results did 
not materially change when past use was restricted to those patients who discontinued 
more than one year ago (results not shown). The odds ratios of the most commonly used 
antidepressants, showed point estimates which were in line with the overall SSRI, TCA 
and other antidepressant point estimates showed in table 2, namely for: amitriptyline 
(OR=1.56, 95%CI: 0.91 – 2.69), paroxetine (OR=2.85; 1.61 – 5.02), citalopram (OR=2.98; 
95%CI: 1.73 – 5.14), and mirtazapine (OR=2.28; 1.15 – 4.50).
table 1. Baseline characteristics (continued)
Cases (n=2312) Controls (n=18295) P-value 
Alcoholism 150 (6.5) 233 (1.3) <0.001
Asthma/COPD 470 (20.3) 2376 (13.0) <0.001
Hypothyroidism 139 (6.0) 729 (4.0) <0.001
Parkinson 25 (1.1) 153 (0.8) <0.001
Malignancies 402 (17.4) 1498 (8.2) <0.001
Ischemic stroke 360 (15.5) 1504 (8.2) <0.001
Heart disease (Myocardial infarction, Angina pectoris) 448 (19.4) 2640 (14.4) <0.001
The characteristics are presented as numbers (%), unless stated otherwise. 
table 2. Association between antidepressant drug use and hyponatremia1 
Case / Control Odds ratiocrude
(95%CI)
Odds ratioadj2
(95%CI)
Odds ratioadj3
(95%CI)
SSRI
Non-use 2024 / 16716 1.00 (Reference) 1.00 (Reference)
Past 169 / 1041 1.16 (0.97 – 1.40) 1.10 (0.90 – 1.33) 1.00 (Reference)
Recurrent 57 / 389 1.16 (0.86 – 1.55) 0.78 (0.56 – 1.08) 0.71 (0.49 – 1.03)
Current 62 / 154 3.36 (2.46 – 4.59) 2.99 (2.11 – 4.22) 2.73 (1.85 – 4.02)
TCA
Non-use 2085 / 17206 1.00 (Reference) 1.00 (Reference)
Past 161 / 805 1.53 (1.27 – 1.86) 1.25 (1.01 – 1.52) 1.00 (Reference)
Recurrent 34 / 180 1.43 (0.97 – 2.11) 0.75 (0.49 – 1.15) 0.60 (0.38 – 0.95)
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table 2. Association between antidepressant drug use and hyponatremia1  (continued)
Case / Control Odds ratiocrude
(95%CI)
Odds ratioadj2
(95%CI)
Odds ratioadj3
(95%CI)
Current 32 / 109 2.45 (1.62 – 3.70) 1.63 (1.04 – 2.57) 1.31 (0.80 – 2.14)
Other
Non-use 2135 / 17451 1.00 (Reference) 1.00 (Reference)
Past 121 / 635 1.42 (1.14 – 1.76) 1.19 (0.94 – 1.51) 1.00 (Reference)
Recurrent 26 / 134 1.63 (1.06 – 2.51) 0.94 (0.58 – 1.52) 0.79 (0.47 – 1.33)
Current 30 / 80 2.56 (1.63 – 4.04) 1.98 (1.20 – 3.26) 1.66 (0.97 – 2.86)
Crude odds ratio =  matched on sex, age and GP. Adjusted odds ratio2, adjusted for the following significant 
covariates (>5%change odds ratio): alcoholism, heart failure, malignancies; and the following comedica-
tion: analgesics, antiepileptics, psycholeptics, antibacterials for systemic use, drugs for acid related dis-
orders, diuretics, agents acting on the renin-angiotensin system, drugs used in diabetes, beta blocking 
agents, anti-inflammatory and antirheumatic products, and the other antidepressant drug groups. Abbre-
viations: TCAs  =  tricyclic antidepressants, SSRIs =  selective serotonin reuptake inhibitors.  1 =  Hyponatre-
mia defined based on a serum sodium level of 130mmol per liter or below and/or hospital admission with 
a specialist diagnosis of hyponatremia at admission.  2  =  Past use as the reference population and adjusted 
for the same significant covariates as model 2.   
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Figure 1. Risk of hyponatremia1 by duration of current antidepressant drug treatment.  
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FIGURE LEGEND: Abbreviations: TCAs = tricyclic antidepressants, SSRIs= selective serotonin 
reuptake inhibitors. Data presented as the odds ratio for the different duration categories of 
current antidepressant use compared to non-use. Adjusted for the following significant covariates 
(>5%change odds ratio): alcoholism, heart failure, malignancies; and the following 
comedication: analgesics, antiepileptics, psycholeptics, antibacterials for systemic use, drugs for 
acid related disorders, diuretics, agents acting on the renin-angiotensin system, drugs used in 
diabetes, beta blocking agents, anti-inflammatory and antirheumatic products, and the other 
antidepressant drug groups. 1= Hyponatremia defined based on a serum sodium level of 
130mmol per liter or below and/or hospital admission with a specialist diagnosis of 
hyponatremia at admission. 
figure 1. Risk of hyponatremia1 by duration of current antidepressant drug treatment.
Abbreviations: TCAs  =  tricyclic antidepressants, SSRIs =  selective serotonin reuptake inhibitors. Data pre-
sented as the odds ratio for the different duration categories of current antidepressant use compared to 
non-use. Adjusted for the following significant covariates (>5%change odds ratio): alcoholism, heart failure, 
malignancies; an  the following comedication: analgesics, antiepilepti s, psycholeptics, antibacterials for 
systemic use, rugs for acid related disorders, diuretics, agents acting n the renin-angioten in system, 
drugs used in diabetes, beta blockin  agents, a ti-inflammatory d antirheumatic products, and the other 
antidepress t drug groups. 1 =  Hyponatremia defined based on a serum sodium level of 130mmol per 
liter or below and/ r hospital admission with a specialist diagnosis of hyponatremia at admission.
Antidepressants and the risk for hyponatremia 101
Duration of treatment
For current SSRI use, a higher risk for hyponatremia was observed during the first 6 
months of treatment (Figure 1), which was most prominent during the first month of 
treatment (OR= 13.37, 95%CI: 6.31 – 28.33). For current TCA use, the increased risk for 
hyponatremia was only present in the first month after initiation of treatment (OR=3.70, 
95%CI: 1.59 – 8.59). No effect of duration for other antidepressant drug treatment was 
observed.
Sensitivity analyses
For the hospitalized cases (i.e. hyponatremia defined at hospital admission with a 
specialist diagnosis of hyponatremia), we observed an increased risk for hyponatremia 
for current SSRI and TCAs use, OR=3.25 (95%CI: 2.05 – 5.03) and OR=2.34 (95%CI: 1.27 
– 4.33), respectively (Table 3). When the case definition was restricted to <125 mmol/L, 
the increased risk for hyponatremia showed similar results for SSRIs (OR= 3.74, 95%CI: 
table 3. Association between antidepressant drug use and hyponatremia defined at hospital admission1   
Case / Control Odds ratiocrude
(95%CI)
Odds ratioadj
(95%CI)
Hospitalization2
SSRI
Non-use 892 / 7676 1.00 (Reference) 1.00 (Reference)
Past 81 / 437 1.34 (1.03 – 1.76) 1.15 (0.86 – 1.54)
Recurrent 26 / 173 1.27 (0.83 – 1.95) 1.10 (0.69 – 1.73)
Current 36 / 86 3.78 (2.51 – 5.70) 3.25 (2.05 – 5.13)
TCA
Non-use 924 / 7873 1.00 (Reference) 1.00 (Reference)
Past 76 / 373 1.58 (1.20 – 2.09) 1.28 (0.94 – 1.73)
Recurrent 18 / 70 1.81 (1.03 – 3.18) 0.90 (0.48 – 1.70)
Current 17 / 56 2.53 (1.44 – 4.47) 2.34 (1.27 – 4.33)
Other
Non-use 963 / 8006 1.00 (Reference) 1.00 (Reference)
Past 54 / 277 1.38 (1.00 – 1.90) 1.10 (0.77 – 1.56)
Recurrent 10 / 47 1.70 (0.84 – 3.44) 0.92 (0.42 – 2.01)
Current 8 / 42 1.08 (0.48 – 2.41) 0.78 (0.34 – 1.84)
Crude odds ratio =  matched on sex, age and GP. Adjusted odds ratio, adjusted for: alcoholism, heart failure, 
liver failure, malignancies; and the following comedication:  analgesics, antiepileptics, psycholeptics, anti-
bacterials for systemic use, drugs for acid related disorders, diuretics, beta blocking agents, and the other 
antidepressant drug groups. 
1 Hyponatremia defined at hospital admission with a specialist diagnosis of hyponatremia.  
Abbreviations: TCAs = tricyclic antidepressants, SSRIs =  selective serotonin reuptake inhibitors. 
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1.84 – 7.60) and TCAs (OR=3.03, 95%CI: 1.06 – 8.68). Other antidepressant use showed no 
association with profound hyponatremia (OR=1.30, 95%CI: 0.36 – 4.69). 
When we assessed effect modification by common comorbidities, we observed 
significant effect modification by glucose lowering agents on the association between 
TCAs and hyponatremia (p=0.018). The risk for hyponatremia was 1.24 (CI: 0.73 – 2.10) 
for TCA users who did not use glucose lowering agents. While, there was a 5.29 (CI: 1.80 
– 15.74) increased risk for hyponatremia in TCAs users who also used glucose lowering 
agents. Other comorbidities showed no significant effect modification on the associa-
tion between antidepressant drugs and hyponatremia. Exclusion of subjects with heart 
and liver failure did not significantly alter our results (results not shown).  
DISCuSSIon
The results from this matched case-control study show that current use of all antidepres-
sants is associated with an increased risk for hyponatremia compared with non-use, the 
risk being higher during the first month of TCA and SSRI treatment. 
TCA and other antidepressant use was associated with hyponatremia in our 
matched case-control study. Especially short term TCA use was associated with a high 
risk for hyponatremia. Prior evidence on the association between TCAs and hypona-
tremia is inconsistent or based on case-reports [5, 9, 14-18, 20-22]. These studies have 
important limitations which restrict their implications; including small sample size (≤15 
exposed cases) [5, 21, 22], failure to adjust for confounding factors at event date [9, 
20], no stratification by treatment duration and no consideration of past users in their 
analyses [5, 9, 20-22]. The results for other antidepressants in our study are more difficult 
to interpret because these might be heterogeneous in their mechanism of action and 
have a low number of cases with the individual drugs. Only venlafaxine has consistently 
been associated with hyponatremia [7, 10, 33], and some case-reports on mirtazapine-
induced hyponatremia have been published [19, 34]. For both TCAs and other antide-
pressants, the indication of use might explain the association with hyponatremia, as the 
association disappeared when compared to past antidepressant users. Antidepressant 
drugs might be prescribed for certain comorbidities which increase the susceptibility 
to hyponatremia. For example, neuropathic pain, which might be a complication of 
diabetes mellitus, is a common indication for TCAs and diabetes mellitus has been 
demonstrated to be a risk factor for hyponatremia [35]. Also, our association between 
TCA use and hyponatremia was modified by glucose lowering drugs (or presence of 
diabetes). Stratified by subjects who used glucose lowering drugs, we observed that in 
both groups the risk for hyponatremia was higher for TCAs, but the association was no 
longer statistically significant within subjects that did not use glucose lowering drugs. 
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This might represent power problems, but also implicates an important role of diabetes 
in the association between TCAs and hyponatremia. 
Consistent with previous literature, SSRIs were evidently associated with hy-
ponatremia [5-9, 11, 13, 23, 33, 36]. It is likely a medication class effect, as individual 
antidepressants with sufficient numbers (e.g. citalopram, paroxetine) demonstrated a 
similar increase in risk for hyponatremia. The highest risk was observed during the first 
month of treatment, which shows a strong consistency with earlier studies in which the 
majority of hyponatremia cases presented within 30 days after initiation of therapy [5, 
11, 23, 36, 37]. An increased risk of SSRI-induced hyponatremia was also observed dur-
ing the first half year, but not for long term use. This confirms the hypothesis that the 
effect of SSRIs on hyponatremia is transient over time [6, 38]. Besides, patients at high 
risk for hyponatremia might develop  it during the first weeks of treatment, leaving the 
low risk patients in the long term treatment group. In line with this observation, we 
observed that recurrent use of any of the antidepressants was not associated with hypo-
natremia, which might also be due to depletion of susceptibles; patients who reinitiate 
the antidepressant are those who can tolerate its effects [39]. It could be hypothesized 
that subjects that did not develop hyponatremia the first time they used an antidepres-
sant, neither developed it later on, unless other risk factors made them possible more 
susceptible to hyponatremia (e.g. heart failure, diarrhea). 
   The underlying biological mechanism of SSRI and venlafaxine induced hypona-
tremia is the non-osmotic inappropriate stimulation of antidiuretic hormone (ADH), 
possible mediated by the stimulation of the serotonin receptors (5-HT1c and 5-HT2) and 
α-1-adrenergic receptors [10, 23, 40-43]. This would especially apply for SSRIs and some 
other antidepressants (e.g. venlafaxine, mirtazapine), but TCAs can also be potent inhibi-
tors of  serotonin [44]. Laboratory investigations did not consistently confirm SIADH as 
the main underlying mechanism of antidepressant-induced hyponatremia [6, 10, 21, 
23]. Our results are in line with the anticipated  results, based on SIADH as the possible 
mechanism, however we cannot draw conclusions regarding the mechanism of action 
as we have no information regarding plasma and urine osmolality. Another proposed 
alternative mechanism suggests an increased nephrogenic response to ADH leading to 
inappropriate anti-diuresis [21]. 
 Our study has some strengths which we would like to emphasize. Our study 
includes a large number of cases with hyponatremia within a population of commu-
nity dwelling adults. We could study multiple aspects of antidepressant drug exposure, 
including important confounders as medical conditions and concomitant medica-
tions. By using 130mmol/L as a cut-off  for hyponatremia we included only the more 
substantial cases of hyponatremia, and we also performed an additional analysis with 
a lower cut-off. Misclassification of cases was unlikely in this situation, as only the more 
serious cases of clinically relevant hyponatremia were included which were confirmed 
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by sodium measurements. By selecting cases which were diagnosed during hospitaliza-
tion, we ruled out selection bias, as hyponatremia was not detected during (routine) 
GP measurements. However, also some limitations should be taken into account. 
Firstly, our data did not allow for adjustment of bodyweight, which is a significant risk 
factor for hyponatremia, although bodyweight might not be distinctly related to drug 
exposure  [11, 21]. Secondly, our study might be subject to residual confounding. We 
had no information regarding the indication of treatment and its severity, although we 
limited confounding by indication through analyses with past use of antidepressants as 
the reference population. Finally, medication exposure was based on prescription data 
and not on actual intake. Episodes of use were calculated based on the prescriptions 
to determine, as accurate as possible, the drug exposure in our large GP database and 
misclassification of exposure would be non-differential. 
In our study, from a large daily practice adult population, we were able to study 
the relative risk of antidepressant exposure for hyponatremia. Our results confirm that 
SSRI treatment is associated with an increased risk for hyponatremia, being higher dur-
ing the first months of SSRI treatment. Also short term TCA users are at risk to develop 
hyponatremia. The HARM wrestling treatment criteria (2009) indicate serum sodium 
measurements during the first 5-9 days after initiation of SSRI treatment, during con-
secutive use of thiazides in the elderly (>70year) [45]. However, until now, no guidelines 
exist regarding serum sodium measurements for exclusive use of SSRIs or TCAs in the 
elderly, while monitoring of sodium levels in daily clinical practice during the first few 
weeks might help to reduce the incidence of hyponatremia. 
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ABStrACt
Background
Hyponatremia is associated with increased morbidity and mortality and is often drug-
induced. In a subanalysis of a recent study, we identified a novel association between 
benzodiazepines and hyponatremia. Here, our objective was to study the potential 
association between benzodiazepines and hyponatremia in greater detail using an 
independent cohort. 
methods
A nested case-control study was performed in a general practioner database containing 
over one million patient records (Integrated Primary Care Information; IPCI). All subjects 
with a serum sodium level of below 130 mmol/L or a hospital admission diagnosis of 
hyponatremia were selected and matched with up to 10 controls from similar practice, 
sex and age. The association with benzodiazepines and their interaction with thiazides 
was studied using conditional logistic regression analyses. 
results
Of the benzodiazepines, the anxiolytics were associated with a more than 2-fold in-
creased risk of hyponatremia (OR 2.08; 95% CI 1.75-2.48); and 1.5 times increased risk 
by use of sedatives (OR 1.51; 95% CI 1.26-1.83). The combination of anxiolytics and 
thiazides increased the risk of hyponatremia > 5-fold (OR 5.02; 95% CI 3.75, 6.72), which 
was significantly higher than the separate use of these drugs .
Conclusion
Benzodiazepines are associated with an increased risk of hyponatremia. Concomitant 
use of thiazide diuretics leads to even higher risks. Use of these drugs deserves caution; 
we recommend serum sodium control measurements and special attention for these 
drugs in case of symptoms of hyponatremia. 
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IntroDuCtIon
Hyponatremia is the most common electrolyte disorder in the general population. It 
may cause symptoms such as nausea and headache and in more severe cases seizures 
and coma.[1, 2] Mild forms are already associated with morbidity, including increased 
risk of falls and fractures, and higher mortality.[3-5] 
Drugs are one of the most frequent causes of hyponatremia, with thiazides being 
the most common .[1, 6, 7] The mechanism of thiazide-induced hyponatremia is not 
completely clear, but appears to involve the following: excess renal loss of electrolytes, 
in combination with impaired renal water excretion (by diminishing NaCl reabsorption 
and increased ADH secretion), electrolyte shift into the cell, and magnesium depletion 
.[1, 8-11] Drugs acting on the central nervous system, antidepressants and antiepileptics, 
have been associated with an increased risk of hyponatremia.[12-14] These drugs seem 
to affect water homeostasis due to the syndrome of inappropriate secretion 
of antidiuretic hormone (SIADH) in three possible ways: they can increase ADH 
secretion centrally, potentiate the effect of endogenous ADH at the renal medulla, and 
reset the osmostat, thus lowering the threshold for ADH secretion. 
Although many drugs have been associated with hyponatremia,[6] it is important to 
be aware of unknown associations with other drugs and unknown potential interactions. 
Recently, we identified an association between benzodiazepines and hyponatremia in 
a population-based study, and showed an interaction with thiazide diuretics.[15] Two 
main subclasses of benzodiazepines can be identified, based on their pharmacological 
mechanism: anxiolytics (e.g. oxazepam) and sedatives. Sedatives cover two main classes 
based on chemical mechanism (e.g. temazepam versus zopiclone). They are indicated 
for anxiety disorders (anxiolytics), and sleep disturbances (sedatives). Some case-reports 
of benzodiazepine-induced hyponatremia have also been reported,[16-18] but this as-
sociation has not been studied in detail. 
Therefore, we conducted this case-control study with patients from general 
practitioner practices recruited throughout The Netherlands to study the risk of benzo-
diazepine-induced hyponatremia and to seek confirmation of the interaction between 
benzodiazepines and thiazides. 
mEtHoDS
Setting
A nested case-control study was conducted in the Integrated Primary Care Information 
(IPCI) database. This longitudinal observational general practitioner (GP) research data-
base contains patient records of 1.5 million patients throughout the Netherlands. In the 
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Netherlands, all citizens are registered with a GP practice, which forms the central point 
of healthcare and acts as a gatekeeper for secondary health care. Therefore, the medical 
record of each patient can be assumed to contain all relevant medical information, in-
cluding medical findings and diagnoses from specialist health care. To further maximize 
the completeness of data, GPs contributing data to the IPCI database are not allowed 
to maintain a system of paper based records next to the electronic medical records. 
The electronic records contain coded and anonymous data on patient demographics, 
symptoms (in free text), diagnoses using the International Classification for Primary Care 
(ICPC) and free text, clinical findings, referrals, laboratory findings and hospitalizations. 
Furthermore, there are records of all drug prescriptions, their indications and dosage 
regimen. Further details of the database have been described elsewhere.[19, 20] The 
system complies with European Union guidelines on the use of electronic healthcare 
data for medical research and has been proven valid for pharmaco-epidemiologic 
studies.[19] The Scientific and Ethical Advisory Board of IPCI project approved the study 
(study protocol N. 02/13).
Selection of cases and controls
Within the IPCI database, all patients who were diagnosed with a clinically relevant 
serum sodium level of below 130 or patients that were hospitalized for hyponatremia 
(admission diagnosis in discharge letter) between January 1st, 1996 and March 1st, 
2011 were identified as a case. All cases were validated through manual review of the 
electronic medical record while blinded to the exposure. The date of diagnosis of the 
hyponatremia was set as the index date.
Up to 10 controls were selected from the same practice by incidence density 
sampling[21] and matched on practice, year of birth and sex. Both cases and controls 
required at least 6 months of valid database history prior to the date of prescription in 
order to allow proper assessment of drug exposure of all study subjects. 
Exposure definition
Drug exposure was assessed on the 4th level of the Anatomical Therapeutical Chemical 
(ATC) coding system.[22] Exposure was defined as exposure to benzodiazepines (anx-
iolytics covering diazepam, oxazepam, lorazepam (ATC class N05ba); sedatives cover-
ing nitrazepam and temazepam (ATC class N05cd); sedatives covering zopiclone and 
zolpidem (ATC class N05cf )) on the index date and was obtained from the prescription 
records. The exposure period was calculated by dividing the dispensed number of units 
by the dosing regimen. Current use was defined as drug exposure at the index date; past 
use was defined as drug exposure before the index date. 
Exposure to thiazides was obtained in the same manner. Exposure to drugs used as 
covariables was assessed on the 3rd ATC level. 
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Covariables
Comorbidities were selected on their International Classification of Primary Care (ICPC) 
diagnosis code:  cerebrovascular disease (transient ischemic attack, stroke), diabetes 
insipidus, hypothyroidism, heart failure, liver failure, alcoholism, ischemic heart disease 
(angina pectoris and myocardial infarction), malignancies, Parkinson’s disease and pul-
monary disease (asthma and chronic obstructive pulmonary disease). 
Concomitant drug use was assessed based on previous reports on their association 
with hyponatremia (drugs for acid related disorders (a02), glucose lowering agents (a10, 
to define the presence of diabetes), cardiac therapy (c01), diuretics (c03), beta-blocking 
agents (c07), calcium channel blockers (c08), agents acting on the renin-angiotensin 
system (c09), thyroid therapy (h03), antibacterials (j01), analgesics (n02), antiepileptics 
(n03), anti-parkinson drugs (n04), psycholeptics (n05) and anti-inflammatory and anti-
rheumatic drugs (m01)).[6] 
Data analysis
Odds ratios (ORs) of hyponatremia caused by drug exposure, were calculated using con-
ditional logistic regression. We also used past use as a reference to control for confound-
ing by indication. In adjusted models, we included comorbidities and drug groups that 
were previously associated with hyponatremia if these changed the point estimate more 
than five percent. For the pharmacological substances that were significantly associated 
with hyponatremia in the main analysis, we assessed the differences between men and 
women. All statistical analyses were performed using SPSS software (version 17.0; SPSS 
Inc., Chicago, Illinois, USA). After correction for multiple testing, p-values below 0.017 
(0.05/3) were considered statistically significant.
rESultS
For this study, 2312 cases of hyponatremia were identified and 18,295 controls were 
selected (Table 1). The apparent difference in age and comorbidities between cases and 
controls is due to variation in the number of available controls with age, which we ac-
counted for by conditional logistic regression (see further).
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Benzodiazepines and hyponatremia
Exposure to benzodiazepines (anxiolytics or sedatives) was significantly associated with 
hyponatremia, after adjustment for other drugs and comorbidities (Table 2). Exposure 
to anxiolytics (ATC class N05ba) was associated with > 2-fold higher risk compared to 
the non-use (OR 2.08; 95% CI 1.75-2.48); and > 1.5-fold risk compared to past use (OR 
table 1. Baseline characteristics of the study population
Cases (n=2312) Controls (n=18295) P-value
Female gender 1579 (68.3) 12386 (67.7) 0.550
Age years, mean (SD) 74.1 (14.4) 71.1 (13.4) <0.001
Benzodiazepine use
Benzodiazepine derivates (anxiolytics) 271 (11.7) 864 (4.7) <0.001
Benzodiazepine derivates (sedatives) 288 (12.5) 797 (4.4) <0.001
Benzodiazepine related drug (zolpidem) 56 (2.4) 223 (1.2) <0.001
Concomitant medication 
Drugs for acid related disorders 630 (27.2) 2479 (13.5) <0.001
Glucose lowering agents 353 (15.3) 1715 (9.4) <0.001
Cardiac therapy 254 (11.0) 1028 (5.6) <0.001
Diuretics 975 (42.2) 3911 (21.4) <0.001
Beta-blocking agents 676 (29.2) 3538 (19.3) <0.001
Calcium channel blockers 305 (13.2) 1741 (9.5) <0.001
Agents acting on the renin-angiotensin system 841 (36.4) 3959 (21.6) <0.001
Thyroid therapy 133 (5.8) 764 (4.2) <0.001
Antibacterials for systemic use 211 (9.1) 229 (1.3) <0.001
Analgesics 270 (11.7) 668 (3.7) <0.001
Antiepileptic drugs 132 (5.7) 221 (1.2) <0.001
Anti-parkinson drugs 36 (1.6) 99 (0.5) <0.001
Psycholeptic drugs 541 (23.4) 1857 (10.1) <0.001
Anti-inflammatory and anti-rheumatic products 130 (5.6) 595 (3.3) <0.001
Co-morbidities
Heart failure 371 (16.0) 1124 (6.1) <0.001
Liver cirrhosis 40 (1.7) 112 (0.6) <0.001
Alcoholism 150 (6.5) 233 (1.3) <0.001
Asthma/COPD 470 (20.3) 2376 (13.0) <0.001
Hypothyroidism 139 (6.0) 729 (4.0) <0.001
Parkinson 25 (1.1) 153 (0.8) <0.001
Malignancies 402 (17.4) 1498 (8.2) <0.001
Ischemic stroke 360 (15.5) 1504 (8.2) <0.001
Heart disease (Myocardial infarction, Angina pectoris) 448 (19.4) 2640 (14.4) <0.001
The characteristics are presented as numbers (%), unless stated otherwise.
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1.60; 95% CI 1.33 – 1.93) Past use increased the risk 1.3 times in comparison to non-use 
(OR 1.30; 95% CI 1.16, 1.46).  Sedatives (ATC class N05cd) were associated with a 1.5-fold 
higher risk of hyponatremia, compared to non-use (OR 1.51; 95% CI 1.26, 1.83) and a 
1.3-fold increased risk compared to past use (OR 1.30; 95% CI 1.06 – 1.60). Past exposure 
was associated with a slightly increased risk (OR 1.17; 95% CI 1.03, 1.33). No association 
was found between the benzodiazepines zolpidem and zopiclon (ATC class N05cf ) and 
hyponatremia after adjustment for the effects of other drugs and comorbidities. 
Differences between men and women
The number of hyponatremia cases was four times higher in women than in men (anx-
iolytics: 213 versus 58; sedatives: 184 versus 44).  Risk estimates were slightly higher in 
men (anxiolytics: OR 2.27; 95% CI 1.53, 3.38 and sedatives: OR 1.82; 95% CI 1.15, 2.87) 
than in women (anxiolytics: OR 1.85; 95% CI 1.54, 2.23 and sedatives: OR 1.43; 95% CI 
1.17, 1.74). 
Interaction with thiazide diuretics
Exposure to either benzodiazepines or thiazides was associated with an increased risk of 
hyponatremia compared to exposure to neither of these drugs  (Table 3). The combina-
tion of anxiolytics and thiazides was associated with a more than five times higher risk 
of hyponatremia than when none of these drugs were used (OR 5.02; 95% CI 3.75, 6.72). 
This risk was significantly higher than exposure to either one of these drugs separately 
table 2. Benzodiazepines and risk of hyponatremia*
Drug Control Case Crude model Adjusted model1 Adjusted model2
N N OR (95% CI) OR (95% CI) OR (95% CI)
Benzodiazepine derivatives 
(anxiolytics)
Past 4501 717 1.48 (1.33 – 1.65) 1.30 (1.16 – 1.46) 1.00 (ref)
Current 864 271 2.81 (2.40 – 3.30) 2.08 (1.75 – 2.48) 1.60 (1.33 – 1.93)
Benzodiazepine derivatives (sedatives)
Past 2913 479 1.25 (1.11 – 1.41) 1.17 (1.03 – 1.33) 1.00 (ref)
Current 797 288 2.06 (1.74 – 2.45) 1.51 (1.26 – 1.83) 1.30 (1.06 – 1.60)
Zolpidem, Zopiclon
Past 891 173 1.23 (1.02 – 1.48) 1.08 (0.88 – 1.32) 1.00 (ref)
Current 223 56 1.68 (1.23 – 2.30) 1.02 (0.72 – 1.45) 0.95 (0.64 – 1.40)
ATC = Anatomical Therapeutic Chemical; Crude model: matched on year of birth, sex, practice, and adjusted 
for each other; Adjusted model1: adjusted for the significant co-morbidities: heart failure, asthma/copd, 
malignancies, alcoholism and concurrent medications c03 n02 n03 j01 a02; Adjusted model2: adjusted for 
the same covariates as model 1, with past use as the reference population. 
* serum sodium level < 130mmol/L
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(RERI* 2.08; 95% CI 0.64, 3.54). The combination of sedatives and thiazides also showed 
an increased risk compared to exposure of either of these drugs, but the confidence 
intervals overlapped. 
* relative excess risk due to interaction (RERI), as the best reflecting value of the joint effects of two factors 
by an additive pattern.  The interaction is considered significant if the value of zero is not enclosed by the 
95% confidence interval (CI)). 
DISCuSSIon
The results from this nested case-control study confirm an increased risk of hyponatre-
mia associated with benzodiazepines. Benzodiazepines from both subgroups, anxiolyt-
ics and sedatives, were associated with this increased risk. The risk of hyponatremia with 
past use is potentially caused by intermittent use of these drugs. Compared with past 
use, the risk of hyponatremia with current exposure remained. With the current study, 
we cannot assure that benzodiazepines are the directly causal factor or a surrogate for 
other(s), but we suggest a plausible explanation based on a few different biological 
mechanisms, described below.
Benzodiazepines exert their effect by binding to the GABAA receptor in the central 
nerve system (CNS), with a slight variation in action due to differences in affinity to the 
specific subunits.[23] Inhibition of this GABAA receptor in rats increased ADH release, 
which results in water retention and a decrease in serum sodium levels, potentially lead-
ing to hyponatremia.[24] 
table 3. Benzodiazepine and thiazide use and the risk of hyponatremia*
Drug Control Case Risk of hyponatremia1
N N OR (95% CI) P-value
Thiazide 2693 584 2.17 (1.90 – 2.48) < 0.001
Benzodiazepine derivatives (anxiolytics) 691 168 1.77 (1.44 – 2.18) < 0.001
Both 173 103 5.02 (3.75 – 6.72) < 0.001
Thiazide 2705 605 2.23 (1.96 – 2.55) < 0.001
Benzodiazepine derivatives (sedatives) 636 146 1.50 (1.20 – 1.88) < 0.001
Both 161 82 3.39 (2.47 – 4.67) < 0.001
Thiazide 2815 660 2.19 (1.93 – 2.50) < 0.001
Zolpidem, Zopiclon 172 29 0.79 (0.50 – 1.27) 0.53
Both 51 27 3.91 (2.30 – 6.65) < 0.001
ATC = Anatomical Therapeutic Chemical; 1matched on year of birth, sex and practice; adjusted for the sig-
nificant co-morbidities: heart failure, asthma/copd, malignancies, alcoholism and concurrent medications: 
c09 n02 n03 j01 a02 other c03 (except thiazides); * serum sodium level < 130mmol/L 
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In addition to the GABAA receptors, benzodiazepines also bind to peripheral 
benzodiazepine receptors (PBR; renamed translocator protein 18kDa (TSPO).[25-28] Pe-
ripheral benzodiazepine receptors are localized in various tissues throughout the whole 
body and are present in the zona glumerulosa of the adrenals and in the distal convo-
luted tubule of the kidney[29, 30] and are implicated in various mechanisms, such as 
cell growth and steroid synthesis.[31, 32] Expression of these receptors is influenced by 
(ischemic) stress and seems to play a role in maintaining kidney function.[33] Because of 
the presence of these receptors on the site of action of ADH in the renal tubules, a role 
in water and electrolyte balance was previously suggested.[26, 28, 34]
A rat study showed an increase in PBR density after administration of either hydro-
chlorothiazide or [3H] Ro 5-4864 (4’-chlorodiazepam; a PBR-inhibitor).[34] Additionally, 
administration of either of these drugs increased urinary volume and sodium excretion. 
This may contribute to the interaction between benzodiazepines and thiazides as 
observed in our study. This interaction was previously observed in a population-based 
study,[15] in which combined use of benzodiazepines and thiazides was associated with 
hyponatremia, significantly worse in subjects using both drugs concomitantly (serum 
sodium 130.3 ± 2.8 mmol/L in subjects exposed to both benzodiazepines and thiazides, 
versus 133.4 ± 1.8 mmol/L in subjects using benzodiazepines and 132.8 ± 2.3 mmol/L in 
subjects using thiazides only).
Zolpidem and zopiclon were not significantly associated after adjustment for other 
factors. This might be due to selectivity in binding to the GABAA receptor, and a lower 
affinity to the peripheral benzodiazepine receptors. These drugs belong to the imidazo-
pyridine class and have a slightly different receptor-binding pattern than the classical 
benzodiazepines.[23, 35] They exhibit high-affinity binding at central receptors, but the 
affinity to peripheral receptor binding sites is lower than classical benzodiazepines.[35, 
36] 
Indication bias should also be acknowledged as a potential explanation for the 
association between benzodiazepines and hyponatremia. Sleep disturbances, which are 
the main indication for sedatives, lead to disturbed cortisol secretion. Cortisol release is 
suppressed in sleep deprivation,[37] which is related to ADH hypersecretion, leading to 
water retention and hyponatremia.[38, 39] Psychiatric disorders, potential indications for 
anxiolytics, are associated with hyponatremia by the medical treatment (antipsychotics) 
or the disease itself (polydipsia, water intoxication and impaired water excretion).[40] 
Although benzodiazepines are frequently used drugs, mainly in the elderly popula-
tion, and they are consistently associated with falls and a decrease in consciousness, 
they are usually not taken into account in the association with hyponatremia.[12, 41] 
We speculate that these drugs could even be causal in hyponatremia-related falls. Some 
cases have been described in the literature, but these date from earlier days, suggesting 
that this possible association lost attention.[16-18] All hyponatremic cases presented 
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with a state of acute confusion after benzodiazepine intake. In only one case the associa-
tion with the benzodiazepine was confirmed with a water load test and a rechallenge of 
drug administration, fitting the profile of SIADH.[16] 
One of the strengths of this study is the large pool of available data. Data on renal 
function were missing in a substantial proportion of controls, because they were ran-
domly selected and not on the basis of a laboratory measurement, so unfortunately 
we could not adjust for that. Drug use was measured on the basis of pharmacy records. 
Some misclassification could have been present in case of non-compliance, but this is 
most probably independent of the outcome. The outcome hyponatremia was based on 
laboratory measurements or a diagnosis of hyponatremia on admission. This is based on 
the assumption that hyponatremia with a serum sodium level of >130 mmol/L would 
not directly lead to symptoms requiring hospital admission. Misclassicifation, however, 
would most probably be random. 
 Although benzodiazepines are relatively old drugs, the association with 
hyponatremia has not been well studied. We showed an increased risk of this adverse 
drug reaction by benzodiazepines used as sedatives and anxiolytics. In addition, we 
confirmed an interaction with thiazide diuretics, as previously suggested by our former 
study.[15] Further studies are needed on both experimental and clinical levels. Use of 
these drugs deserves caution: elderly with unexplained mental changes or symptoms 
should be tested for hyponatremia and benzodiazepines should be taken into account 
as potential cause. We recommend serum sodium control measurements in subjects 
starting benzodiazepines, especially when thiazides are already in use.
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ABStrACt
Background 
Dehydration, or more appropriately hypovolemia, is the second most frequent pre-
cipitating risk factor for acute kidney injury. Medication has been studied in relation to 
direct acute nephrotoxicity but there are few population-based studies on an indirect 
cause such as dehydration. Therefore, our objective was to investigate which drugs were 
associated with hospital admission because of dehydration. 
methods
We conducted a population-based case–control study within the Dutch IPCI (Integrated 
Primary Care Information) database. The study population included all subjects ≥50 
years who were registered in the IPCI database from 1996 to 2011, and who did not have 
diabetes mellitus, heart failure, severely decreased kidney function, liver failure and/or 
malignancy. Cases were defined as subjects with a hospital admission with dehydration. 
Controls were matched on practice, year of birth, sex and date of onset.
results
A total of 1,246 cases of hospital admission with dehydration were identified. We found 
a significant association with proton pump inhibitors (OR 1.86; 95CI% 1.54-2.26), non-
steroidal anti-inflammatory drugs (OR 1.52; 95%CI 1.15-2.01), opioids (OR 2.06; 95%CI 
1.40-3.03) and benzodiazepines (OR 1.57; 95% CI 1.26-1.96) after adjustment for con-
founding factors. 
Conclusions
This study shows a significant association between hospital admission with dehydra-
tion and use of proton pump inhibitors, non-steroidal anti-inflammatory drugs, opioids 
and benzodiazepines. Additional studies are warranted to confirm these results and to 
elucidate the pathophysiological mechanism.
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IntroDuCtIon
Background
Acute kidney injury occurs with an incidence of approximately 384 per 100,000 person-
years in the general population and is more frequent in elderly aged 80 years and over 
[1]. After sepsis which causes 47% of cases of acute kidney injury, dehydration - or more 
appropriately hypovolemia - is with 32%  the second most frequent precipitating risk 
factor for this outcome [2]. Hypovolemia might result from gastrointestinal fluid loss 
(vomiting, diarrhea, bleeding, external drainage), renal fluid loss (diuretics, osmotic 
diuresis, salt-wasting nephropathies, hypoaldosteronism), skin fluid loss (sweat, burns), 
or third-space sequestration. Medication has been studied in relation to direct acute 
nephrotoxicity but hardly on an indirect cause such as dehydration. Clinically relevant 
hypovolemia is most likely to occur when water is lost together with sodium. Numerous 
studies have investigated the role of medicines in relation to hyponatremia [3]. Only few 
studies [4-6] have investigated drug-induced dehydration/hypovolemia, possibly due to 
the fact that information from both first and second line care is needed.
objective
Therefore, the objective of this study was to investigate drug use and the risk of hospital 
admission with a diagnosis of clinical dehydration , using prospectively gathered elec-
tronic health care records from a community-dwelling adult population. 
mEtHoDS
Design overview
We performed a population-based case–control study, nested in a cohort of patients 
who were registered in the Dutch Integrated Primary Care Information (IPCI) general 
practice research database, to investigate drug use and the risk of dehydration.  The 
Scientific and Ethical Advisory Board of IPCI project approved the study. 
Setting
All data were retrieved from the IPCI project, a longitudinal observational, dynamic 
database, which contains the electronic medical records of a group of more than 600 
general practitioners in the Netherlands. In the Dutch health care system, the general 
practitioner plays a pivotal role and acts as a gatekeeper of all medical care and informa-
tion. Almost all inhabitants of the Netherlands are registered with a general practitioner, 
independently of their health status. Details of the IPCI database have been described 
elsewhere [7, 8]. Briefly, the database contains the complete electronic medical records 
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of approximately 1,000,000 participants. These records contain anonymous longitudinal 
data on demographics, symptoms and diagnoses (coded and in free text), referrals, 
laboratory findings, hospitalizations, discharge letters, and drug prescriptions (inclu-
sive indication and dosage regimen). To maximize completeness of the data, general 
practitioners participating in the IPCI project are not allowed to maintain a system of 
paper-based records besides the electronic medical records. The system complies with 
European Union guidelines on the use of data for medical research and has been proven 
valid for pharmaco-epidemiologic studies [8]. 
Study population
The study population comprised all subjects from the IPCI database who were ≥50 years 
during the study period (January 1st, 1996 to March 1st, 2011) and were at least one 
year registered in the database before the study period. Subjects with heart failure, liver 
failure, a severely decreased kidney function (glomerular filtration rate < 30 milliliter 
per minute), diabetes mellitus and/or malignancy are more likely to receive medication 
prescriptions from the specialist, which are not necessarily captured in the database. 
Therefore, these subjects were censored from the first date indicating such conditions. 
All remaining subjects were followed until hospitalization with dehydration, death, 
transfer out of practice, last data draw-down, or end of the study period, whichever 
came first.
Cases and controls
Cases were all subjects who were admitted to the hospital with a clinical diagnosis of 
dehydration at admission. All cases were validated through manual review of the elec-
tronic available discharge letters while being blinded to the exposure. We excluded all 
hospital admissions with dehydration, secondary to gastrointestinal bleeding, because 
hypovolemia due to non-steroidal anti-inflammatory drugs induced peptic ulcer disease 
is already well recognized. For every case, all available controls were selected from the 
community dwelling population by incidence density sampling, matched on practice, 
sex and year of birth.
Exposure assessment
We had a number of a priori candidates for dehydration. We investigated exposure 
from the separate major classes of blood pressure lowering medicines, which might 
increase the probability of hospitalization with dehydration due to an additional blood 
pressure lowering effect. These included beta blockers, calcium channel blockers, 
angiotensin converting enzyme inhibitors, angiotensin receptor blockers and diuretics 
(low-ceiling thiazides diuretics, low-ceiling non-thiazide diuretics, high-ceiling diuretics 
and potassium-sparing diuretics). Because hypovolemia might be more pronounced 
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with combined losses of water and salt, we also investigated all first-line medication 
that might cause hyponatremia based on a literature review [3, 9, 10] at 3rd level (phar-
macological subgroup) of the anatomical therapeutic chemical (ATC) coding system 
[11]: proton pump inhibitors (PPI), amiodarone, lorcainide, propafenone, bromocriptine, 
vasopressin and analogues, thyroid preparations, mineralocorticoids, trimethoprim-
sulfamethoxazole, ciprofloxacin, cefoperazone, sulbactam, rifabutin, azithromycin, 
carboxamide derivatives, valproic acid, lamotrigine, phenothiazines, butyrophenone 
derivatives, benzodiazepines and anti-depressants. Medication exposure was obtained 
from the prescription files. Fixed dose combinations were recoded into their individual 
active pharmaceutical ingredients. The duration of treatment (prescription length) was 
calculated by dividing the prescribed number of units by the dosing regimen. The dose 
per day was obtained from the last prescription prior to the index date and calculated 
from the prescribed strength and the dosing regimen. Current use was defined as a date 
of onset within the prescription length of a particular medicine. Past use was defined 
as prior exposure not covering the date of onset. If a patient did not use a particular 
medication during the study period this was defined as never use. 
Co-variables
We considered the following co-variables: age, sex, and date of onset (matching vari-
ables) and medical conditions that might cause dehydration such as Addison’s disease 
[12], alcoholism [13], cerebrovascular disease (transient ischemic attack, stroke) [14] , 
diabetes insipidus [15], hypothyroidism [16], ischemic heart disease (angina pectoris 
and myocardial infarction) [17], Parkinson’s disease [18] and pulmonary obstructive 
disease (asthma and chronic obstructive pulmonary disease) [19] . 
Statistical Analysis
We compared characteristics of cases and controls by using conditional logistic regres-
sion analysis. We only investigated associations with medicines for which we had at least 
10 exposed cases. Multivariable modeling in a single model with all exposure categories 
and co-variables to control for is technically not feasible. In addition it is not necessary 
to control a single exposure for all other concomitant medications and comorbidities, 
because many will not confound the exposure-outcome relation for that particular 
association. Therefore, we investigated one by one which medicines confounded the 
exposure-outcome association (bivariable model including exposure and possible 
confounding factor). If there was a relevant degree of confounding, defined as a change 
in estimate by ≥10% of the exposure-outcome association we included the confounder 
in the adjusted model. Results of analysis at individual medication level are included 
as sensitivity analyses. We conducted all conditional logistic regression analyses with 
SAS 9.2, (SAS Institute Inc., Cary, NC, USA). We set the level of significance for all statisti-
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cal tests at a P-value less than 0.05. This level is not yet corrected for multiple testing. 
We consider that the reader should divide the p-value by the number of tested drug 
categories (n=16) to account for this.
rESultS
The source population consisted of 1,016,648 subjects with active follow-up. Of these 
subjects, 291,745 were included in the study population based on the inclusion and 
exclusion criteria as described above. A total of 1,246 subjects were hospitalized with 
dehydration. These could be matched on practice, sex, year of birth and index date to 
12,026 controls. The characteristics of cases and controls are provided in table 1. Despite 
matching on age and sex, there were differences on these variables between cases and 
controls, due to variation in the number of available controls in higher age-groups but 
this is accounted for by conditional logistic regression.  
Sample size was insufficient (<10 cases exposed) to study amiodarone, lor-
cainide, propafenone, bromocriptine, vasopressin and analogues, mineralocorticoids, 
trimethoprim-sulfamethoxazole, ciprofloxacin, cefoperazone, sulbactam, rifabutin, 
azithromycin, carboxamide derivatives, valproic acid, lamotrigine, phenothiazines. The 
majority of medications with sufficient exposure were significantly associated with 
hospital admission with dehydration relative to no current use (including past and 
never use), including a correction for multiple testing, except for beta blockers, calcium 
channel blockers, angiotensin receptor blockers, thiazide diuretics and thyroid hormone 
preparations (table 2, model 1). 
After correction for confounding by indication with past use as reference and cor-
rection for multiple testing, the use of non-thiazide low-ceiling diuretics, high-ceiling 
diuretics, potassium-sparing diuretics, angiotensin converting enzyme inhibitors, 
table 1 Characteristics of the study population
Cases 
(n=1,246)(%)
Controls 
(n=12,026)(%)
Female gender 702 (56.3) 7,002 (58,2)
Age years, mean (SD) 75.9 (11.8) 67.5 (11.0)
Comorbidities
Alcoholism 50 (4.0) 154 ( 1.3)
Asthma/COPD 236 (18.9) 1,277 (10.6)
Heart disease (Myocardial infarction, Angina pectoris) 253 (20.3) 1,137 (9.5)
Hypothyroidism 38 (3.1) 362 (3.0)
Ischemic stroke 183 (14.7) 635 (5.3)
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anti-Parkinson drugs, butyrophenone derivatives, and antidepressants  was no longer 
significantly associated with hospital admission due to dehydration (table 2, model 2). 
4 categories of medicines: proton pump inhibitors (OR 1.86; 95CI% 1.54-2.26), non-
steroidal anti-inflammatory drugs (OR 1.52; 95%CI 1.15-2.01), opioids (OR 2.06; 95%CI 
1.40-3.03) and benzodiazepines (OR 1.57; 1.26-1.96), were significantly associated with 
hospital admission with dehydration in all models, also after adjustment for confound-
ing factors  (table 2, model 3). 
DISCuSSIon
There are four interesting findings in this study. First, we found a significant association 
between hospital admission with dehydration and the use of proton pump inhibitors 
(PPIs). This association remained significant after adjustment for confounding by indica-
tion and was consistent among individual PPIs for which we had a sufficient number 
of exposed cases. Until now, few cases detailing PPI induced hyponatremia have been 
reported [3]. However, the underlying pathophysiological mechanism of PPI induced 
hyponatremia is not entirely clear. It might be a syndrome of inappropriate anti-diuresis 
[20], but also excessive loss of urinary sodium has been reported [21]. Also the increased 
risk of diarrhea due to microscopic colitis or community associated Clostridium difficile 
infection with PPIs might explain the observed association [22-25]. Second, we found a 
significant association between hospital admission with dehydration and the use of non-
steroidal anti-inflammatory drugs (NSAIDs), which was similar between the individual 
NSAIDs with a sufficient number of exposed cases. This might be explained by the fact 
that NSAIDs impair the vasopressin induced upregulation of aquaporin-2 expression in 
response to dehydration [26, 27]. NSAIDs are also associated with acute diarrhea [28] 
and microscopic colitis [29, 30]. Third, we found a significantly increased risk of hospital 
admission with dehydration and the use of benzodiazepines. Because of the localization 
of peripheral benzodiazepine receptors in the kidney,  a role in water and electrolyte 
balance was suggested earlier [31-34], contributing to an increased sodium excretion 
[35-42]. Fourth, we found we found a significantly increased risk of hospital admission 
with dehydration and the use of opioids. Central opiatergic stimulation has been shown 
to reduce water intake provoked by the activation of central angiotensinergic pathways 
[43, 44]. Furthermore, dehydration is a known adverse event for opioids [45, 46]. 
We found no significant association with thiazide diuretics, non-thiazide low-ceiling 
diuretics, beta blockers, calcium channel blockers, angiotensin receptor blockers and 
thyroid hormone preparations relative to no use after correction for multiple testing. 
This might be due to the exclusion of several risk factors for dehydration such as heart 
failure, diabetes mellitus or a severely decreased kidney function. 
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If correction for multiple testing is neglected high-ceiling diuretics appear to in-
crease the risk of hospitalization with dehydration which is consistent with the results of 
another study [6]. The protective effect that is suggested by the comparison of current 
use of thiazide diuretics and angiotensin receptor blockers relative to their past use is 
due to a higher risk with past use. However there is no increased risk relative to never 
use (data not shown). Medication discontinuation for reasons related to hypovolemia, 
such as hypotension, might underlie the increased risk with past use. High-ceiling and 
potassium diuretics, anti-parkinson medication, butyrophenone derivatives, and antide-
pressants showed a significantly increased risk of hospital admission with dehydration 
relative to no use, but not relative to past use. This might be related to insufficient sample 
size. An effect of underlying patient comorbidities with a limited drug attributable risk 
is also possible. In spite of a non-significant association relative to past use, their use 
should alert physicians of a high risk patient. 
During the analysis matching was performed for practice, sex, year of birth and index 
date. For each group of medication we investigated confounding by concomitant 
medication and underlying disease including alcoholism, asthma/COPD, heart disease, 
and ischemic stroke as well as confounding by indication through analysis with past 
use as a reference. We limited confounding from heart failure, liver failure, a severely 
decreased kidney function, diabetes mellitus and/or malignancy by means of exclusion. 
Despite before mentioned strengths, the possibility of residual confounding cannot 
be fully excluded as with any other observational study. We do not have urine sodium 
measurements to elaborate on a specific pathophysiological mechanism. We do not 
have information on over the counter medication, which might include some exposure 
to NSAIDs (only low dose diclofenac) and PPIs. Finally, while interpreting results with 
past use acting as a reference it should be noted that characteristics of patients who 
discontinue medication might differ from those with current use either due to health 
improvement or health deterioration demanding the use of different medication.
PErSPECtIVES
In conclusion, our results show an increased risk of between hospital admission with de-
hydration with current use of PPIs, NSAIDs, benzodiazepines and opioids. The increased 
risk of hospital admission with dehydration with current of high-ceiling and potassium-
sparing diuretics, anti-Parkinson drugs, butyrophenone derivatives, and antidepressants 
might at least partly be explained by comorbidities. 
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ABStrACt
Background
Acute kidney injury (AKI) might complicate antihypertensive therapy. In The Nether-
lands, general practitioner clinical practice guidelines provide clear recommendations 
on monitoring of renal function to minimize this risk. Our objective was to investigate 
how day-to-day clinical practice corresponds to the guidelines.
methods
We conducted a retrospective cohort study in a dynamic population, using data on 
>9,000 adults that was retrieved from the Integrated Primary Care Information database. 
We investigated whether serum creatinine (SCR) was measured within 30 and 365 days 
after the start of (combined) use of a diuretic, an angiotensin-converting enzyme inhibi-
tor, and/or angiotensin receptor blocker. We also investigated the association between 
calendar year, sex, type of therapy, risk factors for AKI and practice and SCR measure-
ment.
results
Of 6,593 subjects who met the study criteria for single drug therapy, SCR was measured 
in 1,233 subjects within 30 days and in 3,896 subjects within 365 days. For combined 
drug therapy recipients (n = 2,497), these were 545 and 1,687, respectively. Associated 
cumulative probabilities were 19 % and 66 % with single drug therapy, and 22 % and 
74 % with combined drug therapy. Significant differences were observed between 
practices. SCR measurement was associated with other characteristics, except for sex. 
Within 365 days, SCR increased >30 % of baseline in 103 subjects (1.6 %) after the start 
of single drug therapy, and in 85 (3.4 %) subjects who initiated combined drug therapy. 
In the majority (>70 %) of these subjects, this did not result in subsequent monitoring or 
adjustment of antihypertensive treatment.
Conclusions
Results from this study suggest that, on average, renal function is not monitored as 
strictly as recommended by relevant clinical practice guidelines. 
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BACKGrounD
Lowering blood pressure reduces progression of Chronic Kidney Disease (CKD) [1], but 
may also be associated with an increased risk of acute kidney injury (AKI) resulting from 
a disturbed auto-regulation of the renin-angiotensin-aldosterone system caused by 
angiotensin-converting-enzyme inhibitors (ACEIs) [4] or angiotensin receptor blockers 
(ARBs) [5], or due to volume depletion caused by diuretics [2]. This is illustrated by results 
from the CHARM trial, where doubling of serum creatinine (SCR) and study medication 
discontinuation, due to SCR elevation, occurred significantly more often in the ARB 
treated group than in the placebo group [3]. Certain medication combinations might 
be more harmful, as illustrated by the ONTARGET trial where combined drug therapy 
with an ACEI and an ARB increased the risk of renal impairment without an increase in 
benefit [4]. Another recent study found a 31% higher risk of AKI with a triple medication 
combination, consisting of non-steroidal anti-inflammatory drugs (NSAIDs) in combina-
tion with a diuretic plus an ACEI or ARB. The highest risk was observed in the first 30 
days of use, and a trend toward an increased risk was observed for double medication 
combinations, including a NSAID in combination with a diuretic, ACEI, or ARB [5]. 
Risk minimization through monitoring of renal function is recommended in clinical 
guidelines, with subtle differences in timing, duration and frequency of monitoring as 
well as with regard to changes of renal function that are considered as acceptable. The 
National Institute for Health and Clinical Excellence (NICE) clinical guideline on CKD 
recommends monitoring of renal function through serum creatinine (SCR) between 1 to 
2 weeks after initiation or dose increase of ACEIs or ARBs. A ≤25% decrease in estimated 
Glomerular Filtration Rate (eGFR) or ≤30% increase in SCR relative to baseline is accepted 
[6]. Dutch GP Clinical Guidelines are stricter, and recommendations also relate to diuret-
ics and not only recommend SCR measurements upon treatment initiation but also SCR 
measurements between 3 and 6 months after introduction or change of therapy and 
yearly thereafter [7]. 
Monitoring of renal function in relation to antihypertensive therapy has been in-
vestigated in a number of studies [8-17], but data on monitoring during the first 30 days 
of use - the period with highest risk of AKI - as well as data on the incidence of abnormal 
renal function during monitoring are limited. Also, possible differences by GP practice 
have not been evaluated thus far.
The objective of this study was to investigate whether monitoring of renal function, 
during initiation of diuretics, ACEIs or ARBs by general practitioners (GPs) is in line with 
the recommendations, as issued by the Dutch College of General Practitioners [7]. 
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mEtHoDS
Study design and Setting
We performed a retrospective cohort study, using data  retrieved from the Integrated 
Primary Care Information (IPCI) project, a longitudinal observational, dynamic database 
which contains the electronic medical records of a group of more than 600 GPs in the 
Netherlands. In the Dutch health care system, the GP plays a pivotal role and acts as a 
gatekeeper of medical care and information. Almost all inhabitants of the Netherlands 
are registered with a GP, independent of their health status. Details of the IPCI database 
have been described elsewhere [18, 19]. Briefly, the database contains the complete 
electronic medical records of approximately 1,000,000 subjects. These records contain 
anonymous longitudinal data on demographics, symptoms and diagnoses [coded 
in International Classification of Primary Care (ICPC) codes, and in free text], referrals, 
laboratory findings, hospitalizations, discharge letters, and medication prescriptions 
(including indication and dosage regimen). To maximize completeness of the data, GPs 
participating in the IPCI project are not allowed to maintain a system of paper-based 
records besides the electronic medical records. The system complies with European 
Union guidelines on the use of data for medical research and has been proven valid for 
pharmaco-epidemiologic studies [19]. The scientific and ethical advisory board of the 
IPCI project approved the study.
Participants
The source population comprised all individuals, who were registered with their GP for 
at least 365 days. The study period started on January 1st, 2005 and ended on December 
31th, 2011. Subjects were followed until death, transfer out of practice, last data draw-
down, or end of the study period, whichever came first.
Study population
From the source population two exposure cohorts were defined, i.e. a single therapy 
cohort and a combined therapy cohort. The single therapy cohort consisted of patients 
aged ≥40 years who received a new (incident) medication prescription with a chemical 
substance from one of the Anatomical Therapeutic Chemical (ATC) classes “C03” (diuret-
ics), “C09A” (ACEI) or “C09C” (ARB) as single therapy. Incident use meant that the patient 
had not used any of these ATC classes in the year before. The combined therapy cohort 
consisted of subjects aged ≥40 years who were already exposed to one of these ATC 
classes and started new use of a drug from another ATC class, as mentioned above dur-
ing follow-up.
The first date of medication prescription that led to inclusion of a subject in the 
study population of single drug therapy or combined drug therapy is referred to as 
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“index date”. For both exposure cohorts the new medication prescription had to be 
refilled at least once within 90 days of the first prescription to avoid misclassification of 
incidental use as chronic therapy. For combined drug therapy the other medication(s) 
to which a subject was already exposed had to be refilled at least once during the first 
period of exposure to the new medication to exclude a switch in therapy.
In the Dutch health care system, GP’s might continue therapy that is initiated by a 
specialist. For these patients, if monitoring of renal function is performed by the special-
ist, SCR measurements might be missing in the database. To include only patients for 
whom the therapy was initiated by the GP, we excluded patients with heart failure prior 
to the index date based on disease codes “K77” (heart failure), “ K82”  (cor pulmonale) and 
free text  “heart failure” and “cardiac decompensation” in the medical record. In addition, 
subjects were excluded who met the criteria for referral to the nephrologist prior to the 
index date, being  macro-albuminuria in combination with any eGFR, micro-albuminuria 
with an eGFR <30 ml/min/1.73m2 in subjects <65 years, or eGFR <45 ml/min/1.73m2 in 
subjects ≥65 years) or without information on eGFR within the year prior to the index 
date. And finally, patients were excluded in those cases where the indication for antihy-
pertensive therapy at the index date was missing or different from hypertension, based 
on disease codes.“K85” (Elevated blood pressure), “K86” (Hypertension uncomplicated), 
or “K87” (Hypertension complicated).
outcome
The outcome of this study was the presence of a SCR measurement performed by the 
GP within 30 days, and within 365 days following the index date. We also investigated 
how SCR evolved during the 365 days following index date and whether a SCR increase 
>30% of baseline resulted in subsequent monitoring or adjustment of antihypertensive 
treatment.
Co-variables
In this study, we studied the influence of the following variables on renal function 
monitoring after index date: calendar year; age; sex; concomitant use of NSAIDs and/or 
high dose (>300mg per day) of acetylsalicylic acid (ASA); diabetes mellitus (DM), based 
on prescription from the ATC class “A10” (Drugs used in diabetes) [20, 21], and eGFR, 
which was obtained from the last available SCR measurement within the one year prior 
to index-date using the equation published by the Chronic Kidney Disease Epidemiol-
ogy (CKD-EPI) Collaboration [22]. We used eGFR categories as provided by the Kidney 
Disease Improving Global Outcomes (KDIGO) foundation: G1 “normal or high” ≥90, G2 
“mildly decreased” 60-89, G3a “mildly to moderately decreased” 45-59, G3b “moderately 
to severely decreased” 30-44 ml/min/1.73m2 [23].
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Statistical analysis
For univariable analyses we calculated cumulative survival probabilities. We used Cox 
proportional hazards regression analysis for multivariable analyses, using GP practice as 
a stratification variable. We tested for interaction between baseline characteristics and 
included interaction terms with a P-value of less than 0.05. We constructed survival plots 
and log(-log(survival)) versus log(time) plots for each baseline co-variable to investigate 
deviation from proportionality. If indicated by these plots, hazard rates varying with time 
were modelled. Analyses that were performed to investigate GP practice differences 
only included GP practice as a multi-level categorical variable. Baseline characteristics 
of single and combined drug therapy were compared with Student’s t-test and Pearson 
χ2-tests. All analyses were conducted with SAS 9.2, (SAS Institute Inc., Cary, NC, USA).
rESultS
The source population consisted of 984,047 subjects with a valid history of at least 365 
days in the IPCI database. After application of inclusion and exclusion criteria 6,593 
subjects were enclosed in the single drug study population and 2,497 subjects in the 
combined drug study population. In comparison to single drug therapy, combined drug 
therapy included older subjects (mean age 64.4 vs. 61.9 years, p-value<0.001), a larger 
proportion of females (53.7% vs. 51.1%, p-value=0.032), and more subjects with diabetes 
mellitus (20.4% vs. 17.8%, p-value=0.004), whereas eGFR (78.0 vs. 77.8 ml/min/1.73m2, 
p-value 0.559) and the proportion of NSAIDs at start of therapy (0.4% vs. 0.5%) were 
comparable between groups. Detailed baseline characteristics are described in table 1.
table 1 Study cohort characteristics
Characteristics
Single drug therapy Combined drug therapy
(N=6,593) (N=2,497)
n (%) n (%)
Males 3,222 (49) 1,157 (46)
Age category 
•   40-49 1,086 (16) 288 (12)
•   50-59 1,861 (28) 603 (24)
•   60-69 2,032 (31) 788 (32)
•   70-79 1,213 (18) 590 (24)
•   80+ 401 (6) 228 (9)
Calendar year at start of treatment  
•   2005 38 (1) 8 (0)
•   2006 168 (3) 34 (1)
•   2007 402 (6) 116 (5)
•   2008 906 (14) 372 (15)
Adherence to renal function monitoring guidelines in patients starting antihypertensive therapy with diuretics and RAAS inhibitors 147
table 1 Study cohort characteristics (continued)
Characteristics
Single drug therapy Combined drug therapy
(N=6,593) (N=2,497)
•   2009 1,641 (25) 682 (27)
•   2010 1,997 (30) 758 (30)
•   2011 1,441 (22) 527 (21)
Estimate Glomerular Filtration Rate – ml/min/1.73m2
•   90+ 2,022 (31) 655 (26)
•   60-89 3,965 (60) 1,471 (59)
•   45-59 525 (8) 318 (13)
•   30-44 81 (1) 53 (2)
Diabetes mellitus 1,173 (18) 509 (20)
NSAIDsa and/or high-dose aspirin 34 (1) 9 (0)
Type of therapy 
•   Diuretic     3,240 (49) - (-)
•   ACEI b       2,243 (34) - (-)
•   ARB c  1,110 (17) - (-)
•   Diuretic and ACEI - (-) 1,663 (67)
•   Diuretic and ARB - (-) 803 (32)
•   ACEI      and  ARB - (-) 31 (1)
ACE = Angiotensin Converting Enzyme Inhibitor; ARB = Angiotensin Receptor Blocker; NSAIDs = Non-Steroi-
dal Anti-Inflammatory Drugs
22 
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For single medication use, 1,233 subjects had one or more SCR measurement within 
30 days after start of treatment and 3,896 subjects had at least one SCR measurement 
within 365 days after start of therapy. These were 1,687,  and 545 for combined therapy, 
respectively. The associated cumulative probability of a renal function measurement was 
18.8% (95% CI 17.9-20.0%) at day 30 and 65.8% (95% CI 64.6-67.0%) at day 365 after start 
of single drug therapy (figure 1). For combined drug therapy these were significantly 
higher, being 21.5% (95% CI 19.9-23.2%) and 74.0% (95% CI 72.1-75.9%), respectively. 
The univariable associations between baseline characteristics and the probability of a 
renal function measurement within 30 and 365 days after index date are described in 
table 2. 
table 2 Availability of a serum creatinine measurement within 30 and 365 days after start of antihyperten-
sive therapy
Single drug therapy Combined drug therapy
Day 30 Day 365 Day 30 Day 365
Cum 
%a
95%CI
Cum 
% a
95%CI
Cum 
% a
95%CI
Cum 
% a
95%CI
Calendar year at start of treatment 
•   2005 8 (3 - 23) 50 (35 - 67) 25 (7 - 69) 88 (58 - 99)
•   2006 15 (10 - 21) 51 (44 - 59) 9 (3 - 25) 56 (40 - 73)
•   2007 13 (10 - 17) 59 (55 - 64) 17 (11 - 25) 73 (64 - 81)
•   2008 18 (15 - 20) 66 (63 - 69) 16 (13 - 21) 73 (69 - 78)
•   2009 17 (15 - 19) 65 (63 - 67) 20 (17 - 23) 74 (70 - 77)
•   2010 20 (18 - 22) 68 (65 - 70) 25 (22 - 28) 73 (70 - 77)
•   2011 23 (21 - 25) 71 (65 - 76) 26 (23 - 30) 90 (70 - 99)
Age category –  years
•   40-49 21 (19 - 24) 61 (58 - 64) 25 (20 - 30) 68 (62 - 74)
•   50-59 17 (15 - 19) 60 (57 - 62) 20 (17 - 24) 70 (66 - 74)
•   60-69 18 (17 - 20) 69 (66 - 71) 22 (19 - 25) 76 (73 - 79)
•   70-79 19 (17 - 22) 72 (69 - 75) 23 (20 - 26) 78 (74 - 82)
•   80+ 22 (18 - 26) 76 (71 - 81) 20 (15 - 26) 76 (69 - 81)
Sex
•   male 19 (17 - 20) 66 (64 - 68) 23 (21 - 25) 74 (72 - 77)
•   female 19 (18 - 20) 66 (64 - 68) 21 (19 - 23) 74 (71 - 76)
Estimate Glomerular Filtration Rate – ml/min/1.73m2
•   90+ 19 (17 - 21) 65 (63 - 68) 22 (19 - 25) 72 (68 - 76)
•   60-89 18 (17 - 20) 65 (64 - 67) 23 (21 - 25) 74 (72 - 77)
•   45-59 20 (17 - 24) 70 (66 - 74) 18 (14 - 22) 75 (70 - 80)
•   30-44 25 (17 - 36) 78 (68 - 87) 23 (14 - 36) 80 (68 - 90)
Diabetes mellitus 
•   No 19 (18 - 20) 61 (60 - 62) 23 (21 - 25) 69 (67 - 71)
•   Yes 19 (17 - 22) 87 (84 - 89) 18 (15 - 21) 92 (89 - 94)
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In the multivariable analyses, the probability of having one or more SCR measure-
ments increased with calendar year both for single drug therapy and combined therapy 
(table 3). Also baseline use of NSAIDs increased the probability of monitoring with both 
therapies, whereas age and eGFR was only associated with an increased probability of 
a SCR measurement following the start of single drug therapy. DM was significantly as-
sociated with the probability of a SCR measurement in a time-dependent manner: in the 
presence of DM the probability of a SCR measurement increased with time from day 41 
after start of single therapy and day 40 after start of dual therapy onwards. With single 
table 2 Availability of a serum creatinine measurement within 30 and 365 days after start of antihyper-
tensive therapy (continued)
Single drug therapy Combined drug therapy
Day 30 Day 365 Day 30 Day 365
Cum 
%a
95%CI
Cum 
% a
95%CI
Cum 
% a
95%CI
Cum 
% a
95%CI
Concomitant use of NSAIDs and/or high-dose aspirin 
•   No 19 (18 - 20) 66 (64 - 67) 22 (20 - 24) 74 (72 - 76)
•   Yes 18 (8 - 35) 83 (69 - 94) 11 (2 - 57) 85 (53 - 99)
Type of therapy
•   Diuretic 17 (16 - 18) 64 (62 - 66) - ( - ) - ( - )
•   ACEI 24 (23 - 26) 73 (71 - 75) - ( - ) - ( - )
•   ARB 14 (12 - 16) 57 (54 - 60) - ( - ) - ( - )
•   Diuretic and ACEI - ( - ) - ( - ) 25 (23 - 28) 75 (73 - 78)
•   Diuretic and ARB - ( - ) - ( - ) 15 (12 - 17) 71 (68 - 74)
•   ACEI and  ARB - ( - ) - ( - ) 19 (9 - 38) 79 (63 - 92)
a Cumulative percentage  (1-cumulative survival probability)*100% ; ACE = Angiotensin Converting Enzyme 
Inhibitor; ARB = Angiotensin Receptor Blocker; NSAIDs = Non-Steroidal Anti-Inflammatory Drugs
table 3 Multivariable analysis: renal function monitoring after start of antihypertensive therapy
Characteristic
single drug therapy* combined drug therapy d
est HR pval 95%CI est HR pval 95%CI
Calendar year at start of treatment (2011 = ref.)
•   2005 -0.88 0.42 0.001 (0.25 - 0.69) 0.21 1.23 0.695 (0.43 - 3.53)
•   2006 -0.37 0.69 0.005 (0.53 - 0.89) -0.26 0.77 0.345 (0.45 - 1.32)
•   2007 -0.51 0.60 <0.001 (0.51 - 0.72) -0.25 0.78 0.106 (0.58 - 1.05)
•   2008 -0.34 0.71 <0.001 (0.62 - 0.81) -0.33 0.72 0.001 (0.59 - 0.88)
•   2009 -0.29 0.75 <0.001 (0.67 - 0.84) -0.23 0.79 0.008 (0.67 - 0.94)
•   2010 -0.15 0.86 0.006 (0.78 - 0.96) -0.07 0.93 0.414 (0.79 - 1.1)
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table 3 Multivariable analysis: renal function monitoring after start of antihypertensive therapy (contin-
ued)
Characteristic
single drug therapy* combined drug therapy d
est HR pval 95%CI est HR pval 95%CI
Age category –years 
(40-49 = ref.)
•  50-59 -0.09 0.92 0.116 (0.83 - 1.02) -0.08 0.93 0.434 (0.76 - 1.12)
•   60-69 0.08 1.08 0.129 (0.98 - 1.21) 0.08 1.09 0.396 (0.9 - 1.31)
•   70-79 0.08 1.08 0.215 (0.96 - 1.22) 0.11 1.12 0.289 (0.91 - 1.38)
•   80+ 0.21 1.24 0.011 (1.05 - 1.46) 0.12 1.12 0.383 (0.86 - 1.46)
Sex (male=ref.)
•   Female 0.01 1.01 0.853 (0.94 - 1.08) 0.04 1.04 0.469 (0.94 - 1.16)
Estimated Glomerular Filtration Rate – ml/min/1.73m2 
(90+ = ref.)
•   60-89 0.06 1.06 0.167 (0.98 - 1.15) -0.04 0.96 0.601 (0.84 - 1.1)
•   45-59 0.17 1.19 0.018 (1.03 - 1.37) -0.01 0.99 0.933 (0.81 - 1.22)
•   30-44 0.19 1.21 0.194 (0.91 - 1.62) 0.32 1.38 0.098 (0.94 - 2.03)
Concomitant use of NSAIDs and/or high-dose aspirin 
(no use = ref.)
•   Yes 0.45 1.58 0.027 (1.05 - 2.36) 0.86 2.35 0.028 (1.1 - 5.05)
Type of therapy a,b
 (type 1 = ref.)
•   Type 2 0.28 <0.001 ( - ) -0.03 0.97 0.626 (0.85 - 1.1)
•   Type 3 -0.11 0.082 ( - ) 0.07 1.08 0.756 (0.67 - 1.72)
Diabetes mellitus (absent = ref.)
•   Present 0.15 0.086 ( - ) -0.25 0.016 ( - )
Diabetes mellitus x Time interaction‡
•    0.16 <0.001 ( - ) 0.23 <0.001 ( - )
Diabetes mellitus x Type of therapy interaction a,c
•   Diabetes mellitus present and 
type 2 therapy
-0.25 0.005 ( - ) - - - ( - )
•   Diabetes mellitus present and 
type 3 therapy
0.11 0.378 ( - ) - - - ( - )
a Hazard rates and 95%CI intervals are not provided for characteristics included in an interaction term; 
b Type of therapy: single drug: type1 = diuretic; type2 = ACEI;type3 = ARB combined drug: type1 = diuretic 
and ACE; type2 = diuretic and ARB; type3 = ACEI and ARB; c If diabetes mellitus is present the estimate for 
the diabetes mellitus time interaction should be multiplied with the natural logarithm of the number of 
days after day 41 following the start of single drug therapy or the number of days after day 40 following the 
start of combined drug therapy.; d Fully adjusted model
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drug therapy, there was a significant interaction between DM and type of therapy: in 
absence of DM the proportion of subjects with a SCR measurement was larger in the 
subgroup with ACEI-based single drug therapy as  compared to subjects who started 
single drug therapy with a diuretic or an ARB. In contrast, there were no differences 
in monitoring within subjects with DM. No differences between types of therapy and 
monitoring were observed with combined drug therapy.
Between GP practices, there were significant differences in the cumulative prob-
ability of renal function monitoring, with a median probability of monitoring of 15.8% 
(IQR 7.0% – 27.8%) at day 30 and a median of 62.5% (IQR 50.0% – 74.9%) at day 365 for 
single therapy, and 12.5% (IQR 0.0% – 27.8%) and 66.7% (IQR 47.9%-80.0%) for combined 
drug therapy (figure 2).
In the cohort with single drug therapy, SCR increased by more than 30% relative 
to baseline in 103 subjects (1.6% of all subjects who started therapy). Review of the 
medical record revealed that in 29 subjects this might be caused by another medical 
condition for example malignancy, cardiovascular events, or infection. Of the remaining 
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74 subjects, 32 received monotherapy, while 42 subjects were switched to combined 
drug therapy prior to the increase of SCR. In 59 (80%) of the 74 subjects, this did not lead 
to subsequent SCR measurements within 1 month, a change of therapy or referral to a 
specialist. In the cohort with combined drug therapy SCR increased by >30% relative to 
baseline in 85 subjects (3.4% of all subjects who started therapy). In 16 subjects other 
medical conditions might explain the increase. Of the remaining 69 subjects, 67 still 
used the same drug at the time of the increased SCR measurement. In 47 (70%) of these 
67 subjects, no actions were taken based on the results of the testing. 
DISCuSSIon
This study shows three important issues. First, that in the majority (>75%) of subjects 
renal function is not monitored during the first 30 days after start of (combined) an-
tihypertensive therapy with diuretics and/or renin-angiotensin-aldosterone system 
inhibitors (RASIs) in contrast to recommendations of the guidelines. Second, there is 
large variability between GP practices with respect to renal function monitoring. Third, 
the incidence of renal impairment (increase in SCR measurement >30% of baseline) dur-
ing the first 365 days after treatment initiation is relatively low (2.6-3.4%), and did not 
lead to subsequent actions in the majority (>70%) of subjects. 
Published data on the extent of monitoring during the first 30 days of antihyper-
tensive therapy are limited. Findings in our study are consistent with the results from a 
previous study that had far lower sample size [13]. No previous study has elaborated on 
differences between GP practices. Our findings suggest that this is relevant for further 
studies related to this topic. Our results suggest that monitoring might have improved 
modestly with calendar year, which was also observed in another study [12].  The extent 
of monitoring in subjects with DM in our study is much lower than what is reported in a 
study from Scotland where monitoring is assessed during approximately the same time 
window after start of therapy [16]. Both in the Netherlands and in the United Kingdom, 
periodic SCR measurement in subjects with DM is a quality indicator of health care. The 
discrepancy between both studies might thus be explained by differences in the respec-
tive performance management and payment system, which could be subject for further 
study. Also we found that DM increased the probability of monitoring, although not 
during the first 30 days. Possibly, renal function monitoring is performed in relation to 
DM rather than as part of antihypertensive therapy initiation. Unlike another study [16], 
we found an increased monitoring in subjects using NSAIDs and/or high-dose ASA at 
the time of index date, both with single drug therapy and when added to combination 
drug therapy, which has been referred to as ‘triple whammy’ earlier [24]. However this 
might also result from other factors associated with the use of NSAIDs and the extent of 
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monitoring is still low, in particular during the first 30 days (table 2), despite the specific 
recommendation by the Dutch college of general practitioners to monitor renal func-
tion if NSAIDs are used in combination with diuretics or RASIs [25]. This low rate is of 
concern as renal function might deteriorate within two days of NSAIDs initiation. [26] 
Subjects without DM who started single drug therapy with an ARB were monitored 
to the same extent as those starting therapy with a diuretic, but significantly less fre-
quently than subjects initiating an ACEI, which is in line with results from other studies 
on monitoring [12, 16]. Still this is surprising as results from the ONTARGET trial do not 
suggest a difference in renal impairment between ARBs and ACEIs [4].  The observed as-
sociations between calendar year and age, as well as the lack of a significant association 
for gender, are consistent with results of other studies [10, 12, 16].
The incidence of renal impairment (SCR measurement increased by >30% relative 
to baseline measurement) within 365 days after index date in our study is higher than 
the rates of discontinuation of study medication due to renal impairment in the ONTAR-
GET trial [4]. However, in the majority of patients in our study the increase in SCR did not 
result in actions such as treatment discontinuation, specialist referral or subsequent SCR 
measurements. The controlled setting of a clinical study might explain the difference 
with monitoring in daily practice as in our study. It is important to note that the rate of 
AKI might be even higher in subjects with additional risks factors, such as heart failure 
and moderate-severe CKD, who were not included in our study population. As with 
monitoring of renal function after start of antihypertensive therapy in general (figure 2), 
also recognition of accelerated decline of renal function and AKI from antihypertensive 
therapy might differ between GPs; however, the low numbers precluded further analysis.
Strengths of our study include its population-based design as well as the stringent 
criteria applied to minimize the risk of underestimation of renal function monitoring. 
Indeed, we excluded short term therapy or patients who switched therapy as well as 
patients likely to be monitored by the specialist although this inevitably limits the gen-
eralizability of our results to subjects without additional risks factors for AKI. In addition, 
despite these before mentioned criteria, a small number of subjects might have received 
specialist care following a referral that was not preceded by a SCR measurement by the 
GP. 
The incidence of non-dialysis requiring community-based AKI has strongly in-
creased between 1996 and 2003 [27], despite renoprotection with ACEI and/or ARBs 
and it has been argued that the use of these medications might underlie this trend [28]. 
This applies at least to subjects on dual RAAS blockade [29, 30] which is currently evalu-
ated during an article 31 referral procedure by the European Medicines Agency (EMEA/
HA/31/1370). Another study showed that several barriers might impede monitoring 
[31]. Comparison of our findings with the results of Kalra and colleagues in 1999 [8] 
suggest that the success of initiatives to bring down these barriers is limited thus far. An 
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obvious reason for a failure to embrace monitoring enthusiastically is the very low yield 
on screening, at least in our study population, in which SCR increased by >30% from 
baseline in just 1.6 to 3.4% of subjects, whereas in a previous large (n=74,096) study 
hyponatremia, hyperkalemia and hypokalemia were only observed in 0.7%, 0.8% and 
1.3% of subjects within 6 months of the initiation of antihypertensive treatment [17].
Studies, including randomized clinical trials, report that quality indicators improve 
with the use of financial incentives to directly reward performance and ‘quality’ in 
healthcare [32, 33]. There are no established indicators for renal function monitoring, 
due to inter-individual differences in renal function decline with ageing and underlying 
disease as well as the absence of validated markers of renal renin-angiotensin system 
activity to identify subjects who are at increased risk of renal impairment or AKI [34, 35]. 
ConCluSIonS
Our study shows that the extent of renal function monitoring with antihypertensive 
therapy might be substantially improved. Renal impairment was found to complicate 
antihypertensive therapy. In a majority of cases other medical conditions that might 
explain the renal impairment were lacking. Subsequent actions were not taken in the 
majority (>70%) of subjects. Future studies should examine to what extent an increase 
in SCR >30% of baseline is associated with patient harm. Also the implementation of 
quality indicators to monitor antihypertensive therapy during the first year after start 
of - or change in - antihypertensive therapy should be investigated, including their 
impact on the individual practice as our study shows a large variability in the extent of 
monitoring between practices. 
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GEnErAl DISCuSSIon
The kidney has several functions that are essential for life, notably homeostasis of the ex-
tracellular environment and regulation of systemic and renal hemodynamics, red blood 
cell production and bone metabolism.  Renal function declines with age but also medi-
cal conditions such as diabetes mellitus impair renal function. It is important to identify 
and minimize risk factors that contribute to renal function decline. Several medicines 
exhibit direct nephrotoxic potential, while others may indirectly interfere with one of 
the renal functions. The consequences may be substantial. In general a decreased renal 
function is associated with an increased risk of hospitalization, cardiovascular events 
and death [1], while direct drug-induced nephrotoxicity has been shown to be a main 
determinant of preventable medication-related hospital admission [2]. Consequently, 
their use is contraindicated in persons with a decreased renal function, e.g. methotrex-
ate [3], gadodiamide [4], and nitrofurantoin [5], while for others dose adjustment is 
indicated, e.g. enalapril [6], allopurinol [7], and metoclopramide[8]. Failure to take ap-
propriate measures might result in acute kidney injury or chronic kidney disease as well 
as other complications such as electrolyte disturbances. 
This thesis had four objectives. The first objective was to describe the epidemiol-
ogy of chronic kidney disease in the general population. The second objective was to 
identify, confirm and quantify new undesirable renal effects of medicines. Hereto, we 
reported the association between overanticoagulation during therapy with vitamin K 
antagonists and the risk of renal function decline (chapter 3.1). In addition we studied 
the association between serum uric acid levels and the occurrence of a simple renal 
cysts. This is relevant as serum uric acid levels are increased by several medicines, such 
as diuretics (chapter 3.2). The third objective was to study the role of medicines in rela-
tion to water and electrolyte disturbances, because of the prominent role of the kidney 
in the homeostasis of water and salts. We investigated whether diuretics with a similar 
indication of use (chlorthalidone and hydrochlorothiazide) are differently associated 
with hyponatremia (chapter 4.1). Furthermore, we investigated the association between 
antidepressants and hyponatremia (chapter 4.2), and benzodiazepines and hypovole-
mia which might result from a combined loss of water and sodium (chapter 4.3). The 
fourth and last objective was to investigate renal function monitoring in patients at risk 
of renal function decline. For this research, we studied the adherence to renal function 
monitoring guidelines in patients initiating antihypertensive therapy with diuretics and 
renin-angiotensin system inhibitors (chapter 5). 
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main findings
1. Prevalence and incidence of chronic kidney disease
Knowledge on the incidence and prevalence of chronic kidney disease in the general 
population is important because it provides insight into renal function decline as a re-
sult of ageing and underlying comorbidities. Incidence rates of chronic kidney disease in 
the literature are very limited and most lack results stratified for age, sex and underlying 
diabetes mellitus [9-18]. To study the prevalence and incidence of chronic kidney dis-
ease we used data from the Integrated Primary Care Information (IPCI) project, which is 
a Dutch GP database that holds the complete, anonymized electronic patient records of 
more than one million subjects. We found a marked increase in the prevalence of chronic 
kidney disease with age, female sex, and diabetes mellitus. Indeed, the prevalence of 
chronic kidney disease was higher than 75% in diabetic female participants aged 85 
years and over (chapter 2). Especially in the very elderly, we found a substantially higher 
prevalence of chronic kidney disease than rates reported by cohort studies [19-23]. We 
found an overall incidence rate of chronic kidney disease in adults of 1,213 per 100,000 
person-years. Here as well, the incidence increased with age, female sex and diabetes 
mellitus. The highest incidence rate of CKD namely 25,000 per 100,000 person-years, 
was identified  in women with diabetes mellitus, aged ≥85 years and over. Our results 
provide insight into the extent of chronic kidney disease in the Netherlands and might 
help to increase awareness of chronic kidney disease amongst primary care providers. 
Given the large number of drugs requiring dose adaptations in case of renal function 
decrease, it is likely that many elderly with insidious renal function loss may be relatively 
overdosed. Indeed, recognition of chronic kidney disease remains low among primary 
care providers [24, 25], while early referral to a nephrologist might help to improve 
patients outcomes [26]. 
2. Identification of new undesirable renal effects of medicines
The second objective was to identify, confirm and quantify new undesirable effects of 
medicines in relation to the kidney. Recently, other studies suggested that overantico-
agulation, defined as an International Normalized Ratio (INR)>3.0, in patients on warfa-
rin therapy might be associated with an impaired renal function [27-30]. This might be 
relevant to many individuals as in 2010 approximately 398,000 patients of the Dutch 
population of 16.6 million people were treated with oral anticoagulation therapy with 
vitamin K antagonists, mainly acenocoumarol or phenprocoumon [31, 32]. Already the 
degree of anticoagulation is strictly regulated because the therapeutic range is narrow 
and it has been shown that underanticoagulation has been associated with an increased 
risk of stroke, while overanticoagulation has been associated with an increased risk 
of bleeding [33-35]. To study the association between overanticoagulation and renal 
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function decline we used data from the Rotterdam study, which is an ongoing prospec-
tive population-based cohort study of chronic diseases in the elderly in the Ommoord 
district in the city of Rotterdam, the Netherlands. It includes approximately 15,000 
subjects aged 45 years or over in three cohorts that were recruited in 1990, 2000 and 
2006. All cohorts undergo repeated examinations every 3–4 years in characteristics that 
change over time contributing to studies on cardiovascular, dermatological, endocrine, 
liver, neurological, ophthalmic, psychiatric and respiratory disease as well as genetic and 
biomarker studies and pharmaco-epidemiologic studies. Within the Rotterdam study, 
we identified a cohort of patients on vitamin K anticoagulation and could not establish 
an association between an INR between 3 and 6 and risk of renal function decline, pos-
sibly due to a relatively small sample size or because of a transient effect. However, we 
did observe a significant additional decline in renal function for INR>6, after adjustment 
for age, sex, heart failure, baseline glomerular filtration rate and indication for vitamin 
K antagonist therapy (chapter 3.1). A previous study suggested that the occurrence 
of an INR above 6.0 is not infrequent [36]. Hence, apart from the risk of bleeding, the 
potential of renal function decline with long-term anticoagulant treatment might be 
an additional argument to prevent INRs above 6.0. Additional prospective studies are 
needed to further assess the effects of INRs below 6.0 on renal function decline as well 
as to identify high risk groups.
Several medications, such as diuretics, can raise serum uric acid. Generally, such an 
increase is asymptomatic, but it might also trigger gout. A recent case-control study in 
patients with gout reported a higher prevalence of simple renal cysts than in a control 
group of age- and sex-matched healthy kidney donors [37]. However, because the 
incidence rate of gout is relatively low [38, 39], the association would concern only a 
limited number of subjects. Because an increased serum urate  level without gout is 
much more frequent, we investigated the association between serum uric acid and the 
presence of a simple renal cyst. In females, we found that the risk of a simple renal cyst 
increased by 78% from the lowest to the highest serum uric acid level, while in males we 
only found a higher prevalence of a simple renal cyst for serum uric acid 4.0 mg/dl and 
above compared to a serum uric acid below 4.0 mg/dl (chapter 3.2). As many more small 
cysts may be present beneath the limit of detection [40], we hypothesize that serum uric 
acid might contribute to the progression of renal function decline through renal cyst 
formation [41]. This is an interesting subject for further research.
3. role of the kidney in electrolyte disturbances
The kidney plays a pivotal role in the homeostasis of water and salts, including sodium. 
Therefore, the third objective was to study how medicines affect the kidney in its role 
of water and electrolyte homeostasis. Several medicines cause hyponatremia [42], an 
adverse effect which has mainly been described  for diuretics such as chlorthalidone and 
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hydrochlorothiazide. These diuretics are often considered as interchangeable, although 
two meta-analyses [43, 44] and two randomized clinical studies [45, 46] showed greater 
blood pressure reduction with chlorthalidone than with hydrochlorothiazide. In particu-
lar, the reduction of nighttime mean systolic blood pressure contributed to the renewed 
interest in chlorthalidone [47]. A recent propensity score–matched observational cohort 
study suggested that subjects treated with chlorthalidone were more likely to be hospi-
talized with hyponatremia than those prescribed hydrochlorothiazide [48], concluding 
that this might be a reason to prefer treatment with hydrochlorothiazide over treatment 
with chlorthalidone. In chapter 4, we used data from the Integrated Primary Care Infor-
mation (IPCI) project to study these medicines in association to hyponatremia. We found 
that at equivalent milligram dose per day chlorthalidone was indeed associated with a 
significantly higher risk of hyponatremia in comparison to hydrochlorothiazide (chapter 
4.1). However, the majority of prior clinical studies suggest a similar drop in (daytime) 
blood pressure for chlorthalidone compared to twice the amount of hydrochlorothia-
zide [45, 46, 49-51]. At this equipotent dose per day we did not find an increase in the 
risk of hyponatremia with chlorthalidone 12.5 milligram per day compared to hydro-
chlorothiazide 25 milligram per day as well as with chlorthalidone 25 milligram per day 
compared to hydrochlorothiazide 50 milligram per day. In view of studies suggesting 
better outcomes with chlorthalidone, the findings in this thesis suggest that hyponatre-
mia should not be a reason to refrain from direct head-to-head clinical studies between 
equipotent doses of chlorthalidone and hydrochlorothiazide.  
With anti-depressants we were able to confirm the well-established association of 
Selective Serotonin Reuptake Inhibitors (SSRIs) with hyponatremia (chapter 4.2) [52-61]. 
Of specific interest , we found a significantly increased risk of hyponatremia during the 
first month of use of tricyclic antidepressants (TCAs), while results from previous studies 
on the association between tricyclic antidepressants and hyponatremia were inconsis-
tent. Some studies suggest a contributory role of tricyclic antidepressants [62-68], while 
other studies could not confirm an association between hyponatremia and tricyclic 
antidepressants [53, 59, 69]. These studies have limitations; including small sample size 
[53, 67], failure to adjust for confounding factors at event date [59, 68, 69], no stratifica-
tion by treatment duration and no consideration of past use in their analyses [53, 59, 
67-69]. Further studies should provide insight into the optimal interval and duration of 
monitoring for hyponatremia after start of treatment with antidepressants.
We also studied the association between hyponatremia and benzodiazepines. 
Earlier case-reports of benzodiazepine-induced hyponatremia [70-72], were recently 
confirmed in a population-based study [73]. In our research we also confirmed this 
association and in addition we showed a significantly increased relative excess risk for 
combined use of benzodiazepines and hydrochlorothiazide (chapter 4.3). Further ex-
perimental studies should be performed to unravel the pathophysiological mechanism. 
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Interestingly, benzodiazepines were also associated with an increased risk of 
hospital admission with clinical hypovolemia – in clinical practice often referred to as 
dehydration - after adjustment for confounding factors and confounding by indication 
(chapter 4.4). Possibly this is due to an increased combined loss of water and sodium in 
accordance with experimental studies suggesting a natriuretic effect of benzodiazepines 
[74-76]. Other drugs that were also associated with hospital admission with clinical hy-
povolemia included proton pump inhibitors, non-steroidal anti-inflammatory drugs and 
opioids. Possible underlying mechanisms are diverse and include an excessive loss of 
urinary sodium, an increased risk of diarrhea and impairment of the vasopressin induced 
up regulation of aquaporin-2 expression in response to dehydration.  Use of high ceiling 
diuretics was also associated with hypovolemia but this effect disappeared upon correc-
tion for multiple testing. We did not find an association with other medicines, including 
the other classes of diuretics and agents acting on the renin angiotensin aldosterone 
system, upon adjustment for confounding by indication using past use as a reference, 
while these drugs have been associated with acute kidney injury before [77]. This find-
ing underlines the importance of adjustment for confounding by indication in studies 
investigation the relation between drug exposure and hypovolemia and possibly also 
acute kidney injury. 
4. monitoring of renal safety
The fourth and final objective of this thesis was to study whether clinical practice 
guidelines on the monitoring of kidney function are followed. Hereto, we studied 
the adherence to renal function monitoring guidelines in patients initiating anti-
hypertensive therapy with a combination of diuretics and renin-angiotensin system 
inhibitors. Consistent with the results from a previous study with a lower sample size 
[13], we found that in the majority of subjects renal function is not monitored during 
the first 30 days after start of (combined) antihypertensive therapy with diuretics and/
or renin-angiotensin-aldosterone system inhibitors in contrast to recommendations 
from the guidelines (chapter 5). Also, we found that the extent of monitoring in subjects 
with diabetes mellitus is much lower than what is reported in a study from Scotland. 
This might be explained by differences in the respective performance management and 
payment system [16]. Finally, we found that the incidence of renal impairment during 
the first 365 days upon treatment initiation is relatively low (2.6-3.4%), and did not lead 
to subsequent actions in the majority of affected subjects. In summary, clinical practice 
guidelines for monitoring renal safety are currently insufficiently adhered to. In the first 
year, consequences of this low adherence seem to be modest but only a longer follow-
up can tell whether low adherence results in a higher incidence of renal function impair-
ment. Furthermore, it is important to investigate why there is a rather large discrepancy 
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between the recommendations from the clinical guidelines and the real-life situation of 
low adherence by prescribers. 
Potential bias and confounding
For this research we used data from either IPCI, a general practitioner database or from 
the Rotterdam study which is a prospective cohort study. As for all observational re-
search, there is the potential of bias and/or confounding
A limitation of the use of a general practitioner database is that data is collected in 
the process of day-to-day care. Annual screening for chronic kidney disease is a quality 
of care indicator within the bundled payment system for diabetes care. Therefore, the 
incidence and prevalence of chronic kidney disease in individuals who are not subject 
to annual screening for chronic kidney disease may have been underestimated. Another 
limitation to the studies with data from a general practitioner database is that, although 
prescription records are registered for all individuals, prescriptions initiated by special-
ists or prescriptions given during hospitalization might be missing. Misclassification of 
exposure will result in an underestimation of the effect size if the drugs of interest are 
indeed associated with the outcome. Exposure is also misclassified for medicines which 
are available without a prescription, the so-called over-the-counter (OTC) medicines. 
Finally, we encountered the potential of exposure misclassification as we used prescrip-
tion data only and did not have information on dispensing or actual intake, misclassifica-
tion of exposure. With regard to outcome misclassification, as hyponatremia was based 
on laboratory measurement or specialist diagnosis, we might have misclassified patients 
with hyponatremia for whom lab results were not available within the database. This 
would have resulted in an underestimation of the effect. 
Measurements in the Rotterdam Study are performed in all participants without 
prior knowledge of the research hypothesis. This implies that no major bias or confound-
ing is anticipated. With regard to the study about the association between serum uric 
acid and a simple renal cyst, in a substantial number of participants, one or both kidneys 
could not be visualized for technical reasons.  However,  absence of kidney imaging is 
not related to serum uric acid measurement and thus would not result in potential bias 
or confounding. 
future Perspectives
The change from paper based patient records to electronic medical records offer distinct 
advantages for patient and health care professionals, including improved quality, coor-
dination and patient participation. These electronic medical records capture a wealth of 
information and can also be used for research purposes allowing, apart from other ben-
efits, to observe changes within patients over time, a feature which is crucial for kidney 
function monitoring. Recently, the implementation of a limited pay for performance has 
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resulted in a more structured assessment of risk factors for chronic kidney disease, such 
as hypertension, weight, smoking and diabetes mellitus. With this information being 
systematically available on all patients at risk, it will be possible to completely adjust 
for other risk factors, when investigating the contributory role of medication in the 
progression of chronic kidney disease. So far, information on weight was not available 
on all patients within the IPCI database. Information on weight is important in research 
on medication induced electrolyte disturbances as it has been shown that patient 
characteristics such as weight modify this association [78]. Initially we intended to study 
the association between drug use and risk of acute kidney injury but we realized that 
this research would be difficult when based on primary care data only. Indeed, acute 
kidney injury is mainly diagnosed in the hospital, but precise information on medication 
exposure and other risk factors is often only available from primary care data. It would 
be interesting to investigate whether the association between use of proton pump in-
hibitors, non-steroidal anti-inflammatory drugs and opioids not only holds for hospital 
admission with hypovolemia but also for acute kidney injury as an outcome.
The findings in this thesis with regard to overanticoagulation and renal function 
decline are relatively new, being the first independent observational study to confirm 
this association. Linkage of primary care data with data from anticoagulation clinics 
would offer an opportunity for further research. We are the first to report a relation be-
tween serum uric acid and simple renal cysts. Already more research on serum uric acid 
has been done in patients with autosomal-dominant polycystic kidney disease. How-
ever as many cysts might lie beneath the level of detection, more research is needed to 
investigate whether lowering serum uric acid serum uric acid retards the progression of 
renal function decline. 
Electrolyte disturbances are known adverse events of many medicines, although 
new associations continue to be discovered, also with regard to medicines that were 
registered a long time ago. Indeed we did find an association for selective serotonin 
reuptake inhibitors, tricyclic antidepressants and benzodiazepines, all drugs already 
long on the market.  Our studies highlight the importance of safety monitoring even for 
relatively “old” drugs. 
Finally, our observation that clinical guidelines on renal function monitoring are 
not strictly followed offers a huge potential to improve drug safety through provision 
of clear, concise and non-contradictory information.  Renal function is currently one of 
the quality indicators in the care for patients with diabetes mellitus, but not in relation 
to pharmacotherapy. With growing complexity of health care, computer decision sup-
port systems and research based on electronic health care records should be further 
exploited to bring pharmacotherapy with minimal adverse effects one step closer. 
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SummAry
Preservation of kidney function, often represented by the estimated glomerular filtration 
rate, is important because a decreased renal function is associated with an increased risk 
of morbidity and mortality. Despite this, drug-induced nephrotoxicity has been shown 
to be a main determinant of preventable medication-related hospital admission. 
Chapter 1 gives a general introduction to the different topics that were studied in 
this thesis and provides an overview of the data sources used. The chapter concludes 
with the outline of the thesis. 
Chapter 2 describes that the epidemiology of chronic kidney disease in the general 
population of the Netherlands. It shows that a decreased glomerular filtration rate is 
present in more than 50 percent of elderly (≥85 years) patients. The fact that with the use 
of these observational data a higher prevalence of decreased glomerular filtration rate 
was observed than in selected cohort studies, suggests that it’s prevalence might have 
been underestimated as a result of selection bias. 
Chapter 3 describes two associations between drug use and renal function decline. 
First, it describes the renal function decline in patients who used anticoagulation 
therapy (chapter 3.1), which appeared to be larger amongst patients with repeated 
events of overanticoagulation (INR>6.0). Second, it describes that the prevalence of 
a simple renal cyst increases with serum uric acid (chapter 3.2). As many more small 
cysts may be present beneath the limit of detection serum uric acid, which is increased 
by several medications, might contribute to the progression of renal function decline 
through renal cyst formation.
Chapter 4 describes the role of the kidney in water and electrolyte disturbances. 
It shows that hydrochlorothiazide and chlorthalidone, two blood pressure lowering 
medications that are generally considered interchangeable, have a different risk of 
hyponatremia at equivalent milligram dose per day. However, these agents are not 
equipotent. With an equipotent dose per day there appeared to be no difference in 
the risk of hyponatremia in contrast to the results from a previous study (chapter 4.1). 
With tricyclic antidepressants there was a significantly increased risk of hyponatremia 
during the first month of use (chapter 4.2). Also benzodiazepines were associated with 
an increased risk of hyponatremia. There was an increased relative excess risk for the 
combined use of benzodiazepines and hydrochlorothiazide (chapter 4.3). Interestingly, 
benzodiazepines were also associated with an increased risk of hospital admission with 
clinical hypovolemia – in clinical practice often referred to as dehydration. Other drugs 
that were also associated with hospital admission with clinical hypovolemia included 
proton pump inhibitors, non-steroidal anti-inflammatory drugs and opioids (chapter 
4.4).
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Chapter 5 describes studied the adherence to renal function monitoring guidelines 
in patients  initiating anti-hypertensive therapy with diuretics, renin-angiotensin system 
inhibitors and/or a combination. It appeared that in the majority of subjects renal func-
tion was not monitored during the first 30 days after start of therapy, although also a 
large variability across general practitioners was observed.
Finally in Chapter 6 the main findings of the research presented in this thesis are 
discussed, appraisals on the methodological consideration of these studies are made 
together with concluding remarks based on the work in this thesis.
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SAmEnVAttInG
Behoud van nierfunctie, vaak gepresenteerd door de geschatte glomerulaire filtratie 
snelheid, is belangrijk, omdat een verminderde nierfunctie is gerelateerd aan een ver-
hoogd ziekte- en sterftecijfer. Desniettegenstaande is aangetoond dat geneesmiddel 
geïnduceerde nierschade de belangrijkste oorzaak is ziekenhuis opname als gen de 
gebruikte gevolg van geneesmiddel gebruik.
Hoofdstuk 1 geeft een algemene introductie op de verschillende onderwerpen die 
in dit proefschrift zijn bestudeerd. Tevens wordt een overzicht van de gebruikte gege-
vensbronnen gepresenteerd. Het hoofdstuk wordt afgesloten met een overzicht van de 
hoofdstukken opgenomen in dit proefschrift.
Hoofdstuk 2 beschrijft het voorkomen van chronische nierziekten in de algemene 
bevolking van Nederland. Het laat zien dat een verminderde glomerulaire filtratie snel-
heid aanwezig is in meer dan de helft van de oudere (≥85 jaar) patiënten. Het feit dat 
met het gebruik van deze observationele data het voorkomen van een verminderde 
glomerulaire filtratie snelheid hoger wordt geschat dan in specifieke cohortstudies, sug-
gereert dat het voorkomen eerder kan zijn onderschat ten gevolge van selectie. 
Hoofdstuk 3 beschrijft twee associaties tussen het gebruik van geneesmiddelen en 
de achteruitgang van de nierfunctie. Eerst beschrijft het de achteruitgang van de nier-
functie in patiënten die geneesmiddelen gebruiken welke de bloedstolling vertragen, 
waarbij de achteruitgang groter is in patiënten met een herhaaldelijk doorgeschoten 
antistolling (INR>6.0). 
Hoofdstuk 4 beschrijft de rol van de nier in water en elektrolyt stoornissen. Het 
laat zien dat hydrochloorthiazide en chloortalidon, twee bloeddruk verlagende genees-
middelen die vaak als uitwisselbaar worden gezien, een verschillend risico geven op 
verlaagd natrium bij een gelijke dosering in milligrammen. Echter, de sterkte van deze 
geneesmiddelen verschilt. Bij een dosering die een gelijke daling van de bloeddruk 
geeft, lijkt er geen verschil te zijn in het risico op een verlaagd natrium, in tegenstel-
ling tot de resultaten van een eerdere studie (hoofdstuk 4.1). Het risico op een verlaagd 
natrium is significant verhoogd gedurende de eerste maand van het gebruik van tricy-
clische antidepressiva (hoofdstuk 4.2). Ook benzodiazepines zijn geassocieerd met een 
significant verhoogd risico op verlaagd natrium. Het risico bij gecombineerd gebruik 
van benzodiazepines en hydrochloorthiazide is groter dan de som van de losse delen 
(hoofdstuk 4.3). Belangwekkend genoeg, waren benzodiazepines ook geassocieerd met 
een verhoogd risico op ziekenhuisopname met een klinische diagnose van hypovole-
mie – in de praktijk vaak aangeduid als dehydratie. Andere geneesmiddelen die hiermee 
een verband hadden, waren proton pomp remmers, niet-steroïde anti-inflammatoire 
geneesmiddelen en opiaten (hoofdstuk 4.4)
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Hoofdstuk 5 beschrijft de compliantie aan de richtlijnen die het controleren van 
de nierfunctie bij mensen die starten met bloeddruk verlagende medicatie middels 
diuretica, remmers van het renine-angiotensine systeem en/of een combinatie voor-
schrijven. Het bleek dat in een meerderheid van de gevallen de nierfunctie niet wordt 
gecontroleerd binnen de eerste 30 dagen na start van therapie, hoewel er een grote 
variatie werd gezien tussen de verschillende huisartsen.
Tenslotte worden in hoofdstuk 6 de belangrijkste bevindingen van dit proefschrift 
bediscussieerd en de methodologische aspecten van de studies besproken.
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